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Fatty acid synthase (FASN), a lipogenic enzyme, is responsible for the de novo synthesis 
of endogenously derived fatty acids in the human body including palmitate; the 
building block of protein palmitoylation. Recent work has suggested that alongside an 
established role in promoting cell proliferation FASN may also specifically promote an 
invasive phenotype; although this is less-well documented. Understanding the 
influence of FASN on cell invasion is critical given that FASN is commonly 
overexpressed in prostate cancer and is associated with poor survival and tumour 
progression.  In this study it was found that the depletion of FASN altered the cellular 
metabolome of prostate cancer cells and decreased their rate of proliferation. 
Moreover, changes in prostate cancer cell morphology were found to be synonymous 
with FASN expression levels.  In addition, FASN knockdown increased cell 
adhesiveness, impaired HGF-mediated cell migration and reduced 3D invasion of 
prostate cancer cells. These changes in migratory ability suggest that FASN can 
mediate actin cytoskeletal remodelling, a process known to be downstream of Rho 
family GTPase signalling.  Here, the modulation of FASN expression was observed to 
impact specifically on the palmitoylation of the atypical GTPase RhoU. RhoU has 
previously been shown to be required to deliver paxillin serine phosphorylation to 
drive adhesion turnover. In this study it was found that the loss of RhoU palmitoylation 
led to reduced adhesion turnover downstream of paxillin serine phosphorylation. The 
addition of exogenous palmitate was able to rescue adhesive and morphological 
defects seen in FASN deleted prostate cancer cells.  Interestingly, it was also observed 
that the expression of the Rho GTPase Cdc42 decreased concomitantly with loss of 
FASN expression, but this is not dependent on palmitoylation; rather the findings from 
this study suggest that stable Cdc42 expression is dependent on the palmitoylation 
status of RhoU. Thus by modulating FASN activity and reducing the availability of in 
cellulo palmitate a novel relationship between RhoU and Cdc42 has been exposed 
which directly influences cell migration potential and provides compelling evidence 
that FASN activity directly supports cell migration.  Additionally, a pilot patho-
epidemiological study using radical prostatectomy specimens revealed an association 
between increased expression of FASN, RhoU and Cdc42 with prostate cancer severity.   
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Chapter 1 – Introduction  
1.1 The Prostate and Prostate Cancer 
1.1.1. Prostate anatomy and function 
The prostate is a tubuloalveolar exocrine gland of the male reproductive system which 
by adulthood is roughly the size of a walnut and weighs approximately 20 grams 
(Hammerich et al., 2009). It is located in the subperitoneal compartment between the 
pelvic diaphragm and the peritoneal cavity (Bhavsar and Verma, 2014). The prostate is 
divided into four distinct regions including the peripheral zone, central zone, transition 
zone and the anterior fibromuscular zone (Figure 1.1).  The peripheral zone comprises 
most of the prostatic glandular tissue which covers the posterior and lateral aspects of 
the prostate and surrounds the distal urethra. The central zone is defined by its cone-
like shape with the apex of this structure surrounding the ejaculatory ducts. The 
transition zone consists of two equal portions of the glandular tissue which surround 
the proximal urethra.  The glandular component of the prostate is composed of large 
peripheral ducts which contain acini at the terminal end (McNeal et al., 1991). The 
lumen of the ducts and acini are lined by two layers of epithelial cells, basal and 
luminal, as well as a minor population of neuroendocrine cells which are mainly 
distributed within the basal layer (Tomlins et al., 2006).  The luminal secretory cells 
express the androgen receptor (AR) and secrete several products including prostate-
specific antigen (PSA) and acid muscin (Oyasu et al., 2008). The basal epithelial cells 
form a flattened layer over the surrounding basement membrane which keeps the 
underlying stroma separate from the luminal cells (Bonkhoff et al., 1994; Oyasu et al., 
2008). The basal cell layer is also thought to contain a small stem cell population that 
gives rise to all epithelial cell lineages (Bonkhoff et al., 1994; Oyasu et al., 2008). 
Neuroendocrine cells also differentiate from basal cells and are strictly AR negative 
(Oyasu et al., 2008). The main function of these cells is unknown, however they are 
thought have an endocrine-paracrine regulatory role in growth and development in 
addition to maintaining homeostatic control of the secretory processes of the prostate 
(Oyasu et al., 2008).  The anterior fibromuscular zone of the prostate is devoid of 
glandular components and is formed from striated muscle and fibrous tissue which is 
important in regulating sphincter functions (Hammerich et al., 2009).   
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In addition to zonal classification, the prostate can also been divided by a lobe 
classification system. This consists of the anterior lobe (roughly correlates to the 
transitional zone), posterior lobe (roughly correlates to the peripheral zone), lateral 
lobes (consists of all zones) and median lobe (roughly correlates to the central zone) 
(Kumar and Majumder, 1995).  
The prostate gland has several functions including controlling urine output from the 
bladder as well as the seminal fluid during ejaculation, providing essential proteins for 
the function of sperm including acid phosphatase, citrate and zinc (also acts as an 
antibacterial agent), and producing polyamine which regulates the alkaline pH nature 
of the sperm  within the acidic female cervix (Kumar and Majumder, 1995).  
 
1.1.2 Prostate carcinogenesis 
Prostate cancer  is the most commonly diagnosed noncutaneous malignancy in the 
world and has now become the leading cause of cancer related deaths in males of the 
western population (Tomlins et al., 2006).  Current figures show  that one in eight men 
will get prostate cancer accounting for a total of 40,000 incident cases and 
approximately 10,000 prostate cancer related deaths each year in the United Kingdom 
(Wilt and Ahmed, 2013).  The five-year survival rate of patients with localized prostate 
cancer is approximately 98% which drops drastically to 28% if the prostate cancer has 
spread to other parts of the body (ACS, 2016). Despite modern efforts of early 
detection, 10-20% of cases present with widespread metastasis at the time of 
diagnosis (Dasgupta et al., 2012). This has led to an increased need for the 
development of more stringent detection tools and novel therapeutics in the 
treatment of this disease (Wilt and Ahmed, 2013).  
Prostate cancer is a multifocal disease with 75% of the cases occurring in the 
peripheral zone; 20-25% of cases occurring in the transition zone; and 1-5% of cases 
occurring in the central zone (Figure 1.1) (Akin et al., 2006). The transition zone is also 
the most common location for the development of another well-known condition that 
afflicts the prostate in older men, benign prostatic hyperplasia (BPH). BPH develops 
due to hormonal imbalances which alter the expression of growth factor receptors in 
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glandular epithelial cells causing an increase in cellular proliferation. This rapid growth 
leads to the subsequent enlargement of discrete nodules within the transition zone 
which increases the overall size of the prostate (Dasgupta et al., 2012). Interestingly, 
there is a high incidence of prostate cancer arising in prostates that already have BPH. 
Despite this, BPH is not a precursor to prostate cancer and is usually easily 
distinguishable by the existence of a well-defined basal cell layer and underlying 
stroma  (Chang et al., 2012).  Although prostate cancer can in some cases mimic the 
obstructive symptoms of BPH, due to it primarily developing in the peripheral zone of 
the prostate it is rarely associated with any urinary-related symptoms. This means in 
most individuals prostate cancer in the early stages is asymptomatic or clinically silent 
and it is only when the disease progresses to the advanced stages that symptoms start 
manifesting (Hammerich et al., 2009).  
Pathologically, biopsies have indicated that several morphological lesions are potential 
precursors to the development of prostate cancer which are identified by the cellular, 
histological and architectural nature of the glandular epithelium (Chrisofos et al., 
2007). Currently, the earlier stages of prostate cancer carcinogenesis are still being 
debated.   The most recent evidence suggests that inflammation plays a role in the 
development of prostate cancer (Felgueiras et al., 2014).  In an ageing prostate, 
inflammation associated focal atrophy lesions are common and are characterised by a 
fraction of epithelial cells with an increased proliferation index and reduced apoptotic 
rate compared to normal epithelium (De Marzo et al., 2007).  These lesions have been 
defined as proliferative inflammatory atrophy (PIA) and are located in the peripheral 
zone of the prostate. Morphological studies have shown that PIA is a precursor lesion 
to prostate cancer in addition to the most frequently associated precursor lesion to 
prostate cancer, prostatic intraepithelial neoplasia (PIN) (Putzi and De Marzo, 2000).  
PIN is the dysplasia of the epithelium lining the prostate glands which results in tissue 
disorganisation and is usually defined as either low-grade or high-grade (Ayala and Ro, 
2007). Low-grade PIN is characterized by crowded and irregularly spaced epithelial 
cells with variable degrees of nuclear enlargement.  In High-grade PIN, most cells 
exhibit anisonucleosis in addition to hyperchromasia (elevated chromatin) and 

























Figure 1.1 Anatomical sections of the human prostate: The prostate can be divided 
into four main parts, starting with the inner-most section, the transition zone, which 
lies upon the central zone that is within the peripheral zone and has the anterior 
fibromuscular stroma sitting on-top. The table below shows where within the 
prostate abnormalities are most likely to occur. Red indicates a high prevalence, 
orange indicates a low prevalence, yellow indicates rare prevalence, and white 
indicates none. This figure was adapted from (Hammrich et al, 2009).  
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High-grade PIN shares several similarities with prostate cancer, including zonal 
distribution frequency, cellular crowding and stratification, hyperchromatism, 
proliferative and apoptotic indices, and increased microvessel density (Chrisofos et al., 
2007).  In addition, urologic pathologists have discovered that in the peripheral zone of 
the prostate, areas of transition exist between High-grade PIN and cancer (Figure 1.1). 
Prostatic ducts with High-grade PIN appear in continuity with smaller, separate 
malignant acini within the microcarcinoma foci (McNeal et al., 1991). The major 
difference between High-grade PIN and prostate cancer is that in High-grade PIN the 
basal cell layer is disrupted but cells do not invade into the basement membrane 
unlike in prostate cancer (Chrisofos et al., 2007). Unlike PIA, males who develop high-
grade PIN are increasingly monitored due to the increased likelihood of developing 
prostate cancer which could take up to 10 years from diagnosis (Kryvenko et al., 2012).   
 
1.1.3 Tumour grading and staging   
Histologically, the majority of prostate cancers are diagnosed as acinar 
adenocarcinomas. This tumour type is characterised by the formation of an acini 
within neoplastic tissue that is composed of malignant cells with a cuboidal-to-
columnar shape. Comparatively, non-acinar carcinomas or other types of prostatic 
carcinomas account for 5-10% of carcinomas that originate in the prostate. These 
histological variants include ductal adenocarcinoma, neuroendocrine carcinoma, 
sarcomatoid carcinoma, urothelial carcinoma, squamous and adenosquamous 
carcinoma and basal cell carcinoma (Humphrey, 2012).  
The Gleason grading system is the most widely used grading scheme in the world. The 
technique was developed by Dr Donald F. Gleason in the 1960s-1970s and was 
designed to be a prognosis indicator that measured the aggressiveness of prostate 
cancer (Humphrey, 2004). This method uses H&E-stained tissue specimens that have 
been taken from biopsies and prepared onto microscope slides. The slides are then 
examined by a pathologist who will assess the histological pattern and give a score 
based on the degree of differentiation in glandular tissue and by the growth pattern of 
the tumour within the prostatic stroma (Chen and Zhou, 2016; Humphrey, 2004).     
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The classical Gleason system has five levels of histological grades (Table 1.1).  Grade 1 
is the lowest grade on the scale and is defined by glands that are well-differentiated 
and uniform. As the grades increase, glands become increasingly less recognisable and 
poorly-differentiated. Specimens with a Grade 5 pattern show practically no 
differentiation with sheets of tumour mass becoming indistinguishable from the 
surrounding stroma (Humphrey, 2004). 
Due to most patients presenting with a heterogeneous population of malignant cells, 
two grades are given per specimen to the two most common tumour patterns.  The 
primary grade is assigned to the dominant pattern of the tumour and has to 
correspond to more than 50% of the histological architecture. The secondary grade is 
assigned to the next-most frequent pattern and has to correspond to less than 50%, 
but more than 5% of the histological architecture otherwise it is ignored (Chen and 
Zhou, 2016; Humphrey, 2004). The primary and secondary grades are added together 
to get a ‘Gleason score’, i.e if primary tumour pattern of the biopsy is Grade 3 and the 
secondary tumour pattern is Grade 4, then the Gleason score is 3+4=7.  Different 
individual scores can give the same overall Gleason score (i.e 4+3=7 and 3+4=7), 
however if the primary grade is higher than the secondary, then the carcinoma is more 
aggressive (Wright et al., 2009). Some pathologists also give a tertiary grade which 
generally corresponds to a small part of the tissue with the most aggressive pattern. 
The secondary grade is replaced by the tertiary grade if it constitutes more than 5% of 
the tumour  (Gordetsky and Epstein, 2016) 
Several studies have shown the validity of using the Gleason scoring system to predict 
overall prostate cancer survival in men (Koochekpour et al., 2012; Mian et al., 2002; 
Wright et al., 2009). An example of this can be seen in a study by Wright et al where 
they found that men with a Gleason score of 6 or less, 3+4, 4+3 and 8-10 had a 10-year 





























Table 1.1 Example tissue sections corresponding to their respective Gleason grade as 
defined by histological assessment: Figure was adapted from (Humphrey et al, 2004).  
 
Grade pattern 1: 
The cancerous prostate closely resembles normal 
prostate tissue.  A well-circumscribed nodular lesion 
composed of uniform, closely packed, well-differentiated 
glands of moderate size. Stroma is intact.  
 
Grade pattern 2: 
Variation between well-differentiated and moderately-
differentiated glands moderate in size. Tumour mass is 
less well-circumscribed and stoma can be seen filtering 
between the glands.    
 
Grade pattern 3: 
Comprised of individual, discrete and distinct neoplastic 
glands (moderately differentiated) which are variable in 
shape and size (small to moderate). Cancerous cells have 
begun invading into the surrounding tissue, or have an 
infiltrative pattern.  
 
Grade pattern 4: 
Features fused glands which are no longer individual or 
distinct. This results in a poorly-differentiated tumour 
with broad, irregular fused glandular or cribriform 
patterns. Gland sizes can range from anywhere from 
small and large in size. A significant proportion of cells 
have invaded into the surrounding stroma.  
 
Grade pattern 5: 
This tissue has no recognizable glands. Most poorly-
differentiated pattern. Necrosis can sometimes be seen 
in the centre of the tissue surrounded by papillary, 




In addition to Gleason scoring, staging of the cancer is also carried out to determine if 
the tumour has spread beyond the prostate. TNM (Tumour, Node, and Metastasis) 
staging was developed by the Union for International Cancer Control (UICC).  The 
classification system works by assessing the size and extent of the tumour (T), degree 
of spread to the regional lymph nodes (N) and identifying sites of metastasis (M). Each 
classification group has a number and letter assigned to it to give more in-depth 
information about tumour localisation, nodes examined and where the cancer has 
spread to (Wallace et al., 1975). 
 
1.1.4 Progression to castrate resistance in prostate cancer 
A substantial minority of the 40,000 incidence prostate cancer cases will present with 
locoregional or metastatic spread at the time of diagnosis. Those whose disease is at 
an earlier stage and found to be localised at presentation may later progress to a more 
advanced stage of prostate cancer after initial treatment. At this juncture, the next 
option is to treat the cancer through hormone manipulation using primary androgen 
deprivation therapy (ADT) (Afshar et al., 2015; Lonergan and Tindall, 2011).  Androgens 
and the AR receptor play an essential role in the normal growth and development of 
the prostate gland. Prostate cancer cells are also initially dependent on androgen 
stimulation. Activation of the AR via circulating androgens leads to a conformational 
change in the AR which allows it to dissociate from heat-shock proteins (HSPs). The AR 
then localizes to the nucleus where it binds androgen-response elements in the 
promotor regions of target genes involved in survival and growth. Activation or 
repression of these target genes increases the ratio of proliferating cells relative to 
cells undergoing apoptosis which leads to increased tumour growth (Feldman and 
Feldman, 2001). ADT has been shown to provide effective prostate cancer remission, 
however after a mean time of 2-3 years  the disease usually progresses despite 
continuous deprivation treatment (Karantanos et al., 2013).  This type of cancer is no 
longer dependent on androgens and is known as castrate-resistant prostate cancer 
(CRPC). The androgen-independent phenotype encompassed by CRPC has been shown 
to be more malignant and metastatic than androgen-dependent prostate cancer 
(Karantanos et al., 2013; Thalmann et al., 1994).  
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There are currently five proposed models for the mechanisms of developing androgen 
independence in prostate cancer (Figure 1.2) (Feldman and Feldman, 2001; Pienta and 
Bradley, 2006). The first is the hypersensitive pathway which increases AR expression 
(usually by gene amplification), enhances AR sensitivity, and increases DHT locally 
through 5α-reductase. This pathway is not strictly speaking androgen independent; 
however the cells are far less dependent on the concentration of circulating androgens 
as the threshold for AR pathway activation is much lower.  The second model is the 
promiscuous pathway which broadens the binding specificity of the androgen receptor 
through mutations in its ligand-binding domain. This allows AR to bind hormones and 
non-androgenic steroid molecules normally present in the circulation and resume 
normal activity (Veldscholte et al., 1992).  The third model is called the outlaw pathway 
and it relies on non-steroid molecules such as hormones or receptor tyrosine kinases 
(RTKs). AKT (protein kinase B) and mitogen-activated protein kinase (MAPK) are two 
RTK pathways which have been shown to cross-talk and phosphorylate AR. This 
pathway leads to a ligand-independent AR which is able to function normally.  The 
fourth mechanism is the bypass pathway which activates parallel survival pathways 
obviating the need for AR or its ligand altogether. Examples of these pathways include 
the AKT and MAPK, or pathways which upregulate the expression of the anti-apoptotic 
protein BCL2 (B-cell lymphoma 2).  The fifth model involves prostate cancer stem cells 
which are not natively dependent on the androgen receptor for growth and survival. 
The cells continually resupply the tumour cell population regardless of ADT (Feldman 
































Model Ligand dependence Mechanism 
Hypersensitive AR  Androgen dependent Amplified AR. 
Sensitive AR. 
Increased DHT. 
Promiscuous AR Pseudo-androgens Mutated androgen receptor 
broadens binding specificity.  
Non-androgens and hormone 
activation. 
Outlaw AR Androgen independent Activated PI3K 
Activated MAPK 
Mutant PTEN 
Bypass AR Androgen independent Activation of alternative 
signalling pathways (AKT and 
MAPK).  
Overexpression of BCL2. 
Activation of other 
oncogenes.  
Prostate cancer stem cell  
(lurker cell) 
Androgen independent Malignant epithelial stem 
cells.  
 
Figure 1.2 Pathways to androgen independence: There are currently five pathways 
that lead to androgen-independence in prostate cancer including the hypersensitive 
pathway, promiscuous pathway, outlaw pathway, bypass pathway, and the prostate 
cancer stem cell/lurker cell pathway. Details of the underlying mechanism for each of 
these pathways are presented in the figure above.  Figure was adapted from (Feldman 
and Feldman, 2001).  
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1.2  Metastasis  
1.2.1 Metastatic cascade 
It is cancer metastasis and not cancer at the primary site which is mainly responsible 
for cancer mortality; overall accounting for 90% of cancer related deaths.  Metastasis is 
a process which involves the dissemination of cancer cells from the primary tumour 
site to a distant site or organ in the body (Yamaguchi et al., 2005). Approximately 90% 
of prostate cancer patients with CRPC will develop metastasis, which is mainly to the 
bone. Those with metastasised CRPC have a poor prognosis and a mean survival time 
of only 16-18 months (Karantanos et al., 2013). At this point drug treatments such as 
abiraterone, enzulutamide, docetaxel, samarium-152 and zoledronic acid are offered 
as well as sipuleucel-T immunotherapy, bone targeting radium-233 and second-line 
cabazitaxel (Afshar et al., 2015). These treatments have been shown to increase overall 
survival time by up to 5 months (Karantanos et al., 2013). However, due to the 
systemic nature of disseminated cancer cells and resistance to existing therapeutic 
agent’s metastatic disease is virtually incurable.  (Guan, 2015).  
Metastasis is a multi-step process which is often referred to as the metastatic cascade 
(Figure 1.3) (van Zijl et al., 2011a).  It is initiated by the detachment of cancer cells 
from the primary tumour. Under normal circumstances, epithelial and endothelial cells 
trying to disseminate from the rest of the cell population would undergo anoikis, a 
form of programmed cell death caused by the detachment of cells from the 
extracellular matrix (ECM) (Sakamoto and Kyprianou, 2010). Metastatic cells are 
thought to break away from the primary tumour and resist anoikis by undergoing the 
process of epithelial-mesenchymal transition (EMT) (Alizadeh et al., 2014). EMT 
involves non-motile, polarized epithelial cells, which are collectively embedded via cell-
to-cell and cell-matrix adhesions, becoming individual, non-polarized, motile and 
invasive mesenchymal cells (Yilmaz and Christofori, 2009).  There is considerable data 
which suggests that EMT contributes to prostate cancer progression and metastasis, 
however it has been shown to be dispensable for the metastasis of other cancers such 
as lung and pancreatic (Fischer et al., 2015; Khan et al., 2015; Zheng et al., 2015).  
During EMT, cells lose several cell-cell adhesion proteins that are classical markers of 
an epithelial phenotype including E-cadherin, occludin, ZO-1, claudin, cytokeratin, 
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catenin and desmoplakin. These are substituted with markers typical of a 
mesenchymal phenotype such as N-cadherin and vimentin, both of which have been 
linked with cell invasiveness and resistance to anoikis in prostate cancer. (Heerboth et 
al., 2015; Khan et al., 2015; Wei et al., 2008). The levels of these proteins are regulated 
by the pleiotropic action of EMT-inducing proteins such as Snail, Zeb1, Zeb2, Slug and 
Twist (Khan et al., 2015). It should also be noted that during metastasis, prostate 
cancer cells can undergo partial EMT (Chao et al., 2012).  This phenotype is associated 
with a higher aggressiveness when compared to complete epithelial or mesenchymal 
states and does not involve the complete loss of epithelial markers (Armstrong et al., 
2011; Li and Kang, 2016).  
Once detached from the primary tumour, cancer cells invade into the surrounding 
tumour-associated stroma and then into the adjacent normal tissue parenchyma 
(Figure 1.3).  To infiltrate into the stroma cancer cells must first breach the basement 
membrane (BM), a specialized ECM that separates the epithelium from the underlying 
connective tissue (Valastyan and Weinberg, 2011). Cancer cells accomplish this by 
active proteolysis, a process coordinated by matrix metalloproteinases (MMPs). MMPs 
are zinc-dependent endopeptidase which are involved in the degradation of the ECM 
and play an important role in tissue remodelling. Analysis of MMP mRNA and protein 
levels in prostate cancer patient tissue and serum has revealed that the expression of 
MMP2, MMP7, MMP9, MMP13, MMP14 (MT1-MMP), MMP15 (MT2-MMP) and 
MMP26 is correlated with advanced or metastatic disease (Gong et al., 2014).  Most 
MMPs are secreted as inactive pro-enzymes which become activated when cleaved by 
extracellular proteinases. MT1-MMP and MT2-MMP are the exception as they contain 
transmembrane domains indicating they are expressed at the cell surface rather than 
secreted (Ellerbroek and Stack, 1999).   
Once the invading cells have dissolved the BM they are confronted with what is known 
as a “reactive” stroma.  Reactive stromas develop as a result of primary tumour 
progression. They share many attributes with stroma tissue that is chronically inflamed 
or in the midst of wound repair. The ECM of the stroma is composed of many proteins 
including collagens, elastin, laminins, tenascin, fibulin, versican and fibronectin (Krušlin 
et al., 2015; Tuxhorn et al., 2002). Two fibroblast cell types, carcinoma-associated 
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fibroblasts (CAFs) and myofibroblasts, are also a main component of the reactive 
stroma in prostate cancer (Figure 1.3).  These stromal cells play a role in further 
enhancing the aggressive nature of cancer cells through there secretion of chemokines 
and growth factors (Barron and Rowley, 2012). An example of this is the abundant 
secretion of hepatocyte growth factor (HGF) in the prostate tumour 
microenvironment.  HGF has been identified as a prominent growth factor for driving 
prostate cancer progression and metastasis through its binding to the cell surface 
receptor c-Met (Varkaris et al., 2011).  
Once the carcinoma cells have navigated through the ECM of the stroma the next 
stage is to migrate into the lymph nodes or haematogenous vessels in a process known 
as Intravasation (Figure 1.3). Cancer cells can enter these vessels either by 
transmigrating between the endothelial cells (paracellular) or through the endothelial 
cells (transcellular) (Reymond et al., 2013).  When the cancer cells have successfully 
entered into the lumina of blood vessels they can disseminate widely throughout the 
body.  
Whilst in the blood vessels cancer cells have to survive a variety of stresses including 
becoming trapped by various capillary beds, prolonged matrix detachment, 
hemodynamic shear forces and predation by cells of the innate immune system. In 
addition, once at a distal site, colonization may not occur due to an incompatibility for 
the cancer cell to adapt within foreign tissue architecture. It is thus speculated that 
less than 0.1% of disseminated cancer cells successfully develop secondary tumours 
(van Zijl et al., 2011b).  Successful carcinoma cells penetrate the endothelial and 
pericyte layers and extravasate into the stromal microenvironment of the distant 
organ. Here cancer cells can revert to a more epithelial cell type in a process known as 
mesenchymal-epithelial transition (MET) and form a microcolony which is initially 
programmed for excelled growth at this new site (Figure 1.3) (Valastyan and Weinberg, 
2011).  In the case of prostate cancer, the main sites of metastasis are to the bone, 




























Tumour cell (non-metastatic) 
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Figure 1.3 Diagram of the metastatic cascade:  A selective few cancer cells will 
acquire a metastatic phenotype and disseminate from the primary tumour into the 
surrounding stroma. Eventually some metastatic cells will intravasate into blood or 
lymphatic vessels where they will be carried to distant sites in the body. Cells that 
survive can then extravasate out of the blood or lymphatic vessels and form a 
secondary tumour site.  
32 
 
1.2.2 Cell migration and invasion 
A prerequisite of metastasis is the adoption of a migratory phenotype by cancer cells 
(Friedl and Wolf, 2003). It is through migration and invasion that cancer cells are able 
to navigate the stoma, enter lymphatic or blood vessels and spread to distant organs 
or tissues (Friedl and Wolf, 2003).  During metastasis cancer cells are exposed to 
different environmental conditions which may require them to alter their “mode” of 
migration in order to progress (Friedl and Alexander, 2011; Friedl and Wolf, 2003).  To 
date,  tumour cells have been observed to migrate as individual single cells or as a 
collective body of well-organised adherent cells (Figure 1.4) (Clark and Vignjevic, 
2015).  
All forms of migration rely on the ability of cancer cells to reorganise their actin 
cytoskeleton which in turn leads to an alteration in the shape of the cell making them 
more adaptable to their surrounding environment (Machesky, 2008). Single-cell 
migration is characterized by a lack of cell-cell interactions during migration with cells 
either displaying a mesenchymal-like phenotype or an amoeboid-like phenotype (Clark 
and Vignjevic, 2015).   Both of these phenotypes have previously been observed in PC3 
and DU145 prostate cancer cell populations (Morley et al., 2014; Taddei et al., 2011). 
Cancer cells that adopt a mesenchymal phenotype typically have fibroblast-like spindle 
shaped morphology and move via a five-step migration cycle.  During the first step of 
this cycle cells become polarised producing protrusions which are either large, broad 
and fan-like, termed lamellipodia, or microspike projections that emanate from the 
frontier of this structure,  termed filopodia (Ridley et al., 2003). The leading edge 
protrusion then stabilizes itself by anchoring to the underlying ECM through the 
formation of focal contacts. The physical ECM barrier situated rearward of the leading 
edge is then broken down via focalised proteolysis. Actomyosin-mediated contraction 
then allows the cell body to effectively translocate in the direction of migration leaving 
a tail-like projection at the rear-end which retracts following focal contact disassembly 
(Friedl and Wolf, 2009). In addition to forming leading edge protrusions, cancer cells 
can also form ventral surface protrusions called invadopodia. Invadopodia are 
especially important in extravasation and allow the cell to move into, or through the 

























Figure 1.4 Mechanisms of single cell and collective cell migration:  There are currently 
two modes of cell migration, single cell and multicellular migration. Single cells either 
migrate with a mesenchymal phenotype which is characterised by an elongated cell 
shape that uses protease degradation, or an amoeboid phenotype which is 
characterised by high contractility, a rounded cell shape and protease degradation.  In 
multicellular migration cancer cells can invade collectively in a small cluster, as sheets, a 
solid strand or in files (line of cells migrating on a single path in contact with the leading 






































Cells that adopt an amoeboid-like morphology have spherical shapes, low adhesion 
force and high actomyosin-mediated contractility (Friedl and Alexander, 2011). 
Amoeboid-like cells are characterized by rapid deformability, adapting their shape 
according to the surrounding ECM which allows them to penetrate though narrow 
spaces. Propulsion of the cell through the interstitial matrix is achieved by dynamic 
cycles of expansion and contraction of the cells body. During movement amoeboid-like 
cancer cells produce protrusive structures known as “blebs” which act as sensors 
testing if the cell can bypass the obstructing ECM. Similar to mesenchymal motility, 
amoeboid movement also relies on proteolysis to break down ECM fibres (Krakhmal et 
al., 2015; Orgaz et al., 2014). 
Collective migration has also been reported in prostate cancer, both in vivo and in 
vitro, and involves the movement of a group of cells that all travel in the same relative 
direction (Brandt et al., 1996; Cui and Yamada, 2013; Friedl and Wolf, 2003).  Cells that 
invade collectively may adopt different morphologies which is dependent on the cell 
type, the number of cells moving as a collective, and the structure of the tissue being 
invaded into (Friedl and Alexander, 2011).  These include groups of cells forming small 
clusters, solid strands, or files (Clark and Vignjevic, 2015; Friedl and Alexander, 2011).   
In the majority of cases regarding collective cell migration, one or several leader cells 
with mesenchymal-like characteristics form a tip and generate forward migratory 
traction though pericellular proteolysis  (Friedl and Alexander, 2011).  It has been 
reported that when collective migration occurs in soft tissue the tip of the invading 
mass becomes blunt with several cells of strong polarity protruding into the 
surrounding matrix.  Cells migrating collectively can also display a different phenotype, 
either mesenchymal or epithelial, to their neighbouring cells. Cell-to-cell and cell-
matrix adhesions are an important feature of collective migration. Antagonists of 
integrins, obligate transmembrane receptors that link the cell to the ECM, have been 






1.2.3 The actin cytoskeleton in cell migration  
The continuous movement of cancer cells during metastasis is powered by protrusive 
machinery that is built from the constant reorganisation and turnover of the actin 
cytoskeleton (Yamaguchi and Condeelis, 2007).  The actin cytoskeleton of the cell is 
made from thin flexible helical fibres called filamentous actin (F-actin) (Jiang et al., 
2009). F-actin itself is made from adenosine triphosphate (ATP) dependent 
polymerization of individual actin molecules, termed globular actin (G-actin) (Jiang et 
al., 2009). F- actin filaments grow with functional polarity and are defined by a slow-
growing pointed end, referred to as the minus (-) end, and a fast-growing barded end 
which is commonly referred to as the plus (+) end (Mullins et al., 1998).   Typically, 
extension of actin filaments at the plus (+) end coincides with a dissociation of actin 
subunits at the minus (-) end.  This is due to the hydrolysis of ATP to ADP (adenosine 
diphosphate) which gives ADP-bound G-actin monomers a much reduced binding 
affinity to the filaments (Small et al., 1978).   It is believed in accordance of Brownian 
motion that there is a relative fluctuation of the actin plus (+) end polymerising against 
the plasma membrane.  In this model, whilst one actin plus (+) end associates with the 
membrane, another actin filament can bend providing space for actin monomer 
insertion to the plus (+) end (Peskin et al., 1993).  Actin filament assembly is regulated 
by heterodimeric capping proteins such as gelsolin and CapZ which inhibit the addition 
or loss of actin subunits at the barbed ends ensuring a well-defined cell shape for 
motility is achieved (Cooper and Sept, 2008).  Actin assembly is mainly controlled by 
the seven subunit protein complex, the actin-related proteins 2/3 (Arp2/3) complex. 
The Arp2/3 complex is responsible for creating new nucleation cores that allow for 
continuous actin filament polymerization at the migrating or invasive front of a cell 
(Welch et al., 1997).  Depending on the geometry of the polymerising actin filaments 
cells can form several different types of protrusions including lamellipodia, filopodia, 
invadopodia and pseudopodia (Machesky, 2008; Murphy and Courtneidge, 2011). 
The continuous reorganisation of the actin cytoskeleton is essential during cell 
migration and invasion. A variety of extracellular stimuli can trigger these changes 
through the Rho GTPase family of proteins which are considered to be the master 
regulators of the actin cytoskeleton (Sit and Manser, 2011).  
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1.3 Rho GTPases 
1.3.1 The family of Rho GTPases and their activation 
The Rho GTPases are a group of proteins that have been implicated in the initiation of 
many cellular process including cell division, cytoskeletal reorganisation, motility, cell 
adhesion, vesicular trafficking and transcriptional regulation (Vega and Ridley, 2008).  
The Rho GTPases form a subgroup of the Ras-like protein superfamily of GTPases, 
which includes other distinct families such as Ras, Rab, Arf and Ran (Vega and Ridley, 
2008). Rho members are small molecules, approximately 21-28 kDa in size, that share 
significant structural homology and differ from the other Ras-like GTPases by the 
presence of a Rho-specific insert domain (Parri and Chiarugi, 2010; Vega and Ridley, 
2008). The family of Rho proteins are highly conserved and comprise 20 members 
divided into 8 different subfamilies (Table 1.2).  The family of Rho GTPases are also 
often divided into two distinct types of Rho GTPases, classical and atypical.  In humans, 
the classical Rho GTPases Rac1, RhoA, and Cdc42 remain the best studied in actin 
cytoskeletal reorganisation and cellular locomotion (Sit and Manser, 2011). These 
proteins, in addition to all classical Rho GTPases, act as sensitive molecular switches 
cycling between an inactive GDP-bound state and an active GTP-bound state (Figure 
1.5).  
The activity of the classical Rho GTPases is regulated by guanine nucleotide-exchange 
factors (GEFs), GTPase-activating proteins (GAPs) and guanine nucleotide-dissociation 
inhibitors (GDIs) (Heasman and Ridley, 2008). Over 70 GEFs have been described in 
humans and there function is to catalyse the exchange of GDP to GTP which leads to 
an increase in the proteins activity. Conversely, GAPs, of which over 80 have been 
identified in mammals, stimulate the hydrolysis of GTP leading to an increase in 
inactive GDP-bound Rho proteins. GDIs function to sequester particular Rho proteins 
into the cytoplasm away from any regulators or targets and prevent their activation 
through inhibiting the release of GDP from its partner GTPase (DerMardirossian and 






































































Table 1.2 Rho GTPase subclass, corresponding family members, and observed post-
translation modification:  Grey colouring indicates classical Rho GTPase and colourless 
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Figure 1.5 Regulation of Rho GTPase activity: At the membrane Rho GTPases cycle 
between an inactive GDP bound form and an active GTP bound form. Rho GTPases 
are activated by GEFs and inactivated by GAPs. The GTPase activation is also 
inhibited by the binding of GDIs which sequester the GTPase into the cytoplasm. The 
Rho GTPases are targeted to membrane by the post-translational addition of lipid 
moieties (prenylation or palmitoylation). 
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Unlike the classical Rho GTPases, the atypical GTPases are not generally regulated by 
GTP-GDP cycling and so do not require GEFs, GAPs or GDIs to modulate their activity. 
Instead, these proteins have been found to be in a constitutive GTP-bound state which 
may be the result of high intrinsic nucleotide exchange activity or due to mutations in 
their GTPase domain which permanently locks the protein in a GTP-bound state 
(Fransson et al., 2003; Hodge and Ridley, 2016).  This means other mechanisms have 
been adopted to regulate their activity; which to date have not been fully elucidated. 
Currently, it is believed that protein-protein interactions or protein phosphorylation 
may be involved in regulating the atypical Rho GTPases.  An example of this has been 
shown by the ability of plexin-B2, one of the three plexin-B proteins, to induce cell 
rounding through its interaction with Rnd3/RhoE (McColl et al., 2016). 
 
1.3.2 Intracellular regulation of the Rho GTPases by lipids 
The Rho GTPase proteins are also frequently post-translationally modified by lipids 
(Figure 1.5). This promotes specific subcellular localization of the proteins to 
membrane compartments that directly influence their interaction with other proteins 
and initiates downstream signalling (Roberts et al., 2008). The only exceptions are the 
two Rho GTPases RhoBTB1 and RhoBTB2 which are regarded as tumour suppressors 
and most likely localise to different cellular regions when coupled to cullin 3 (CUL3) 
ubiquitin ligase complexes (Berthold et al., 2008).  There are two types of post-
translational lipid modifications that can take place in Rho GTPases, prenylation and 
palmitoylation.  These modifications are initiated by the recognition of a carboxyl-
terminal CAAX tetrapeptide motif (C=cysteine, A= aliphatic amino acid, and X=any 
amino acid) (Roberts et al., 2008).  Prenylation is the irreversible addition of either a 
farnesyl (15-carbon chain) or geranylgeranyl (20-carbon chain) isoprenoid lipid to the 
cysteine residue of the CAAX motif (Hodge and Ridley, 2016). Once bound, the 
terminal AAX peptide residues are cleaved by the Ras-converting enzyme 1 (Rce1) 
endoprotease. Then the prenylated cysteine residue is carboxymethalyted by 
isoprenylcysteine-O-carboxyl methyltransferase (Icmt).  
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Taken together these additional steps of processing increase the hydrophobicity of the 
protein and facilitate membrane association (Sebti and Der, 2003).  Several Rho 
GTPase proteins have been found to be prenylated as shown in Table 1.2. 
Palmitoylation is the covalent addition of the 16-carbon fatty acid palmitate 
predominately to the cysteine residues of a protein (Aicart-Ramos et al., 2011). 
Palmitoyl linkage can also occur on serine and threonine residues of a protein, 
however this has been less frequently documented (Anderson and Ragan, 2016). 
Unlike prenylation, palmitoylation is a reversible modification that enables Rho GTPase 
proteins to rapidly shuttle between intracellular membrane compartments.   The 
atypical GTPases RhoU and RhoV are exclusively modified by palmitoylation (Hodge 
and Ridley, 2016).  Other Rho GTPases such as Rac1 and the brain splice variant of 
Cdc42 have shown to be both palmitoylated and prenylated (Navarro-Lerida et al., 
2012; Nishimura and Linder, 2013).  
Both lipid modifications have been shown to be important in the normal signalling of 
Rho GTPases. Prevention of prenylation through  pharmacological inhibition has been 
shown to mislocalize and decrease the activity of RhoA which in turn led to a decrease 
in the expression of several pro-invasive molecules including  MMP7, tissue inhibitor of 
metalloproteinase 2 (TIMP2) and urokinase-type plasminogen activator (u-PA) 
(Caraglia et al., 2006; Konstantinopoulos et al., 2007).  Similarly, the inhibition of 
palmitoylation in NIH 3T3 fibroblast cells led to the significant mislocalization of RhoU, 
decreased phosphorylation of PAK1, a member of the serine/threonine p21 activated 
kinases (PAKs),  and led to pronounced morphology changes (Berzat et al., 2005).   
 
1.3.3 Rho GTPases are master regulators of the actin cytoskeleton and 
xxxxxcell migration 
The Rho GTPases Cdc42, Rac1 and RhoA are well characterised in their ability to 
reorganise the actin cytoskeleton which is fundamental in inducing morphological 
changes and motility in cancer cells (Raftopoulou and Hall, 2004).   Rac1 and Cdc42 are 
required at the front of migrating cells and drive motility through the formation actin 
based protrusive structures.  Rac1 activity induces the formation of lamellipodia, whilst 
Cdc42 activity induces the formation of filopodia.  Alternatively, RhoA activity is 
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associated with cell contractility and rear end retraction (Raftopoulou and Hall, 2004).  
All three of these Rho GTPases have been shown to induce cell migration in prostate 
cancer cells in vitro (Kato et al., 2014; Reymond et al., 2012; Zheng et al., 2006). 
The cellular targets of Rac1, Cdc42 and RhoA that promote changes to the actin 
cytoskeleton have been extensively studied.  Cdc42 primarily initiates the formation of 
filopodia through WASP (Wiskott-Aldrich Syndrome Protein).  Rac1 on the other hand 
initiates the formation of lamellipodia through SCAR/WAVE (suppressor of cAMP 
receptor/WASP verprolin-homologous). Both WASP and SCAR/WAVE are actin-
nucleation promoting factors that regulate the activity of the Arp2/3 complex which is 
responsible for the polymerization of new actin filaments (Sossey-Alaoui et al., 2005).    
Rac1, Cdc42 and RhoA can also regulate cofilin, a small ubiquitous protein that is 
essential in regulating actin dynamics. Cofilin functions to depolymerize filaments to 
generate free actin that can be recycled for another round of polymerization 
(Yamaguchi et al., 2005). The Rho GTPases regulate cofilin by activating LIM kinase 
(LIMK) via PAK1. Cofilin is then phosphorylated and inactivated by LIMK which allows 
for F-actin stability and elongation (Raftopoulou and Hall, 2004; Sit and Manser, 2011).  
Upon formation, the leading edge protrusion is anchored to the cell membrane and 
stabilised through focal adhesions. Focal adhesions are composed from a cluster of 
integrins and they connect to the cytoskeleton via linker proteins such as paxillin, 
zyxin, talin, vinculin and α-actinin (Huttenlocher and Horwitz, 2011; Smith et al., 2013). 
Rac1 and Cdc42 are responsible for the formation of focal adhesions at the leading 
edge of the cell which later mature into larger focal adhesions under the control of 
RhoA (Nobes and Hall, 1995). Adhesions are essential in cell migration as failure of this 
process results in the protruding membrane folding back onto the dorsal surface of the 
cell which creates membrane ruffles without distinct polarity (Parsons et al., 2010a).  
Once the leading edge protrusion is stabilised contractility is required to move the cell 
body along the ECM. RhoA controls this function through ROCK (Rho-associated, 
coiled-coil containing protein kinase 1) which phosphorylates and activates myosin 
light chain (MLC) kinase (Narumiya et al., 2009).  MLC kinase then phosphorylates the 
myosin light chain of myosin which allows it to tether to actin filaments and exert 
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contractile forces which leads to the cell body translocating (O'Connor and Chen, 
2013).  RhoA is also responsible for the formation of dorsal stress fibres which are 
assembled through the activation of its downstream effectors ROCK and mDia1. Focal 
adhesions are often connected to actin stress fibres during migration and their 
connection to myosin aids cell contractility  (Huttenlocher and Horwitz, 2011). 
Continuous turnover of focal adhesions as the cell in migrating is also essential. Rac1, 
Cdc42, and RhoA have all been shown to regulate focal adhesion turnover 
(Huttenlocher and Horwitz, 2011; Parsons et al., 2010b). RhoA predominantly 
regulates the disassembly of focal adhesions at the rear-end of the cell which allows  it 
to retract in the direction of migration (Parsons et al., 2010b).    
During migration there is a significant amount of crosstalk between the Rho GTPases. 
For instance, Cdc42 controls the polarity and directional persistence of a cell during 
migration. One way it accomplishes this is by activing the Rac-GEF’s βPIX and TIAM1 
which recruits Rac1 to the front of the cell (Cau and Hall, 2005).  In addition, Cdc42 has 
also been shown to exist in a complex with Rac1, the polarity protein complex known 
as partitioning defective 6 (PAR6), and protein kinase C (PKC) which has shown to be 
important for the ability of Rac1 to promote tumorigenesis (Sahai and Marshall, 2002; 
Wang et al., 2012).  Crosstalk has also been observed between Rac1 and RhoA which 
exist in a double-negative feedback loop with each other. During the protrusion stage 
of cell migration Rac1 activity is high whilst RhoA activity is low, and during the 
contraction stage the opposite is occurring. This bistable relationship ensures that 
separate processes don’t impede each other which results in efficient cell migration 
(Byrne et al., 2016).  Rac1 inhibits RhoA through the activation of its GAP, p190RhoGAP 
(Mammoto et al., 2007). Conversely, RhoA can activate the Rac-GAP ARHGAP22 
through ROCK which inhibits Rac1 activity. This suppression of Rac1 by RhoA is 
particularly notable in cells that migrate with an amoeboid phenotype (Parri and 
Chiarugi, 2010). Crosstalk between Cdc42 and RhoA has also been shown to be 
important in polarized cell migration. βPIX interacts with Cdc42 and regulates its 
localisation and activity at the cell front. At the same time the βPIX-Cdc42 complex 
binds srGAP1 which is needed to suppress RhoA activity. Depletion of βPIX in fibroblast 





























Figure 1.6 Rho GTPase regulated pathways that induce changes in the actin 
cytoskeleton:  Rac1 and Cdc42 induce actin polymerization at the leading edge of the 
cell through SCAR/WAVE and WASP respectively. Both these nucleation factors 
complexes activate Arp2/3. Rac1 and Cdc42 can also mediate actin polymerization 
through PAK1 which acts on LIMK to regulate cofilin.  During leading edge protrusion 
Rac1 and Cdc42 suppress RhoA activation through different mechanisms.  RhoA 
activates ROCK which phosphorylates and inhibits MLC phosphatase leading to an 
increase in MLC phosphorylation and the generation of actomysoin contractility. RhoA 
also induces actin filament polymerization through mDIA and ROCK. LIMK is 
phosphorylated by ROCK which leads to cofilin phosphorylation.  During contraction 
RhoA has been shown to supress Rac1 activity which prevents the further protrusions.  
44 
 
1.3.4 The atypical Rho GTPases in cancer cell migration 
Relative to Rac1, Cdc42 and RhoA less is known about how some of the other Rho 
GTPases, particularly the atypical Rho GTPases, regulate actin cytoskeletal dynamics 
and cell migration. One atypical GTPase RhoF has been shown to utilise the actin 
nucleation effectors mDia1 and mDia2 to generate long actin- rich filopodia 
independent of the canonical Cdc42-WASP-Arp2/3 pathway (Pellegrin and Mellor, 
2005).  RhoD, which was more recently grouped as an atypical GTPase, was shown to 
be important in the directed migration of fibroblast cells and involved in the formation 
of actin stress fibres in fibroblast, cervical, osteosarcoma and glioblastoma cells (Blom 
et al., 2017). RhoD is believed to activate WHAMM (WASP homologue associated with 
golgi membranes and microtubules) and FILIP1 (filamin A binding protein). WHAMM 
binds and regulates the Arp2/3 complex whilst FILIP1 binds and regulates filamin A 
which is involved in actin filament cross linking (Gad et al., 2012).  Interestingly, RhoH 
actually functions to antagonise Rac1 impairing cortical F-actin assembly and cell 
migration (Vega and Ridley, 2008). 
RhoU is an atypical Rho GTPase that has accumulated quite a bit of attention more in 
the last decade or so.  RhoU, alternatively known as wrch-1, was first identified in 2001 
as a Wnt-inducible gene which was reported to be mediating Wnt-driven oncogenic 
transformation in mouse mammary epithelial cells (Berzat et al., 2005; Tao et al., 
2001). RhoU shares significant sequence homology with Cdc42 but has an extended N-
terminal proline rich domain which has only been found in one other atypical Rho 
GTPase, RhoV (Aspenstrom et al., 2007; Faure and Fort, 2011).  This domain can bind 
several SH3 domain-containing proteins including growth factor receptor-bound 
protein 2 (Grb2), noncatalytic region of tyrosine kinase adaptor protein 2 (Nck1), Src 
and p120 (Risse et al., 2013). Interaction with Grb2 and Nck1 has been observed to 
increase the levels of active RhoU in fibroblast cells (Shutes et al., 2004).  Conversely, 
Src, a non-receptor tyrosine kinase,  can phosphorylate RhoU at residue Y254 within its 
c-terminal which leads to the translocation of RhoU from the plasma membrane to 





RhoU has been shown to induce and regulate stress fibre formation, cell adhesion and 
cell migration in neural crest, prostate cancer, cervical cancer, breast cancer, 
pancreatic cancer,  fibroblast and immune cells (Alinezhad et al., 2016; Dart et al., 
2015; Fort et al., 2011; Ory et al., 2007; Zhang et al., 2011). RhoU interacts with the 
epidermal growth factor receptor (EGFR) receptor which leads to an increase in 
migration speed of pancreatic cancer cells through increased Jun N-terminal kinase 
(JNK)/ Activator protein 1 (AP1) signalling (Zhang et al., 2011). In a study by 
Aspenstrom et al, pyk2 was identified as a binding partner of RhoU. This interaction 
was dependent on the presence and activity of Src. The RhoU-pyk2 complex was found 
to be important for the formation of filopodia and unperturbed cell migration in T-cells 
(Aspenstrom et al., 2007; Vega and Ridley, 2008).   Increased filopodia formation and 
stress fibre dissolution has also been observed in fibroblasts which are overexpressing 
RhoU (Saras et al., 2004).  In addition to being involved in the formation of filopodia, 
active RhoU has been observed to localise at podosomes and influence their 
organisation in osteoclast cells (Brazier et al., 2009).  
In a study by Alinezhad et al the authors reported that RhoU mRNA expression 
increased significantly in cancerous prostate tissue relative to benign prostate tissue 
(Alinezhad et al., 2016). In the same study RhoU was silenced in PC3 prostate cancer 
cells which led to impaired 2D migration and 3D invasion; however cytotoxicity and 
proliferative defects which were measured and confirmed in response to RhoU 
silencing were not controlled for in these assays (Alinezhad et al., 2016). 
Cell adhesion turnover is also mediated by the activity of RhoU. In breast cancer cells 
knockdown of RhoU led to a decrease in the phosphorylation of paxillin which resulted 
in increased adhesiveness, larger focal adhesions and decreased cell migration (Dart et 
al., 2015). In a different study, RhoU silencing decreased MLC phosphorylation which 
resulted in increased adhesiveness and focal adhesion size in Hela S3 cells (Chuang et 
al., 2007). In the same study, a decrease in AKT and JNK phosphorylation was also 
observed and believed to be responsible for the migration defect seen in RhoU 
silenced Hela S3 cells (Chuang et al., 2007). In T-cell acute lymphoblastic leukaemia 
cells (T-ALL), the expression of RhoU was found to be regulated by neurogenic locus 
notch homolog protein 1 (NOTCH1), a member of the Notch family.   
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RhoU depletion induced a rounded morphology and decreased migration, however 
unlike the previous studies in breast and cervical cancer, decreased adhesion in T-ALL 
cells (Bhavsar et al., 2013). Similarly, RhoU silenced neural crest cells were observed to 
have a rounder morphology, reduced migratory and adherence capacity relative to 
control cells (Fort et al., 2011). These studies collectively show that RhoU is essential in 
cell adhesion to the ECM; however its specific function may be cell type specific.  
RhoU is also known to have several other binding partners implicated in cell migration 
and adhesion including PAK4, PAK1, and the cytoplasmic tyrosine kinase FAK (focal 
adhesion kinase) (Dart et al., 2015; Risse et al., 2013; Ruusala and Aspenström, 2008; 
Tao et al., 2001).   However, despite these findings, the complete mechanism of RhoU, 
along with several other Rho GTPases, is still unclear in cancer cell migration.  What 
currently is relatively well established within the context of Rho GTPase activity is their 
dependency on lipid modifications such as palmitoylation (as briefly discussed in 
section 1.3.2).  Cancer cells are more dynamically able to regulate intracellular proteins 
and pathways due to their acquisition of a lipogenic phenotype.  
 
1.4 FASN and the lipogenic phenotype in prostate cancer 
1.4.1 Altered metabolism in cancer  
It has long been recognised now that cancer cells exhibit alterations in their metabolic 
activity. This metabolic reprogramming increases the production of metabolic 
intermediates that are required for the synthesis of proteins, nucleic acids and lipids, 
all of which are a prerequisite for cancer cells that rapidly proliferate (Baenke et al., 
2013).  There are currently two distinct and major changes in metabolism, attributing 
to a shift from catabolic to anabolic metabolism, which separate cancer cells from their 
normal cell counterparts.  The first was identified by Otto Warburg in 1920 and 
describes an avid consumption of glucose by cancer cells which metabolise it via 
glycolysis leading to the production of lactic acid and pyruvate (the Warburg Effect)  
(Flavin et al., 2011).  Each glucose molecule that is metabolized produces two pyruvate 
and four ATP molecules (two used in pathway, so a net of two are produced)  (Alfarouk 
et al., 2014). It is believed cancer cells shifted to relying on glycolysis for several 
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reasons. Firstly, the reaction produces ATP 100 times faster than mitochondrial 
oxidative phosphorylation (the main method of metabolism in normal cells).  Secondly, 
glycolysis allows for the production of ATP in the absence of oxygen (anaerobic) which 
is particularly advantageous for cancer cells trying to adapt to hypoxic conditions 
(Cairns et al., 2011). The glycolytic end product pyruvate is converted into acetyl-CoA 
in the mitochondria before entering the tricarboxylic acid cycle (TCA).  In cancer the 
substantial increase in glycolysis leads to a large turnover of acetyl-CoA. Acetyl-CoA is 
utilised by the second metabolic pathway altered in cancer, de novo fatty acid (FA) 
synthesis (Suburu and Chen, 2012). 
The synthesis of fatty acids in both eukaryotes and prokaryotes is crucial for fulfilling a 
variety of functions in cells, most of which are non-redundant (Maier et al., 2010). 
Fatty acids are aliphatic acids that serve as long term energy storage compounds 
yielding large quantities of ATP when metabolised. They also provide structural 
support in the form of glycerol esters for most cell membranes. Moreover, they have 
regulatory roles as secondary messengers performing many important roles in 
metabolic regulation (Maier et al., 2010; Rangan and Smith, 2002).  
In normal human tissue de novo FA synthesis is suppressed and the expression of 
lipogenic enzymes is maintained at low levels. Normal cells preferentially rely on lipids 
that are from the diet to satisfy their metabolic needs. In comparison, increased 
lipogenesis is a major hallmark for tumour progression with cancer cells switching to 
dependence on de novo fatty acid synthesis in order to sustain rapid cell growth (Zaidi 
et al., 2013). The main metabolic enzyme responsible for the expression of fatty acids 
in the cell is fatty acid synthase (FASN) (Flavin et al., 2011).   
 
1.4.2 The structural organisation of FASN  
Currently, two classes of FASN have been identified, type I, which is utilised by 
mammals and fungi, and type II, which is found in archaebacteria and eubacteria.  Type 
I FASN is a large single multifunctional polypeptide and differs from type II FASN which 


























Figure 1.7 Schematic diagram of the structure of Fatty acid synthase:                                                             
The head-to-head dimer model which is based on two monomers coming together and 
coiling to essentially form a symmetrical homodimer. Structural enzymes include β-
Ketoacyl synthase (KS), malonyl/acetyltransferase (MAT), dehydrase (DH), enoyl 




Human FASN is a homodimer that consists of two identical protein subunits 
approximately 250 kDa in size.  The protein is characterised by three domains. Domain 
I contains three catalytic enzymes including β-Ketoacyl synthase (KS), 
malonyl/acetyltransferase (MAT), and dehydrase (DH). Domain II contains enoyl 
reductase (ER), Ketoacyl reductase (KR), and acyl carrier protein (ACP), and domain III 
contains thioesterase (TE) (Figure 1.7). These N-terminal domains (domain I) are 
separated from the C-terminal domains (domain II and III) by a ~640 amino acid long 
interdomain peptide (Chirala and Wakil, 2004). This interdomain region is believed to 
play an important role in the architecture of catalytically active FASN through its ability 
to bring the active centres of each domain together (Chirala et al., 2001). 
 FASN exists in a head-to-head coiled conformation comprising a body with two 
“arms”, being composed of the dimmers ER and KS, and also the pseudodimeric DH 
pairs, and two “legs” being made up of the MAT domains (Figure 1.7). Due to the 
inherent mobility of the TE and ACP domains, they are currently unambiguously 
assigned in this structure (Smith, 2006). However, a reaction chamber exists  where 
the KS and MAT enzymes lie closer to the centre of the dimer allowing for more 
proficient access to the ACP domain of either monomer (Smith, 2006).  Whilst the 
head-to-head coiled conformation is currently the most accepted model for the 
structure of FASN, the definitive structure still remains to be elucidated. The 
identification of hinge regions suggests that the FASN complex may in-fact be able to 
adopt a wide range of conformations (Chirala and Wakil, 2004).  
 
1.4.3 The function of FASN  
The stoichiometry of fatty acyl chain assembly has been well defined in concert with 
the elucidation of FASN structure (Figure 1.8).  Prior to the late 1950s it was assumed 
that fatty acid synthesis was a direct result of mitochondrial β-oxidation pathway 
reversal which is primarily involved in the degradation of fatty acids (Lynen and Ochoa, 
1953).  However, the de novo biosynthesis of fatty acids in animals actually occurs 
through a series of decarboxylative condensation reactions which involve sequential 

























Figure 1.8 Reaction sequence for the biosynthesis of fatty acids by FASN: 
Decarboxylative condensation sees a stepwise elongation of the starter substrate 
acetyl-CoA by two carbons donated from malonyl-CoA. MAT initiates substrate 
loading. Decarboxylative condensation is catalysed by KS, with KR, DH, and ER 
responsible for modifying the acyl chain β-carbon position until full saturation of 
the fatty acid. 
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The process begins with the shuttling of citrate out of the mitochondria where it is 
converted into oxaloacetate and acetyl-CoA (coenzyme A) by ATP-citrate lyase (ACL).  
Acetyl-CoA is then transported to the cytoplasm where it is carboxylated by the rate 
limiting enzyme acetyl-CoA carboxylase (ACC) with the aid of ATP, CO2, and biotin to 
form malonyl-CoA.  The de novo synthesis of fatty acids is regulated by acetyl-CoA 
carboxylase which itself is regulated in a variety of ways including allosterically by 
citrate, hormonally by glucagon, epinephrine and insulin, or nutritionally (Naik, 2011).  
Sequential translocation of primer substrates acetate and malonate from their 
respective CoA thioester derivatives to the 4’-phosphopantetheine thiol of the ACP 
domain occurs. The phosphopantetheine contains a prosthetic group which is 
described as a long flexible arm that aids substrate bound thiol in binding different 
catalytic sites within FASN (Maier et al., 2010).   Transfer of the substrates is catalysed 
by the monospecific acetyl and malonyl transacylases.  Saturated acyl moieties from 
the acyl-ACP thioester are then transferred to the active cysteine residue of the KS 
domain. Here, decarboxylation of malonyl moieties yields a reactive carbanion which 
carries out a nucelophilic attack on the carbonyl carbon of the KS-bound acetyl moiety 
generating acetoacetyl-ACP and CO2 from these substrates (Chirala and Wakil, 2004; 
Naik, 2011; Smith et al., 2003). The β-ketoacyl intermediate, acetoacetyl-ACP, 
undergoes reduction at the 3-keto group which is catalysed by NADPH dependent β-
ketoacyl reductase (KR) to form β-hydroxacyl chain.  The β-hydroxacyl product is 
dehydrated by β-hydroxyacyl dehydratase (DH) to yield a 2,3 unsaturated acyl enzyme.  
A second reduction by NADPH dependent enoyl reductase (ER) occurs to form a fully 
saturated four carbon acyl enzyme attached to ACP called butyryl-ACP. The saturated 
fatty acyl chain is then transferred from the pathetheine –SH group of ACP to the 
cysteine –SH group of KS by KS freeing ACP to accept a new malonyl residue (Chirala 
and Wakil, 2004; Naik, 2011; Smith et al., 2003). Thereafter, sequential addition of two 
carbons derived for malonyl- CoA to the growing acyl chain occurs until a saturated 16-
carbon acyl radical called palmitate is synthesised. Overall the synthesis of palmitate 
requires 50 reactions, most of which are repeated, and a total of seven cycles. 
Palmitate is covalently attached to the serine side chain of the phosphopantetheine 
prosthetic group of ACP. It is hydrolysed and liberated from the complex by the 
enzyme thioesterase as palmitic acid (Figure 1.8) (Chirala and Wakil, 2004; Naik, 2011; 
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Smith et al., 2003). Whilst palmitate is the most abundant fatty acid synthesised by 
FASN, myristate and stearate have also been recorded to be products of FASN activity 
(Kuhajda et al., 1994). 
 
1.4.4 FASN expression  
In normal tissue, FASN is either expressed at very low levels or is practically 
undetectable (Thupari et al., 2004). The exception is in the cells of specialised tissue 
with high lipid metabolism such as liver, adipose, brain,  lactating mammary glands, 
cycling endometrium and type II alveolar cells in the lung (Chirala and Wakil, 2004; Li 
et al., 2004).  
Conversely, FASN has been found to be commonly overexpressed in almost every type 
of cancer and is associated with their development and progression (Kuhajda, 2006; 
Menendez and Lupu, 2007). The earliest studies found that the increased expression of 
Haptoglobin-related protein (Hpr) correlated with poor breast cancer prognosis, 
recurrence and patient survival (Kuhajda et al., 1989; Shurbaji et al., 1991).  Shortly 
after this observation, Hpr was renamed as oncogenic antigen-519 (OA-519) and then 
identified as FASN (Epstein et al., 1995).  Since then FASN has now been shown to be 
associated with a poor prognosis, progression and decreased overall survival in several 
types of cancer including prostate, melanoma, ovarian, gastric, non-small lung, 
pancreatic, colorectal, osteosarcoma, nasopharyngeal, retinoblastoma, soft tissue 
sarcoma, endometrium, diffuse large B-cell lymphoma and nephroblastoma  (Alo et al., 
2007; Camassei et al., 2003a; Camassei et al., 2003b; Cerne et al., 2010; Danilova et al., 
2013; Epstein et al., 1995; Gansler et al., 1997; Hou et al., 2012; Innocenzi et al., 2003; 
Li et al., 2014b; Liu et al., 2012; Ogino et al., 2008; Sugino et al., 2011; Takahiro et al., 
2003; Tsuji et al., 2004; Yang et al., 2011a).  Additionally, there are other types of 
cancers which show increased FASN expression but have not as of yet been correlated 
with patient survival. These include thyroid, kidney, hepatocellular and mesothelium 
(Gabrielson et al., 2001; Hao et al., 2014; Siraj et al., 2014; Szolkiewicz et al., 2002).  
With regards to prostate cancer, FASN has become an increasing attractive target.  
Several studies have collectively shown that FASN is consistently overexpressed in 
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prostatic tumour tissue compared with the adjacent normal tissue (Epstein et al., 
1995; Swinnen et al., 2002; Tischler et al., 2010; Van de Sande et al., 2005).  Moreover, 
FASN has been shown to be a useful biomarker in prostate cancer development and 
progression. Increased FASN expression is a common and early event in the 
development of prostate cancer being detectable in low grade PIN (Swinnen et al., 
2002).  Further Immunohistochemical staining has shown that different patterns of 
FASN expression are highly predictive in separating cases with organ-confined disease 
or capsular penetration versus cases with seminal vesicle invasion or lymph node 
metastasis (Epstein et al., 1995).  FASN expression also correlates with Gleason grade 
and more importantly increases in castrate-resistant prostate cancer (Epstein et al., 
1995; Rossi et al., 2003). In addition to being highly expressed at the protein level, 
studies have also found FASN to be over-expressed in surgical biopsies of prostate 
cancer at the mRNA level. More specifically, a DNA microarray carried out using 
primary prostate cancer tissue as well as established immortalised cell lines showed 
that out of 400 genes that were differentially regulated from normal tissue, FASN 
scored in the top 20 with a 5- fold overexpression (Welsh et al., 2001).  Similar to 
protein levels, an increase in the expression of FASN at the mRNA level has also been 
shown to be associated with the aggressiveness of prostate cancer (Rossi et al., 2003).  
FASN expression has been noted to increase prior to any noticeable augmentations in 
phenotype such as active cell proliferation and accumulation of intracellular lipid 
droplets (Swinnen et al., 2002).  This in accordance with all the published findings at 
this time suggests that FASN contributes strongly towards prostate cancer progression 
and may be a worthwhile target, even in the latter stages of the disease.  
 
1.4.5 FASN regulation  
In non-malignant tissues, FASN expression can be induced by several different 
mediators, although it is usually tightly regulated (Figure 1.9).  The transcription of 
FASN can be stimulated by dietary carbohydrates, amino acids, glucagon and insulin. In 
addition, FASN expression can be stimulated in hormone-sensitive cells, such as the 
mammary breast glands, by various hormones such as prolactin, estrogen, cortisol, and 
progestins (Anderson et al., 2007; Fukuda et al., 1999; Katsurada et al., 1990; Sul and 
54 
 
Wang, 1998).  Dietary fatty acids, particularly polyunsaturated fatty acids (PUFAs) such 
as alpha-linolenic (ALA), have been shown to down-regulate FASN expression in the 
liver and adipose tissue (Moon et al., 2002). However, regardless of their effect on 
FASN expression,  the intake of PUFAs is still linked with an increased risk of developing 
cancer (Azrad et al., 2013).   Sterols and the hormone leptin also repress FASN 
transcriptionally, and together with PUFAs, these mediators keep cellular lipogenesis in 
check (Menendez and Lupu, 2007). 
Although it is not completely clear, nutritional and hormonal regulation of FASN is 
thought to transpire through the induction of Phosphatidylinositol-3 kinase (PI3K)/AKT 
and MAPK signalling (Huang et al., 2016).   PI3K/AKT and MAPK transduction pathways 
affect FASN expression by modulation of its predominant transcription factor, sterol 
regulatory element-binding protein (SREBP)-1c.  SREBP-1c interacts indirectly with 
proto-oncogene FBI-1 (Pokemon), a transcription factor of the bric-à-brac tramtrack 
broad complex/pox viruses and zinc fingers (BTB/POZ) domain family. Together, these 
proteins synergistically activate the transcription of FASN by acting on the proximal 
GC-box and SRE/E-box (Choi et al., 2008). 
In contrast to normal tissue, FASN expression is not tightly regulated in cancer cells 
and is typically overexpressed to levels beyond what would ever normally be seen 
(Figure 1.9). One of the main contributors to the overexpression of FASN in cancer is 
an increase in growth factors and growth factor signalling (Menendez and Lupu, 2007). 
Receptor tyrosine kinases c-Met and HER2 (human epidermal growth factor receptor 
2) have been shown to regulate FASN expression.  An increase in c-Met expression has 
been correlated with a poor prognosis and progression to androgen independence in 
prostate cancer (Liu et al., 2013a; Varkaris et al., 2011). In a cohort of radical 
prostatectomy patients, Immunohistochemical staining revealed that c-Met was 
overexpressed in 83% of bone metastasis cases (Knudsen et al., 2002).  HER2 is a well-
recognised oncogene whose activation has been linked with FASN expression in 
cancer. HER2 is linked to prostate cancer aggressiveness and an increase in its 
expression is associated with Gleason grade, proliferation, and tumour recurrence 
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Figure 1.9 Regulation of FASN expression in normal and cancer cells: In normal 
cells FASN expression is regulated transcriptionally by multiple stimuli (dietary, 
hormonal, starvation). In cancer cells, FASN expression is regulated transcriptionally 
by growth factors and hormones. FASN expression can also be regulated via non-
transcriptional mechanisms in cancer (mTOR and UPS2α). In both normal and 
cancer cells most mechanisms activate the PI3K/AKT and MAPK pathways which 
regulate the major transcription factor for FASN, SREBP1-c.  
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Stimulation of c-Met and HER2 via their cognate growth factors, HGF and EGF 
respectively, leads to the downstream activation of the PI3K/AKT and MAPK signalling 
pathways (Coleman et al., 2009; Saini et al., 2013).   Just as in normal tissue, PI3K/AKT 
and MAPK signalling regulate FASN expression through SREBP-1c (Yang et al., 2002). 
Interestingly, HER2 signalling has also been shown to regulate FASN translationally 
through the activation of mammalian target or rapamycin (mTOR) (Yoon et al., 2007).  
LNCaP prostate cancer cells are PTEN-null and express a high level of endogenous 
FASN protein. Treatment of these cells with the PI3K inhibitor LY294002 decreases 
FASN expression; however this effect is reversed with the introduction of a plasmid 
that expresses constitutively active AKT. PTEN naturally acts to control PI3K/AKT 
signalling and when re-introduced into LNCaP cells can decrease FASN expression 
through restricted PI3K/AKT activation (Van de Sande et al., 2002). 
Unsurprisingly, hormones can also drive the expression of FASN in cancer.  Stimulation 
of LNCaP cells with the androgen DHT significantly increases FASN expression through 
AR activation and SREBP-1c upregulation (Graner et al., 2004).  Interestingly, in 
androgen-independent cell lines PC3 and DU145 FASN expression does not change in 
the presence of DHT but decreases when the AR is post-translationally degraded (Wen 
et al., 2016).  Stimulation of HER2 has been shown to transactivate overexpressed AR 
in DU145 cells and induce MAPK-dependent induction of FASN in the absence of DHT 
(Yeh et al., 1999). These data supports the current notion that androgen receptor 
signalling still occurs in castrate-resistant prostate cancer (Shafi et al., 2013). FASN 
expression can also be induced by several other hormones (estrogen, progestins and 
progesterone) and their respective receptors (estrogen receptor-ER and Progesterone 
receptor-PR) (Lacasa et al., 2001; Lupu and Menendez, 2006). 
FASN has also been shown to be regulated post-transcriptionally by ubiquitin-specific 
protease-2a (USP2a) in prostate cancer. FASN interacts and is stabilized by USP2a 
through the removal of ubiquitin which protects it from proteasome degradation.  
USP2a knockdown leads to a decrease in FASN expression which coincides with a 




1.4.6 The lipid network  
Palmitate, the primary product of FASN activity, represents about 80% of the total 
fatty acids in the cell (Kuhajda et al., 1994). Palmitate can undergo further 
modifications to become secondary fatty acid intermediates that serve specific 
metabolic and cellular functions. This is accomplished in the mitochondria or at the 
cytoplasmic face of the endoplasmic reticulum (ER) membrane.  Here, elongases and 
fatty acyl-CoA desaturases insert double bonds or increase the carbon chain length 
respectively (Vance and Vance, 2008). Esterification of palmitate leads to the 
generation of several secondary lipids including phospholipids, triacylglyceride (TAG), 
diacylglyceride, (DAG), lysophosphatidic acid (LPA), phosphatidic acid (PA) and 
cholesteryl ester (CE) (Zadra et al., 2013).  Phospholipids make up the cell and 
organelle membrane (Schiller and Arnold, 2002). TAG and CE are storage lipids in the 
cell, although CE is specific to cholesterol storage. DAG, PA and LPA function as 
secondary messengers in signal transduction pathways and can act both intra- and 
extracellularly in a paracrine or autocrine manner (Zadra et al., 2013).  
It should be noted that there is a degree of metabolic flexibility that alters in cancer. 
The current findings do suggest that most cancers if not all become more dependent 
on de novo lipogenesis (Rohrig and Schulze, 2016). However, the degree of this 
dependency can range from high to low in different cancer cells of the same origin or 
of a different origin.  This has been observed in a study by Li et al where it was found 
that two different liver tumour types, hepatocellular carcinoma (HCC) and intrahepatic 
cholangiocarcinoma (ICC) responded differently to treatment. HCC express high levels 
of FASN and did not take up any exogenous lipids whilst ICC express low levels of FASN 
and were found to take up exogenous fatty acids (Li et al., 2016). In a different study it 
was shown that the breast cancer cell line SK-Br3, which expresses high levels of FASN, 
was not affected by the supraphysiological addition of linoleic acid or arachidonic acid.  
However when incubated with linolenic acid the SK-Br3 cells exhibited a strong 
suppression in their expression of FASN (Menendez et al., 2004b).  These data suggest 
that the dependency and sensitivity of cancer cells to exogenous lipids and de novo 
lipogenesis is complex and could be unique to cancer type, lipid group, and FASN 
expression level.  
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1.4.7 The role of FASN in cancer  
FASN has been identified to have numerous roles in cancer. One of its better known 
functions is supporting rapid cellular proliferation which relies heavily on de novo fatty 
acid synthesis (Flavin et al., 2010). Current evidence in the literature suggests that 
there are two lipogenic checkpoints in the cell cycle which occur at the G2/M phase 
and the G1/S phase (Scaglia et al., 2014).  For these checkpoints to progress a sufficient 
supply of phospholipids must be available for the membrane expansion of rapidly 
proliferating cells.  FASN overexpression typically means that cancer cells have a large 
pool of phospholipids available to carry out this function. Moreover, since FASN 
activity is not restricted in cancer cells there is very little reason that whilst under 
stable conditions, continuous cell growth cannot occur (Currie et al., 2013).  The 
silencing or inhibition of FASN has been show to decrease the proliferation rate of 
almost every type of cancer including prostate, breast , lung, ovarian, colorectal, 
pancreatic , osteosarcoma, retinoblastoma, nasopharyngeal and liver (Daker et al., 
2012; Deepa et al., 2013; Hu et al., 2016; Nishi et al., 2016; Singh et al., 2015; Veigel et 
al., 2015; Ventura et al., 2015; Yoshii et al., 2013; Zaytseva et al., 2012; Zecchin et al., 
2011; Zhou et al., 2015). 
In addition, a significant proportion of studies also found that targeting FASN is 
cytotoxic to cancer cells (De Schrijver et al., 2003). Interestingly, one study showed 
that unlike in cancer cells, FASN inhibition in the normal mouse embryonic fibroblast 
cell line NIH 3T3 and Müller glial cell line MIO-M1 did not affect cellular proliferation or 
induce toxicity (Deepa et al., 2012). This highlights a greater dependency on FASN in 
cancer cell growth and survival. Reduced viability in response to FASN inhibition could 
be due to numerous factors in addition to lipid starvation.  FASN blockade has been 
shown to induce cell cycle arrest through SKP2 (S phase kinase-associated protein 2) 
downregulation. SKP2 is an F-box protein of SCF family of ubiquitin ligases and is 
known to be a negative regulator of cyclin-dependent kinase inhibitors of the Rb 
pathway including p21, p27, p57 and p130 (Deepa et al., 2013; Knowles et al., 2004). In 
addition, inhibition of FASN in breast cancer cells led to an increase in the nuclear ratio 
of BRCA1, a tumour suppressor protein, as well as induced the nuclear translocation of 
nuclear transcription factor- ĸB (NF- ĸB), a factor which has been shown to have both 
apoptotic and anti-apoptotic roles in cancer (Menendez et al., 2004a).  
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FASN inhibition can also lead to cell death through the toxic accumulation of malonyl-
CoA. Since malonyl-CoA is no longer being utilised in the fatty acid synthesis pathway 
its levels increase which inhibits carnitine palmitoyltransferase (CPT1) (involved in β-
oxidation) resulting in the up-regulation of ceramide and the induction of pro-
apoptotic genes BNIP3, TRAIL, and DARK2 (Bandyopadhyay et al., 2006). The inhibition 
of FASN also leads to the inactivation of the PI3K/AKT/mTOR signalling pathway which 
is a well-known intracellular pro-survival system. AKT phosphorylates and inhibits the 
pro-apoptotic Bcl-2 family members Bad and Bax, caspase-3, caspase-9, GSK-3 and 
FOXO1. mTOR phosphorylation activates S6K1 and 4EBP1, two proteins which control 
cell division and protein biosynthesis (Dhanasekaran et al., 2008; Wagner et al., 2017). 
A decrease in DAG lipids as a result of FASN inhibition has also been shown to 
contribute to cancer cell death (Benjamin et al., 2015). DAG activates PKC which is 
involved in regulating the cell cycle through cycle regulatory molecules such as the 
cyclin-dependent kinases (CDK), CDK inhibitors and cdc25 phosphatases (Black and 
Black, 2012). 
FASN is also known to induce changes in the plasma membrane fatty acid composition. 
Saturated fatty acids produced by FASN increase the size of the cell membrane and 
partition into detergent-resistant lipid raft domains at a higher rate than exogenously 
derived mono-and polyunsaturated fatty acids. These lipid rafts have been implicated 
in a variety of functions including stabilization of signalling receptors, intracellular 
trafficking, cell polarization and cell migration. A study by Swinnen et al showed that 
FASN inhibition significantly reduced lipid incorporation into the membrane which 
destabilised lipid raft-aggregates (Swinnen et al., 2003).  The dynamics of the lateral 
and transversal membrane are also altered in cancer cells due to the more dense 
packing of saturated fatty acids compared to mono-and polyunsaturated fatty acids. 
Normally, the transversal mobility of membrane components, also referred to as “flip-
flop”, occurs at a low rate unless facilitated by specific transporters.  Commonly used 
chemotherapeutics such as doxorubicin use passive flip-flop as a mechanism of entry 
into cells, however there entry is restricted in cancers with “dense” membranes.  A 
study by Rysman et al showed that the silencing of FASN significantly sensitized 
prostate cancer cells and breast cancer cells to doxorubicin-induced cytotoxity 
(Rysman et al., 2010). Breast cancer MCF7 cell clones generated to overexpress FASN 
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showed the opposite effect to FASN inhibition and the cells become more resistant to 
the chemotherapeutic drugs Adriamycin and mitoxantrone (Liu et al., 2008). Due to 
FASN playing a role in resistance, it has been suggested to treat cancer patients with 
FASN inhibitors in combination with the standard chemotherapy drugs (Blancafort et 
al., 2015; Flavin et al., 2010). 
FASN is also thought to play an important role in cell survival through the initiation of 
angiogenesis (Seguin et al., 2012; Zaytseva et al., 2014).  Neovascularisation is an 
important process during metastasis creating microvascular networks that supply 
oxygen and nutrients to the cells. FASN modulates tumour angiogenesis through 
differential expression of vascular endothelial growth factor-A (VEGF-A) isoforms.  In 
melanoma and colorectal cancer cells, FASN inhibition led to the down-regulation of 
the pro-angiogenic isoform VEGF189 and up-regulation of the anti-angiogenic isoform 
VEGF165b (Seguin et al., 2012; Zaytseva et al., 2014). When the FASN silenced colorectal 
cancer cells were implanted into the colonic submucosa of athymic mice a significant 
decrease in microvessel density and the diameter of blood vessels was observed when 
compared to control cells (Zaytseva et al., 2014). 
 
1.4.8 Linking FASN to cancer cell migration and invasion 
When FASN was originally discovered and studied it was thought that its only functions 
in cancer were to act as an energy source in conjunction to glycolysis, and synthesise 
the necessary metabolic products required for cellular proliferation.  It was soon 
identified that FASN expression correlated with pathological stage and a poor 
prognosis (Epstein et al., 1995; Kuhajda et al., 1989).  Despite these clinical findings, 
which were observed almost 30 years ago, it is only within the last decade that FASN 
has been considered as a marker of metastasis and its role in this process being 
researched. During this time it has been difficult to identify the exact underlying 
mechanisms through which FASN induces cell migration and invasion. This in part is 
due to the complex nature of the lipid network that sits downstream of FASN.   
Currently, the majority of studies in the literature seem to suggest that FASN may be 
driving cell migration through activation of the PI3K/AKT pathway.  AKT has been 
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reported to induce the migration and invasion of prostate cancer cells through 
activation of the Rho GTPase Rac1 (Henderson et al., 2015).  The silencing of FASN has 
been shown to suppress PI3K/AKT signalling and impair cell migration in osteosarcoma 
and colorectal cancer cells (Coleman et al., 2009; Li et al., 2012a; Wang et al., 2013b). 
In addition, FASN inhibition with the flavonoid luteolin has been found to block AKT 
phosphorylation and impair HGF-induced scattering of DU145 cells (Coleman et al., 
2009). In these studies the PI3K/AKT pathway is activated by the stimulation of either 
the HER2 or c-Met receptor.  FASN and PI3K/AKT exist in a positive feedback loop and 
it is likely that FASN is regulating PI3K/AKT signalling through modulation of the 
upstream receptor tyrosine kinases.  FASN is able to regulate c-Met and HER2 post-
translationally though palmitoylation which regulates the receptors raft binding 
affinity and stabilises them at the membrane (Anderson and Ragan, 2016; Coleman et 
al., 2016; Levental et al., 2010).  The implications of protein palmitoylation in cancer 
will be discussed in more detail in the next section of this chapter.   
Alternatively, some studies have suggested an opposing paradigm whereby the 
PI3K/AKT pathway modulates FASN to induce cell migration and invasion (Long et al., 
2014; Zhou et al., 2015). Osteocarcinoma cells treated with the PI3K/AKT inhibitor 
LY294002 show a decrease in FASN levels and have a reduced migratory and invasive 
capacity compared to control cells (Wang et al., 2014; Zhou et al., 2015). The 
consequence of this bi-directional relationship between FASN and the PI3K/AKT 
pathway has meant it has remained unclear as to exactly what proteins in this 
signalling axis are inducing a migratory phenotype.  
In addition to activating the PI3K/AKT signalling pathway it was also shown in a study 
by Zhou et al that the regulation of HER2 by FASN increases glycolysis and migration in 
breast cancer cells (Zhou et al., 2016). In this study, the migration of MCF-7 cells 
treated with the FASN inhibitor cerulenin was tested in a wound healing assay and a 
transwell migration assay for 48 hours. Wound closure and trans-migration of 
cerulenin treated MCF-7 cells was found to decrease relative to control cells, although 
it should be noted that in these assays proliferation defects and inhibitor cytotoxity 
was not measured (Zhou et al., 2016). When investigating metabolic disparities, Zhou 
et al found that there was a decrease in glucose uptake and lactate production in 
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cerulenin treated MCF-7 cells indicating a change in glycolysis. Glycolysis results in the 
generation of citrate which is converted into acetyl-CoA, one of the primer substrates 
used by FASN. It is likely that the increase in glycolysis enhances FASN activity and 
increases the subsequent oncogenic signalling which leads to a more invasive and 
migratory phenotype (Zhou et al., 2016).   
FASN has been found to be overexpressed in many primary tumours where it is 
believed to contribute to growth and survival.  Less is known about its role in 
regulating the progression of cancer to a metastatic phenotype; however two studies 
have observed that FASN overexpression is associated with metastatic transformation. 
Gonzalez-Guerrico et al found that FASN overexpression in the normal breast cancer 
cell line MCF10A led to the upregulation of several mesenchymal markers including 
vimentin, N-cadherin and fibronectin. Conversely, the epithelial marker E-cadherin was 
downregulated in these cells. When comparing the FASN overexpressing MFC10A cell 
line to the wild-type they found the former produced tumourspheres which lacked a 
lumen indicating invasive behaviour (Gonzalez-Guerrico et al., 2016).  Similarly, in 
another study it was found that the stable overexpression of FASN in the ovarian 
cancer cell line SW626, which normally expresses very low levels of FASN, induced the 
expression of several EMT markers including N-cadherin, vimentin, slug and snail. The 
expression of these markers correlated with a greater migratory and invasive capacity 
in the cells when compared to wild-type SW626 cells (Jiang et al., 2014). It is currently 
unclear how FASN is involved in regulating EMT in cancer. One study by Yang et al 
suggests that FASN and the EMT-inducing cytokine TGF-β1 (transforming growth factor 
beta 1) exist in a positive feedback loop which induces EMT in non-small cell lung 
cancer (Yang et al., 2016). However, this seems to be dependent on the cell type being 
cisplatin-resistant as TGF-β1 signalling suppressed FASN expression in non-small cell 
lung cancer cells that were not cisplatin-resistant (Yang et al., 2016).  
Proteins involved in cell adhesion turnover, a key process of cell migration, have also 
been linked to FASN expression.  The phosphorylation of FAK and paxillin were 
observed to decrease in FASN inhibited or silenced melanoma and colorectal cancer 
cells (Cao et al., 2015; Zaytseva et al., 2012). Additionally, in the study by Cao et al, 
phosphorylation of the adaptor protein Gab1 (GRB2-associated-binding protein 1), 
63 
 
PAK1 and PAK2 also decreased in response to FASN inhibition (Cao et al., 2015). Whilst 
in the study by Zaytseva et al, phosphorylation of Src and the total levels of the cell 
surface glycoprotein CD44 and the Rho GTPase RhoA were observed to decrease in 
response to FASN knockdown (Zaytseva et al., 2012).   All these proteins have 
previously been shown to be involved in cell motility and there suppression in 
response to FASN inhibition also correlated with a defect in migration in their 
respective studies (Cao et al., 2015; Coleman et al., 2009; Zaytseva et al., 2012). 
In a study by Yoshii et al , the migration of LNCaP prostate cancer cells decreased in 
response to the silencing of FASN with siRNA (Yoshii et al., 2013). In this study they 
performed a DNA microarray analysis and found one of the most significantly down-
regulated genes was RAP2B. RAP2B is part of the RAP family of small GTP-binding 
proteins and is known to induce cytoskeletal reorganisation (Di et al., 2015b).  RAP2B 
has been shown to induce proliferation, migration and invasion in breast cancer cells 
through ERK1/2 signalling (Di et al., 2015a). Further work has not currently been done 
to confirm whether RAP2B is indeed a key protein in FASN-induced cell migration.  
More recently a study found that FASN induced colorectal cancer cell invasion through 
the Wnt signalling pathway. The silencing of FASN impaired the invasive capacity of the 
colorectal cancer cell lines HT-29 and SW40 through matrigel and led to the 
downregulation of the Wnt signalling proteins Wnt5a, Wnt5b and Fzd2 (Wang et al., 
2016). These Wnt proteins are known to target β-catenin and together redistribute E-
cadherin, increase the expression of MMP7, and increase the activity of Cdc42 and 
Rac1 (Iwai et al., 2010). The re-introduction of FASN into the FASN depleted colorectal 
cancer cell lines led to the re-expression of the Wnt proteins and rescued the invasive 
phenotype (Wang et al., 2016). 
The findings from these studies indicate that FASN is linked to a plethora of proteins 
implicated in the migration and invasion of cancer. However, what is not known is 
exactly how FASN expression or activity regulates these proteins. Currently, the vast 
majority of studies, if not all, have silenced or inhibited FASN, and shown that a protein 
associated with motility downstream has become altered.  What is not clear is how 
these proteins are being modulated by FASN, i.e through binding, pathway activation, 
transcriptionally or lipid-mediated. Moreover, there is currently vastly underwhelming 
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evidence which directly links FASN to the Rho GTPase proteins which are key 
regulators of the cytoskeleton and cell migration. RhoA expression has been shown to 
decrease in FASN silenced colorectal cancer cells; however why this occurs 
mechanistically remains to be elucidated (Zaytseva et al., 2012). In addition, no other 
Rho GTPases have been studied as potential targets of FASN in cancer which is 
somewhat surprising given that there activity at the membrane is partly dependent on 
lipid modification (see previous section on Rho GTPase regulation by lipids- 1.3.2).  
Furthermore, this thesis is focussing more specifically on the role of FASN in AR-
independent prostate cancer. To date, it has not been shown if the direct involvement 
of FASN is essential in AR-independent prostate cancer migration.  
 
1.4.9 The palmitoylated protein signalling network 
FASN is responsible for the synthesis of palmitate, the most abundant fatty acid 
produced in cancer cells (Zadra et al., 2013).  Most studies looking at the effects of de 
novo lipogenesis in cancer are usually more concerned with the secondary lipids that 
are formed from palmitate esterification. However, palmitate is also involved in the 
post-translational modification of proteins in a process known as palmitoylation (also 
see previous section on Rho GTPase regulation by lipids- 1.3.2 for more details) (Aicart-
Ramos et al., 2011).   
The palmitoylation of protein thiols can occur spontaneously and non-enzymatically if 
palmitoyl-CoA is enriched within specific membrane microdomains. However, protein 
palmitoylation is catalysed much more rapidly by the palmitoylating enzymes known as 
the DHHC palmitoyltransferases (PATs) (Guan and Fierke, 2011). PATs are 
characterised by a DHHC (Asp-His-His-Cys) motif and exist in a highly diverse family 
with 23 members currently identified in humans (Blaskovic et al., 2013; Guan and 
Fierke, 2011). It is currently unclear why cells express multiple DHHC PATs and what 
determines their specificity for particular substrates. The SNAP receptor (SNARE) 
protein SNAP25 has been observed to be modified by DHHC3, DHHC7 and DHHC17 
(Greaves et al., 2009). In contrast the integrin receptor α6β4 is specifically modified by 
DHHC3 only (Sharma et al., 2012a). The N-terminal and C-terminal cytosolic domains of 
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DHHC proteins have been shown to greatly vary amongst family members and may 
contain sequences which mediate specific protein-protein interactions (Blaskovic et al., 
2013).  
Whilst the DHHC proteins are primarily involved in the S-palmitoylation of cysteine 
residues, a lesser studied group of proteins known as MBOAT (Membrane bound O-
acyl transferase) have been identified to mediate O-palmitoylation of serine and 
threonine residues. Currently 16 MBOAT members have been identified with three 
being involved in protein acylation including Hedgehog acyltransferase (Hhat), 
Porcupine (Porcn) and Ghrelin O-acyltransferase (GOAT) (Resh, 2016). 
Palmitoylated proteins can also undergo deacylation in the cytosol. This process is 
carried out enzymatically by acyl protein thioesterases (APTs) which act to remove the 
acyl moiety from the protein (Aicart-Ramos et al., 2011). Three APTs have so far been 
identified including  APT1, APT2 and APT-1 like (Blaskovic et al., 2013). Similar to DHHC 
PATs, specific proteins are targeted by APTs for deacylation i.e APT1 depalmitoylates 
Gα proteins whilst APT2 depalmitoylates growth-associated protein-43 (GAP43) 
(Blaskovic et al., 2013). 
Palmitoylation has been shown to be essential for protein function and stability. One 
example of this was seen in study by Anilkumar et al where they found the function 
and localisation of the metalloproteinase MMP14 to be dependent on palmitoylation.  
When palmitoylation was blocked MMP14 was unable to internalize and cell migration 
was significantly impaired in HT1080 fibroblast cells (Anilkumar et al., 2005).  In 
another study the function and stability of the chemokine receptor CCR5 was found to 
be dependent on palmitoylation. Inhibition of S-acylation led to CCR5 accumulating 
intracellularly with kinetic experiments showing a profound decrease in its half-life 
which eventually lead to a reduction in the total expression of CCR5 (Percherancier et 
al., 2001).  
To date 300 proteins have been identified to undergo palmitoylation and thus 
essentially exist in a palmitoylated protein signalling network downstream of FASN 
(Martin and Cravatt, 2009).  Despite this, there are only a few studies which have 
looked into the repercussions of blocking FASN activity on downstream protein 
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palmitoylation events.  One study by Bollu et al has shown that FASN inhibition 
decreases EGFR palmitoylation in PC3 prostate cancer cells. This prevented EFGR 
dimerization and kinase activation and even led to protein degradation after 24 hours. 
As expected the downstream signalling of EGFR was abolished and PC3 cell 
proliferation was significantly impaired (Bollu et al., 2015). Another study by Coleman 
et al found c-Met palmitoylation was dependent on FASN activity (Coleman et al., 
2009; Coleman et al., 2016). Prevention of c-Met palmitoylation targeted the receptor 
for degradation and attenuated downstream AKT signalling which impeded the ability 
of DU145 cells to scatter in response to HGF (Coleman et al., 2009).   
Conversely, the overexpression of FASN has also been shown to alter the 
palmitoylation status of proteins. Immortalised prostate epithelial cells (iPrEC) stably 
overexpressing FASN showed a significant increase in Wnt1 palmitoylation which 
caused β-catenin to become active and accumulate at the membrane and cytoplasm. 
Orthotopic transplantation of iPrEC cells overexpressing FASN in nude mice resulted in 
invasive tumours when compared to mice transplanted with wild-type iPrEC cells 
(Fiorentino et al., 2008).  
The findings from these studies highlight the importance of FASN dependent 
palmitoylation in both a normal and tumour based setting.  It is yet to be shown if 
targeting FASN affects the palmitoylation of cytoskeletal regulating proteins such as 











1.5 Aims of the project 
In this thesis, the following aims will be investigated: 
1. Characterise the effect of FASN knockdown on AR-independent prostate cancer 
proliferation, metabolism and cell morphology. 
2. Assess if FASN knockdown alters any aspects of motility in AR-independent 
prostate cancer cells including adhesiveness, 2D migration and 3D invasion.  
3. Identify an underlying mechanism through which FASN could be driving a more 
motile phenotype in AR-independent prostate cancer.  
4. Perform a pilot patho-epidemiological study using radical prostatectomy 
samples to assess if the expression of FASN, along with any proteins identified 













































Chapter 2 – Materials and Methods  
2.1 Materials  
2.1.1 General Materials  
1-Biotinamido-4-[4’-(meleimidomethyl)cyclohexanecarboxamido]butane (Biotin-
BMCC) (ThermoFisher  Scientific, USA)                                                                                    
2-bromopalmitate  (2BP)  (Sigma-Aldrich, UK)                                                                               
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) (Sigma-Aldrich, 
UK)                                                                                                                                                     
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (A&E Scientific)                                
4-Methylene-2-octyl-5-oxotetrahydofuran-3-carboxylic acid (C75) (BioVision)                              
4’, 6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, UK)                                                                     
Acrylamide (30%)  (Severn Biotech Ltd, UK)                                                                                                           
Agarose  (Invitrogen, UK)                                                                                                                           
Ammonium persulfate (APS) (Sigma-Aldrich, UK)                                                                                         
Ampicillin (Sigma-Aldrich, UK)                                                                                                           
Aprotinin  (Sigma-Aldrich, UK)                                                                                                                     
BD MatrigelTM Basement Membrane Matrix  (BD Biosciences, UK)                                                 
Beta (β)- mercaptoethanol  (Sigma-Aldrich, UK)                                                                                
Bovine pituitary extract (BPE) (ThermoFisher  Scientific, USA)                                                         
Bovine serum albumin (BSA)  (VWR International, UK)                                                                         
Bovine serum albumin (BSA)- Fatty acid free  (VWR International, UK)                                                  
Bromophenol blue (Bio-Rad, UK)                                                                                                               
Calcium phosphate transfection kit (Invitrogen, UK)                                                          
Cell dissociation buffer (Sigma-Aldrich, UK)                                                                          
Deoxyribonucleotide triphosphate (dNTPs) (New England Biolabs, UK)                         
DH5αTM competent Escherichia coli (E. coli) cells  (Invitrogen, UK)                               
Dimethyl sulfoxide (DMSO) (Sigma-Aldrich, UK)                                                                      
Dithiothreitol (DTT) (Sigma-Aldrich, UK)                                                                              
Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-Aldrich, UK)                                                                                                     
DNA ladder (New England Biolabs, UK)                                                                                           
Epidermal growth factor (EGF) (ThermoFisher  Scientific, USA)                                   
70 
 
Enhanced chemiluminescence (ECL) Prime western blotting detection reagent (GE 
Healthcare Life Sciences, UK)                                                                                                  
Ethanol (BDH Laboratory Supplies, UK)                                                                                      
Ethidium bromide (ThermoFisher  Scientific, USA)                                                             
Ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich, UK)                                             
Fibronectin (Sigma-Aldrich, UK)                                                                                         
FluorSaveTM Reagent (Calbiochem, UK)                                                                                                
Foetal bovine serum (FBS) (GIBCO®, Invitrogen, UK)                                                             
FuGene 6 (Promega, UK)                                                                                              
Formaldehyde (ThermoFisher  Scientific, USA)                                                                           
X-ray film (Scientific Laboratory Supplies, UK)                                                                  
Gentamycin (Sigma-Aldrich, UK)                                                                                                  
G418 sulphate (Cayman Chemical, USA)                                                                                              
GFP-TRAP (ChromoTek, Germany)                                                                                     
Glycerol (Sigma-Aldrich, UK)                                                                                                             
Glycine (Sigma-Aldrich, UK)                                                                                                                      
HCl (VWR International, UK)                                                                                                                 
Hepatocyte growth factor (HGF) (Recombinant Human) (R&D systems, USA)                                                                               
Hydroxylamine solution (Sigma-Aldrich, UK)                                                                     
Kanamycin solution (Sigma-Aldrich, UK)                                                                                              
Keratinocyte serum free media (KSFM) (ThermoFisher  Scientific, USA)                              
Leupeptin (Sigma-Aldrich, UK)                                                                                                 
Luria-Bertani agar (LB-agar) (Sigma-Aldrich, UK)                                                                                            
Luria-Bertani broth (LB-broth) tablets (Sigma-Aldrich, UK)                                                      
Magnesium Chloride (MgCl2) (Sigma-Aldrich, UK)                                                           
Methanol (VWR International, UK)                                                                                             
Milk powder (Marvel, UK)                                                                                                          
NEB®-10 beta competent E.coli cells (high efficiency) (New England Biolabs, UK)                     
N-Ethylmaleimide (Sigma-Aldrich, UK)                                                                                       
Nitrocellulose membrane (PerkinElmer, UK)                                                                   
NonidetTM P40 substitute (NP-40) (Sigma-Aldrich, UK)                                                      
Nuclease-free water (ThermoFisher  Scientific, USA)                                                                                                                                         
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OptiMEM (Invitrogen, UK)                                                                                                
Orlistat  (Sigma-Aldrich, UK)                                                                                                                    
Paraformaldehyde (PFA) (Sigma-Aldrich, UK)                                                                                      
Penicillin-Streptomycin (Sigma-Aldrich, UK)                                                                             
Phenylmethylsulfonylfluoride (PMSF) (Sigma-Aldrich, UK)                                                              
Phosphate buffered saline (PBS) tablets (Oxoid Limited, UK)                               
Dulbecco’s PBS with Calcium and Magnesium (GIBCO®, Invitrogen, UK)                 
Dulbecco’s PBS without Calcium and Magnesium (LONZA, UK)                                                 
PierceTM ECL  western blotting substrate (ThermoFisher  Scientific, USA)                
Precision Plus ProteinTM All Blue standards (Bio-rad, UK)                                                       
Precision Plus ProteinTM dual colour standards (Bio-rad, UK)                                        
Protein A Agarose beads (Invitrogen, UK)                                                                                    
Protein G Sepharose® beads, Fast Flow (Sigma-Aldrich, UK)                                                                                 
Purelink® HiPure Plasmid Filter Maxi-prep kit (Invitrogen, UK)                              
Puromycin (Sigma-Aldrich, UK)                                                                                                  
REDTaq® ReadyMixTM PCR Reaction Mix (Sigma-Aldrich, UK)                                      
Rhodamine Phalloidin (ThermoFisher  Scientific, USA)                                                         
RNeasy® Mini Kit (Qiagen, Germany)                                                                                       
Roswell Park Memorial Institute (RPMI)-1640 medium (Sigma-Aldrich, UK)                               
Sodium Chloride (NaCl) (Sigma-Aldrich, UK)                                                                                     
Sodium dodecyl sulphate (SDS) (Sigma-Aldrich, UK)                                                           
Sodium deoxycholate (Sigma-Aldrich, UK)                                                                           
Sodium fluoride (NaF) (Alfa Aesar, UK)                                                                                   
Sodium hydroxide (NaOH) (Sigma-Aldrich, UK)                                                                          
Sodium orthovanadate (Na3VO4) (New England Biolabs, UK)                                                            
SuperScript® VILOTM  cDNA Synthesis Kit  (ThermoFisher  Scientific, USA)                            
Tetramethylethylenediamine (TEMED) (Sigma-Aldrich, UK)                                                        
Tris-base (Sigma-Aldrich, UK)                                                                                                  
Triton X-100 (VWR International, UK)                                                                                
Tween® 20 (VWR International, UK)                                                                                       
Type I rat tail collagen (Corning, USA)    
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2.1.2 Buffers  
Blocking solution: 5% w/v milk powder or 5% w/v BSA in Tris buffered saline (TBS)-
Tween 
GFP-Trap wash/dilution buffer: 10 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA.  
GFP-Trap Lysis buffer: 10 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40 
Gel Sample buffer (2x): 100 mM Tris-HCl pH 6.8, 4% w/v SDS, 20% v/v glycerol, 2% β-
mercaptoethanol, 0.2% w/v bromophenol blue.              
Gel Sample buffer (6x): 375 mM Tris-HCl pH 6.8, 10% w/v SDS, 30% v/v glycerol, 6% β-
mercaptoethanol, 0.2% w/v bromophenol blue.              
Mild stripping buffer: 25 mM Glycine pH 2, 1% w/v SDS 
Palmitoylation buffer 1: 1 M hydroxylamine, 50 mM Tris, 150 mM NaCl, 5 mM EDTA, 
0.2% Triton X-100, pH 7.4 
Palmitoylation buffer 2: 4 µM BMCC-Biotin, 50 mM Tris, 150 mM NaCl, 5 mM EDTA, 
0.2% Triton X-100, pH 6.2 
Protease inhibitor cocktail: 1 mM DTT, 10 µg/ml leupeptin, 1 µg/ml aprotinin, 10 mM 
PMSF, 10 mM NaF, 1 mM Na3VO4        
RIPA buffer: 20 mM Tris-HCl  pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% v/v Triton X-100, 
0.5% w/v SDS, 1%  w/v sodium deoxycholate  
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) running buffer 
(10x): 250 mM Tris-base, 1.92 M Glycine, 1% w/v SDS. Dilute to 1 x with distilled water 
for use  
 SDS-PAGE transfer buffer (10x): 250 mM Tris-base, 1.92 M Glycine. Dilute to 1 x with 
distilled water and methanol (20 % v/v) for use  
(Tris acetate EDTA) TAE buffer: 40 mM Tris-HCl, 20mM acetate 10 mM EDTA in ddH20 
TBS-Tween (TBST): 25 mM Tris-HCl pH 7.6, 50 mM NaCl, 0.1% v/v Tween 20  
73 
 
  2.1.3 Plasmids  





pEGFP-N1 Kind gift from Professor 





pEGFP-N1 Kind gift from Professor 












pcDNA/4/TO Kind gift from Stephen 






pEGFP-C1 Bought  from Addgene (Alaa 
El-Husseini  Lab - Addgene 
plasmid # 20142) 
GFP-Cdc42 
(palmitoylated) 
pEGFP-C1 Bought from Addgene (Alaa 
El-Husseini Lab - Addgene 
plasmid # 20141) 
       Table 2.1 Constructs list  
 2.1.4 Primers      




Cdc42 prenylated Reverse 
 
tcatagcagcacacacctg 






β-actin Reverse ctccttaatgtcacgcacgat 
 
      Table 2.2 List of Primers 
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2.1.5 Antibodies list      


























































Mouse Roche - 1:1000 
HSP90 
 
Rabbit Santa-Cruz - 1:2500 
IgG mouse 
 
Mouse Santa-Cruz - 1:330 
IgG rabbit 
 















Rabbit Invitrogen - 1:1000 
Rac1 
 
Mouse Millipore - 1:1000 
RhoU 
 
Rabbit Abcam - 1:1000 
       Table 2.3 Primary antibodies 
 




Alexa Fluor®488  
anti-mouse 
 
Goat Invitrogen 1:400 - 
Alexa Fluor®488  
anti-rabbit 
 
Goat Invitrogen 1:400 - 
Alexa Fluor®647  
anti-mouse 
 













Goat DAKO - 1:2000 
Streptavidin-HRP  CalbioChem - 1:5000 








2.2 Methods – In Vitro Laboratory studies   
2.2.1 Cell lines and culture conditions 
Human prostate cancer cell lines PC3 (derived from a bone metastasis) and DU145 
(derived from a brain metastasis) were obtained from Claire Wells, King’s College 
London. Both cell lines were cultured in Roswell Park Memorial Institute-1640 (RPMI-
1640) media supplemented with 10% v/v fetal bovine serum (FBS) and 1 mM penicillin-
streptomycin. The primary human prostate cancer cell line 1542 (obtained from Claire 
Wells, King’s College London) was grown in keratinocyte serum-free media (KSFM) 
supplemented with 10% v/v FBS, 1 mM penicillin-streptomycin, 0.1 mg/ml bovine 
pituitary extract (BPE) and 5 ng/ml epidermal growth factor (EGF). The 1542 cell line 
was generated as part of a matched pairs set whereby cancerous and benign cells were 
excised from a radical prostatectomy, and then immortalised and cultured for in vitro 
use (Bright et al., 1997).  More specially, the 1542 malignant cell line was excised from 
a grossly apparent tumour nodule and then characterised to be of epithelial origin 
through cytokeratin immunostaining and cancerous through loss of heterozygosity 
analysis (Bright et al., 1997). HEK293 cells (ATCC) were maintained in Dulbecco’s 
modified Eagle’s media (DMEM) supplemented with 10% v/v FBS and 1 mM penicillin-
streptomycin.  PC3, DU145 and 1542 cells were sent to the Dana-Farber Cancer 
Institute, Harvard (Massimo Loda group), where Giorgia Zadra generated stable FASN 
knockdown in each of our cell lines. This was done using pLKO.1 lentiviral constructs 
containing two different shRNA sequences generated by the RNAi Consortium (shFASN 
A3- CATGGAGCGTATCTGTGAGAA, shFASN A4- CGAGAGCACCTTTGATGACAT). In 
addition, a complimentary control shRNA was also generated for each cell line (shRNA 
Control- ACAACAGCCACAACGTCTATA). All stably supressed and control shRNA cell 
lines were grown in the same media as their respective wild-type non-infected cell line 
counterpart with the addition of 1 µg/ml puromycin added to the media. All cell lines 
were cultured at 37°C in a tissue culture incubator with humidified air and CO2 levels at 
5% typical atmospheric levels. The passaging of cells occurred once they reached 
above sub-confluent levels.  During cell passaging the growth medium was removed 
from the flasks and the cells were washed once with 1x Phosphate Buffered Saline 
(PBS). Upon removal of PBS, trypsin/EDTA was added to the cells and then the flasks 
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were placed in the tissue culture incubator for 5-10 minutes. Once adherent cells were 
detached from the bottom of the flasks, the respective FBS supplemented media of 
each cell line was added to neutralise the trypsin. Cells were then pelleted by 
centrifugation at 1200 rpm for 5 minutes. Once complete, the supernatant was 
carefully removed and the pellets were resuspended in their respective media and split 
to a desired volume. Flasks were filled up with the appropriate volume of media and 
then placed back into the tissue culture incubator.  
                                                                                                                                                               
2.2.2 Acid treatment of coverslips  
13 mm diameter round glass coverslips were placed in a beaker overnight containing a 
4:6 solution mix of 1 M hydrochloric acid (HCl) and ethanol respectively. The following 
day the solution mix was dispensed gently avoiding any loss of coverslips and then the 
beaker was filled with 100 ml dH2O. The dH2O was brought to boil and then dispensed. 
After this the coverslips were washed six times with dH2O and then coverslips were 
placed on whatman paper and left to dry. The coverslips were then placed into a 50 ml 
glass bottle and autoclaved for complete sterilisation.  
                                                                                                                                                                 
2.2.3 Matrix coating of coverslips or wells 
Matrix components Matrigel and type I rat tail Collagen were diluted to a final 
concentration of 10 µg/ml. Matrigel was diluted in 1x PBS, whilst type I Collagen was 
diluted in filter sterilised dH2O with 0.02 M glacial acetic acid. Working concentrations 
of the matrices were then added to wells with, or without coverslips and then placed 
in the 4°C coldroom overnight. Before use, wells and coverslips would be washed twice 
with 1x PBS.  
                                                                                                                                                           
2.2.4 Transient transfections 
           Calcium phosphate transfection 
The calcium phosphate transfection kit was used to transfect HEK293 cells. Cells were 
seeded at a density of 1x105/ml and then placed in the tissue culture incubator for 24 
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hours.  On the next day, media from the dishes was aspirated and replaced with fresh 
DMEM media. The transfection reaction was set up using the condition described in 
Table 2.5. 
10 cm tissue culture dish 2 cm tissue culture dish 
To tube A add: 
30 µl 2 M CaCl2                                                   
20 µg DNA                                      
Make volume up to 300 µl with 
sterile water 
 
To tube B add: 
Add 300 µl HEPES buffered saline  
To tube A add: 
6 µl 2 M CaCl2                                                   
4 µg DNA                                      
Make volume up to 60 µl with 
sterile water 
 
To tube B add: 
Add 60 µl HEPES buffered saline 
           Table 2.5 Calcium phosphate transfection reaction mix 
The contents of tube A were added to tube B and then the reaction mix was carefully 
aerated with gentle pipetting (Table 2.5). The transfection mix was then left at room 
temperature for 30 minutes. Once complexed, the mix was added to the cells in a 
dropwise fashion followed by a gentle gyration to evenly spread the mix. The dishes 
were incubated at 37°C overnight before replacing the medium with fresh medium. 
Then the dishes were left for a further 24 hours in the 37°C incubator before being 
harvested.  
           Fugene 6 and Viafect 
Cells were seeded at a density of 2x104/ml on coverslips, 5x104/ml in the well of a 6 
well plate, and 1x105/ml in a 10 cm dish. Cells were left to adhere for 24 hours at 37°C 
and then the medium in the plates were replaced with either fresh medium or 
optiMEM. The transfection mix was then prepared according to Table 2.6. 
Fugene 6 / Viafect 
2x104/ml – 5x104/ml 1x105/ml 
92-97 μl OptiMEM 
3-8  μl transfection reagent 
1-2 μg DNA 
470 μl OptiMEM 
30 μl transfection reagent 
10 μg DNA 
            Table 2.6 Fugene 6 and viafect transfection reaction mix 
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The transfection mixes were left to complex for 25 minutes (Fugene6) and 17 minutes 
(Viafect) at room temperature. Once complexed the transfection mixes were added in 
a dropwise fashion to the plates/dishes, gyrated and placed in the 37°C incubator for 
6-48 hours. If transfected in optiMEM for 6 hours media was replaced with fresh cell 
culture medium with 10% FBS and left to incubate for a further 24 hours. If 
transfecting in cell culture medium for 48 hours, media would be replaced with fresh 
growth medium after 24 hours.  
                                                                                                                                                            
2.2.5 Immunofluorescence   
Cells were seeded onto either glass or matrix-coated coverslips at a seeding density of 
2x104/ml and left to settle for 2 days. Cells were then fixed in 4% Paraformaldehyde 
(PFA) for 20 minutes at room temperature before washing three times with 1x PBS. If 
staining was performed at a later date then PFA was removed from wells and replaced 
with 1x PBS before placing the plates at 4°C in the fridge. After PBS washing, cells were 
permeabilised in 0.2% Triton X-100:PBS for 5 minutes. Coverslips were washed three 
times in 1x PBS and then blocked with 5% Milk:PBS followed by 3% BSA:PBS, or 3% 
BSA:PBS alone for 30 minutes. Coverslips were then incubated with a primary antibody 
diluted in 3% BSA:PBS for 2 hours in a dark humidified environment (Table 2.3). 
Coverslips were then washed three times with 1x PBS before being incubated with 
secondary antibodies (Table 2.4). Secondary antibodies were diluted in 3% BSA:PBS 
along with Rhodamine-Phalloidin and DAPI for 1 hour and 5 minutes in a dark 
humidified environment. After final incubation coverslips were washed twice with 1x 
PBS and then twice with ddH2O before mounting onto slides using FluorSave.  Slides 
were left in the dark overnight either on the bench or in the fridge at 4°C before 
visualising on the Olympus IX71 inverted time-lapse microscope.  
                                                                                                                                                            
2.2.6 2D Random migration assay and time-lapse microscopy   
Cells in full growth medium were seeded into matrix-coated wells of a 12 well plate at 
a cell density of 1x103/ml and placed in the 37° incubator overnight. The next day each 
well was washed twice with 1x PBS followed by the addition of serum starvation 
80 
 
media.  Plates were placed back in the 37° incubator for overnight serum starvation. 
Immediately prior to time-lapse acquisition, the media was supplemented with 20 
ng/ml Hepatocyte growth factor (HGF) and 20 mM HEPES before the plates were 
sealed with parafilm and placed on the 37°C heated stage of the Olympus IX71 
inverted time-lapse microscope.  If the experiment involved using FASN inhibitors, 
then cells were incubated with 30 µM Orlistat and 25 µM C75 for 24 hours and 1 hour 
respectively before adding HGF and starting the image acquisition. Images were 
captured at 5 minute intervals for 16 hours using a Retiga SRV CCD camera and 
collated using the Image-Pro Plus software.  After acquisition and extraction was 
complete, movie files were saved in AVI format and then imported into the open 
source software programme ImageJ.  Once open in ImageJ, the Manual Tracking plugin 
was booted up and point and click style tracking was performed.  Each click records the 
X and Y coordinates of a cell from one frame to the next. Typically, around 50-60 cells 
are tracked over at least three independent experiments per condition. These values 
are then saved and imported into Mathematica where post-tracking analysis is 
performed using the Chemotaxis 6.0 notebooks developed in-house by Graham Dunn 
and Gareth E. Jones. 
                                                                                                                                                                 
2.2.7 Western blotting    
           Cell lysis 
Cells were seeded into 6 or 12 well plates at a density of 1x105/ml (Full growth 
medium experiment) or 5x104/ml (stimulation experiment). For stimulation 
experiments, cells would be seeded in full growth medium and then serum starved for 
24 hours before stimulating with HGF for 15 minutes and lysing. For looking at the 
expression of proteins in normal growth conditions, cells were left for 24 hours and 
then lysed. Wells of plates were washed twice with 1x PBS before adding the 
appropriate volume of gel sample buffer (2x). Immediately cells were scraped and 
transferred into labelled eppendorf tubes. Lysates were then boiled for 5 minutes and 





Prostate tissue samples were kindly donated by Dr Jonathan Morris and were taken 
from patients who underwent a prostate biopsy. Three of the samples are from 
patients who tested positive for BPH (G36, G40 and H5) and four of the samples are 
from patients who tested positive for prostate cancer (F2, F4, D4 and F16). The 
samples required no ethical permission to use as they were obtained before the 
human tissue act (2004) came into action. Each prostate sample was placed into the 
well of a 4 well plate containing RIPA buffer (3 μl per mg) and then incubated on ice for 
20 minutes. A scalpel was used to dice and shear the samples into smaller sections. 
Samples were then placed into eppendorf tubes and vortexed briefly before being 
subjected to high pulse centrifuging for 3 minutes at 4°C. Each tube then had an 
additional 200 μl of RIPA buffer added before attempting to homogenize with a syringe 
and needle. Complete homogenisation of tissue was not successful; however the liquid 
sample from each tube was drawn up and placed into fresh eppendorf tubes. The 
Bradford assay was used to confirm protein was extracted from each tissue sample. 
Following this the appropriate volume of 6 x gel sample buffer (to make 1 x) was added 
and then all the samples were boiled for 5 minutes at 95°C before placing them in the -
80°C freezer.  
             Gel electrophoresis and immunoblotting 
Lysates were thawed and then boiled (usually up to a minute) before running. Equal 
amounts of each sample were loaded (protein concentration was not measured) and 
proteins were separated by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) on 6.5%-12.5% gels.  Proteins were then electroblotted 
onto nitrocellulose membrane for 1-2 hours at 100 volts.  Membranes were blocked in 
Tris-buffered saline with Tween20 (TBST) containing 5% w/v non-fat milk powder, or 
5% w/v BSA for 1 hour at room temperature. Blots were then incubated on a roller 
overnight at 4°C in primary antibody diluted in either 5% Milk:TBST or 5% BSA:TBST 
(Table 2.3).  Any unbound primary antibody was removed from the blots by washing 
them three times for 15 minutes in TBST. Membranes were incubated on a roller for 1 
hour and 30 minutes in either 5% Milk:TBST or 5% BSA:TBST with the appropriate 
horseradish peroxidase conjugated secondary antibody (Table 2.4).  Membranes were 
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washed a further three times in TBST to remove any unbound secondary antibody and 
then proteins were detected using ECL or ECL prime detection kits.  
            Stripping of nitrocellulose membrane 
In some cases membranes were re-probed to visualise proteins that could not be 
probed for the first time round. In this case, membranes were incubated with constant 
agitation in stripping buffer twice for 15 minutes at room temperature. Stripping 
buffer was then removed and replaced with 1x PBS for a brief 5 minute wash before 
blocking and re-probing with a primary antibody as previously stated.  
          Densitometry  
Scanned and digitized autoradiographs were opened into imageJ and converted into 8-
bit images. Then densitometric analysis of protein bands was carried out by measuring 
the band densities. This was done by drawing a rectangular box of the same size 
around the desired bands and then using the measuring tool to measure the mean 
grey value within the box.  Band densities of the proteins of interest were normalised 
to the band densities of a loading control. Once adjusted, these values were converted 
to a mean fold value relative to one condition.  
 
2.2.8 Immunoprecipitation     
         General antibody Immunoprecipitation  
Wells and dishes were washed twice with 1x PBS and then lysed in GFP-Trap lysis 
buffer supplemented with protease inhibitors (1 mM DTT, 10 µg/ml leupeptin, 1 µg/ml 
aprotinin, 10 mM PMSF, 10 mM NaF, 1 mM Na3VO4)  for 10 minutes on ice. Cells were 
thoroughly scraped and transferred into eppendorf tubes prior to centrifugation of the 
lysates at 13,000 x g for 10 minutes at 4°C.  During this time protein A/G beads were 
washed in GFP-Trap wash buffer three times. Supernatant from the eppendorf’s was 
transferred into eppendorf tubes containing protein A/G beads and the sample was 
left to pre-clear for 1 hour at 4°C whilst spinning.  A small amount of sample is kept 
back for the input and pipetted into a fresh eppendorf’s. An equal volume of gel 
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sample buffer (2x) is added to the lysate and the sample is boiled for 3 minutes before 
placing in -20°C.  After pre-clear is complete eppendorf tubes are centrifuged at     
2,500 x g to separate the beads from the lysate. The lysate is then pipetted into a fresh 
eppendorf tube and incubated with a primary antibody (either 3 µl or 1 µg) for either 3 
hours or overnight (Table 2.3). Fresh protein A/G beads are washed three times with 
GFP-Trap wash buffer and then mixed with the lysates for 1-2 hours at 4°C whilst 
spinning. The bead bound immune complexes were spun down at 2,500 x g and 
washed five times in GFP-Trap wash buffer before resuspending in 2x gel sample buffer 
and boiling for 5 minutes.  
           GFP Trap 
Medium was removed from wells or dishes and replaced with ice cold 1x PBS before 
scrapping cells into eppendorf tubes. Eppendorf tubes were centrifuged at 300 xg for 3 
minutes at 4°C. The resulting pellet was washed by resuspension in ice cold 1x PBS and 
centrifuged a further two times. Cell pellets were then resuspended in GFP-Trap lysis 
buffer (containing protease inhibitors) and kept on ice for 30 minutes with vigorous 
pipetting every 10 minutes. In the case of 1542 cells, lysis was carried out similar to 
that in the general immunoprecipitation procedure with the exception that once cell 
debris was scraped into eppendorf tubes they were left to lyse on ice for a further 20 
minutes. Lysates were centrifuged at 20,000 x g for 10 minutes at 4°C. During this time 
GFP-Trap beads were equilibrated by washing then three times with GFP-Trap wash 
buffer.  Lysates were then mixed with GFP-Trap beads and left to rotate for 1 hour at 
4°C. As with above, a small sample of lysate was kept to be used as the input readout. 
Lysates were centrifuged at 2,500 x g and the protein complexed GFP-Trap beads were 
washed a further 3-5 times with GFP-Trap lysis buffer. Gel samples buffer (2x) was 
added to the beads and boiled for 5-10 minutes. 
                                                                                                                                                            
2.2.9 Palmitoylation assay     
This assay was carried out to look at the palmitoylation of overexpressed and 
endogenous proteins. Cells seeded into plates or dishes were serum starved for 24 
hours before carrying out the assay. An immunoprecipitation was performed as 
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described above to capture the protein of interest. The beads were then incubated 
with 20-50 mM N-Ethylmaleimide (NEM) for 2 hours or overnight at 4°C. Beads were 
then washed three time with GFP-Trap wash buffer to remove excess NEM and then 
incubated in Palmitoylation buffer 1  (1 M hydroxylamine, 50 mM Tris, 150 mM NaCl, 5 
mM EDTA, 0.2% Triton X-100, pH 7.4) for 1-2 hours at room temperature on a shaker.  
Control samples were incubated in Palmitoylation buffer 1 without hydroxylamine 
leaving palmitoylated residues unmodified. Palmitoylation buffer 1 was then removed 
from beads by centrifugation at 2,500 x g and replaced with Palmitoylation buffer 2  (4 
µM BMCC-Biotin, 50 mM Tris, 150 mM NaCl, 5 mM EDTA, 0.2% Triton X-100, pH 6.2) 
for 1-2 hours at room temperature on a shaker. Following incubation beads were 
washed three times with GFP-Trap wash buffer to remove excess biotin and then 
resuspended in gel sample buffer 2x and boiled for 3 minutes before storing them at -
20°C. 
 
2.2.10 MTT Proliferation and adhesion assay 
             Adhesion  
Cells were seeded into plastic or matrix-coated 96 well plates at a cell density of 1x104 
in serum free media and placed in the 37°C incubator for 1 hour.  Each well was 
washed twice with 1x PBS before adding Thiazolyl Blue Tetrazolium Bromide (MTT) 
diluted in serum free media (500 µg/ml) to each well and placing the plates in the 37°C 
incubator for 3 hours. MTT media was removed from the wells and the converted dye 
was then solubilized for 10 minutes using DMSO. The absorbance of the samples was 
measured at 540 nm using the alpha fusion plate reader.  
            Proliferation  
Cells were seeded into plastic or matrix-coated 96 well plates at a cell density of 5x102 
in full growth medium and then placed in the 37°C incubator for 7 days.  At day 1, 3, 5 
and 7 plates were taken from the incubator and MTT was added to the wells in the 
same fashion described in the adhesion protocol with no deviations. It should be noted 
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that MTT is reduced metabolically by dehydrogenase enzymes and so proliferation is 
reflective of the metabolic activity of the cells being tested (Mosmann, 1983). 
                                                                                                                                                                    
2.2.11 Inverted Invasion assay 
Cells were passaged to a density of 4x105/ml and then centrifuged in an eppendorf 
tube at 1200 rpm for 5 minutes. During this time the collagen mixture was prepared on 
ice (Table 2.7). 
 1.5 mg/ml gel (1ml) 
dH2O 350 µl 
5x DMEM 200 µl 
1M NaOH 7.52 µl 
Collagen (3.39 mg) 442.47 µl 
                   Table 2.7 Collagen matrix mix for inverted invasion assay 
The collagen mixture was mixed thoroughly, but gently. Supernatant from the 
eppendorf tubes was removed and then the collagen mixture was added to the tubes 
resuspending the cell pellets. A 96 well plate was placed on ice and to each well 100 µl 
collagen: cell mix was added. The 96 well plate was centrifuged at 600 xg for 6 minutes 
at 4°C forcing the suspended cells to move to the bottom of the plate. After checking 
on the microscope that the cells were on an even field, the plate was placed in the 
37°C incubator. After 2 hours the plate was removed and 100 µl of medium + 10% FBS 
was pipetted into the top of each well and the plate was placed back in the 37°C 
incubator for a further 24 hours. After 24 hours 100 µl 8% formaldehyde containing            
1 µl Hoechst stain was pipetted into each well and then the plate was left at 4°C 
overnight with continuous shaking.  
The plates were imaged on the A1R confocal microscope where a series of z-stacked 
images were taken. From this analysis was done in the open access programme Fuji 
which involved comparing the invasion of cells at 50 microns relative to the bottom. 
Thresholding and particle analysis of cells was performed on both planes allowing for 
the relative % of Invasion to be calculated.  
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2.2.12 High Resolution-Magic Angle Spinning Nuclear Magnetic Resonance 
ssssss (MAS-NMR) sample preparation  
Cells were seeded into 10 cm dishes at a cell density of 1x105/ml and left to grow to 
80% confluency. Nine plates were seeded per condition. Medium in the dishes was 
replaced with fresh medium +10% FBS one and a half days before harvesting. Media 
was removed from plates with 1 ml from each plate being centrifuged at 1200 rpm to 
remove any cellular debris and then pipetted into fresh eppendorf tubes. Plates were 
washed once with ice cold 1x PBS +Ca +Mg. For moderately adherent cell lines PC3 and 
DU145, 6 ml of 1x PBS +Ca +Mg was added to each plate and the cells were scraped 
and transferred into 15 ml Falcon tubes. For the highly adherent 1542 cell line 6 ml of 
cell dissociation buffer was added to each plate before placing them in the 37°C 
incubator for 20-30 minutes before scrapping and transferring into 15 ml Falcons 
tubes.  15 ml Falcon tubes were centrifuged at 1000 rpm for 4 minutes. Supernatant 
from the 15 ml Falcon tubes was discarded and cell pellets were re-suspended in 500 
µl 1x PBS +Ca +Mg, transferred into eppendorf tubes and centrifuged at 200 x g for 5 
minutes at 4°C. Supernatant from the eppendorf tubes was aspirated and then cell 
pellets and eppendorf tubes containing the 1 ml of media were snap frozen by 
immersion in liquid nitrogen for 3 minutes.  Samples were then stored at -80°C or 
lyophilized overnight and stored at -20°C.   
Samples were then sent for analysis to Tokuwa Kanno, a PhD student working in Dr 
Jason Mason’s Lab group at King’s College London. For the cell pellets high resolution-
magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectra was 
recorded on the Bruker Avance 400 MHz spectrometer. For media (liquid state NMR), 
spectra were acquired on a Bruker Avance II 700 MHz NMR spectrometer.  
 
2.2.13 Palmitate-BSA conjugate and cell treatment 
Sodium palmitate (13.9 mg) was dissolved in 1 ml 50% v/v ethanol to make a 50 mM 
stock. Eppendorf tubes were placed in a heat pad and left for around 20-30 minutes at 
70°C. Once the sodium palmitate had dissolved, the solution was diluted 1:10 to give a 
concentration of 5 mM sodium palmitate in 1 ml 50% v/v ethanol. Fatty acid free-BSA 
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(250 mg) was dissolved in 5 ml MilliQH20 and then 4 volumes of 5% fatty acid free-BSA 
was mixed with 1 volume of 5 mM Palmitate. The mixture was placed in a 37°C water 
bath and left to conjugate for 1 hour forming a 1 mM palmitate-BSA complex. Aliquots 
were stored at - 20°C.  Before using in cell culture, aliquots were defrosted on ice and 
then allowed to activate at 55°C for at least 15 minutes. Palmitate was used at a 
concentration of 50 µM in all experiments and incubated with cells for 1 hour.  This 
time-point was chosen based on the observation of a time-lapse video which showed 
the cells morphology recovering at this point. Fatty acid free-BSA was used as a control 
and added to the cells of a different well at the same concentration for the same 
amount of time as cells incubated with palmitate.  
 
2.2.14 Silencing of RhoU in prostate cancer cells  
1542 cells were seeded to a density of 1x105/ml in 6-well plates. Cells were reverse 
transfected with either control siRNA (sequence – AATTCTCCGAACGTGTCACGT) 
purchased from Qiagen or the RhoU SMARTpool siRNA (sequence 1- 
GTACTGCTGTTTCGTATGA, sequence 2- GAACGTCAGTGAGAAATGG, sequence 3- 
CAGAGAAGATGTCAAAGTC, sequence 4- AAGCAGGACTCCAGATAAA) purchased from 
Dharmacon. Control siRNA (50 nM) and RhoU SMARTpool siRNA (50 nM) were added 
to 500 μl Optim-Mem and 7.5 μl RNAiMAX before being gently mixed and pipetted in 
their respective wells for 30 minutes at room temperature. Plates were then placed in 
the 37°C incubator for 72 hours before the cells were lysed as normal.  
 
 2.2.15 Blocking palmitoylation with 2BP in prostate cancer cells 
1542 cells were seeded to a density of 1x105/ml in 6-well plates and left for 24 hours in 
the 37°C incubator. The following day 2 μl of either DMSO or 2 μl of 2-bromopalmitate 
(2BP) 100 μM dissolved in DMSO was added to the cells of individual wells. Plates were 
placed back in the 37°C incubator for 24 hours before the cells were lysed as normal. 
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 2.2.16 Cell storage and recovery  
Cell lines were frozen down at the earliest possible passage to preserve their 
phenotypic nature.  Cells were grown to near full confluency and then passaged as 
normal. After centrifugation pellets were resuspended in 90% FBS and 10% DMSO, 
pipetted in cryogenic vials, and then left to steadily freeze in a Mr Frosty at -80°C 
overnight. Cyrogenic vials were then permanently placed in liquid nitrogen storage 
until needed for cell culture. For the recovery of cells, cryogenic vials were placed in a 
30°C water bath until thawed and then mixed 1:1 with full growth medium before 
adding 4 ml of full growth medium, centrifuging, and adding the resuspended cells in 
growth medium into a flask.  Medium was generally changed the next day.       
                                                                                                                                                        
2.2.17 Transformation of Escherichia coli cells  
DH5α and NEB®-10 beta E.coli cells were thawed on ice for 10 minutes. 1 µl of plasmid 
DNA was then added to the bacteria, without mixing, and then left on ice for 30 
minutes. Cells were then heat shocked by placing tubes in a 42°C water bath for 30 
seconds and then back on ice immediately for 2 minutes. 500 µl LB-broth was added to 
the transformed bacteria and incubated in a shaking incubator at 37°C for 1 hour. The 
transformed bacteria were plated onto LB-agar plates containing the appropriate 
antibiotic and incubated at 37°C overnight.  
                                                                                                                                                           
2.2.18 DNA plasmid purification   
Plasmid DNA was isolated and purified from overnight grown transformed E.coli 
bacteria using the Invitrogen Purelink® HiPure Plasmid Filter Maxi-prep kit.  The 
procedure was carried out according to the manufacturers recommended protocol. 
The resulting purified DNA was resuspended in TE buffer and stored at -20°C.   
                                                                                                                                                      
2.2.19 RNA extraction and purification    
Cells were seeded into 6 well plates at a cell density of 5x105/ml and then placed in the 
37°C incubator overnight. Media was removed and wells were washed once with 1x 
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PBS. RNA was then extracted and purified from the cells according to the 
manufacturer’s instructions using the Qiagen RNeasy® Mini Kit. RNA was resuspended 
in nuclease-free water and stored long term at -80°C.  
 
2.2.20 cDNA synthesis     
RNA was converted into DNA using the Vilo cDNA synthesis kit purchased from Sigma. 
RNA concentration and purity was measured using the Nanodrop and then 1 µg of RNA 
was converted into 1 µg of DNA using the reaction mixture in Table 2.8. Once gently 
mixed, the reaction was initiated by incubating the PCR tubes at 25°C for 10 minutes, 
followed by 1 hour incubation at 42°C, and then finally the reaction was terminated 
following a 5 minute incubation at 85°C.  The resulting DNA product was stored at -
20°C.  
Component  Volume/conc. 
5x Vilo reaction mix 4 µl 
10x SuperScript Enzyme mix 2 µl 
RNA 1 µg 
DEPC-treated water Up to 20 µl 
 
 
2.2.21 Polymerase Chain Reaction (PCR)  
PCR was carried out as a diagnostic tool using the REDTaq® ReadyMixTM PCR Reaction 
Mix. Sterile PCR tubes comprised the following reaction mix of 25 µl RedTaq ready mix 
(with Magnesium), 0.5 µM forward and reverse primers and 100 ng cDNA. The 
reaction volume was then made up to 50 µl with nuclease-free water. The PCR tubes 
were gently flicked, briefly centrifuged, and then placed in the PCR thermal cycler to 
undergo conditions described in Table 2.9. Samples were stored at -20°C 
 
 
Table 2.8 RNA to cDNA reaction mix 
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Number of cycles Process Temperature Time 
1 Pre-incubation 95°C 5 minutes 
30-35 Denaturation 94°C 1 minute 
Annealing 55°C 1 minute 
Extension 72°C 1 minute 
1 Final extension 72°C 10 minutes 
Table 2.9 Conditions for PCR amplification 
 
2.2.22 DNA Gel Electrophoresis   
Electrophoresis gels consisted of Tris-acetate-EDTA (TAE) buffer containing 1-2% 
agarose and ethidium bromide (1:10,000). Once the gels had set they were covered 
with 1x TAE buffer and 20 µl of PCR amplification sample was loaded, alongside a DNA 
marker into the wells. The DNA fragments migrated through the gel at 100V for 1-2 
hours before being visualised under ultraviolet (UV) light.  
 
2.2.23 Statistical analysis    
An unpaired Students t-test and a one-way ANOVA (analysis of variance) Tukey test 
was used to measure statistical significance. In addition, statistical significance, in 
terms of difference between cell line growth rates, was assessed using the 
‘compareGrowthCurves’ function of the statmod software package of R 
(http://bioinf.wehi.edu.au/software/compareCurves).  This software performs a mean 
t-statistic between two groups of growth curves which gives a P-value from a 1000 
permutations.  The initial P-values were then adjusted for multiple testing between 
groups using the Holm’s method (Baldwin et al., 2007). A P-value of ≤0.05 (95% 
confidence interval) was used to consider statistical significance and would be indicted 
by a *. Increased significance was recorded at P-values ≤0.01 (99% confidence interval) 
**, and ≤0.001 (99.9% confidence interval) ***. Statistical packages used to calculate 
significance include IBM SPSS (statistical package for the social sciences), Statmod, 




2.3 Methods – Pilot patho-epidemiological study    
This pilot patho-epidemiological study was performed in collaboration with Professor 
Lars Holmberg, previous Director of the Regional Cancer Centre Uppsala Örebro and 
Professor at the department of Surgical Sciences, Uppsala University, Uppsala, 
Sweden. The staining and preparation was kindly funded by Professor Lars Holmberg 
using his Grant from the Swedish Cancer Society.  
2.3.1 Cohort and tissue microarray (TMA) preparation 
The cohort consists of 85 patients who underwent a radical prostatectomy. All samples 
were collected retrospectively at the UCAN biobank in Uppsala, Sweden and were 
histologically assessed by the pathologists Dr Anna Tolf and Dr Anca Dragomir 
(Uppsalsa University).  Cores from the tissue samples were isolated to pertain to the 
dominant Gleason (DG), Highest Gleason (HG) and benign tissue. The dominant 
Gleason corresponds to the most widespread Gleason grade patterns of the core, 
whilst the highest Gleason corresponds to an area of the core with the most poorly 
differentiated tissue and thus the worst Gleason grades.  The Gleason grading system 
for radical prostatectomy specimens was in accordance with the WHO classification of 
Tumours of the Urinary system, 2004. These cores were embedded on four separate 
tissue microarray’s (TMA).  Overall preparation of the TMA’s was overlooked by 
Professor Fredrik Pontén and Professor Michael Häggman.  
 
2.3.2 Staining and scoring of TMA’s  
TMA’s were immunohistochemically stained by Dr Per-Henrik Edqvist (project 
coordinator, Uppsala University) for the proteins FASN, RhoU, Cdc42, c-Met, HER2 and 
Ki67 (Table 2.10).  The overall staining intensity for the proteins FASN, RhoU and Cdc42 
was assessed and scored by myself and confirmed by Dr Ashish Chandra, a lead 
pathologist for Uro-Oncology at Guy’s and St Thomas’ Hospital.  Cdc42 staining was 
also confirmed by Dr Kiruthikah Thillai, a specialist registrar in Medical Oncology at 
Guy’s and St Thomas’ Hospital. Whilst the staining for c-Met and HER2 was assessed 
and scored by Dr Michelangelo Fiorentino and Dr Francesca Giunchi, two molecular 
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pathologists from the University of Bologna. FASN and RhoU were scored into 
categories of one to four, which correlated with a staining intensity that increased with 
each order of magnitude ranging from low to high. These categories were then 
dichotomised as negative/low staining intensity (categories one and two), and high 
staining (categories three and four). Cdc42 staining intensity was scored into three 
categories, which were then also dichotomised as categories one and two versus 
category three.  c-Met and HER2 staining was dichotomised upfront into medium/low 
and high. For Ki67 a percentage score was given (scored by Dr Michelangelo Fiorentino 
and Dr Francesca Giunchi), which was defined by the percentage of positively stained 
cells among the entirety of the core.  It was assessed as a dichotomous variable with a 
≤5% cut-off point, consistent with past studies (Fisher et al., 2013).  









2.3.3 Statistical analysis for Epi-study 
First, a univariate logistic regression model was conducted to identify how tissue type 
(exposure variable defined as DG, HG, or benign tissue) was associated with increased 
levels of  FASN , RhoU, Cdc42, c-Met and HER2 (outcome variables defined as 
dichotomous measurements).  Next, a univariate and multivariable logistic regression 
model was conducted to assess how the expression of FASN, RhoU, Cdc42, c-Met and 
HER2 (exposure variables) was associated with increased levels of Ki67 expression 
(outcome variable defined as a dichotomous measurement).  
All tissue staining analysis were conducted with Statistical Analysis Systems (SAS) 
release 9.4 (SAS Institute, Cary, NC).  
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Chapter 3 – Metabolomic and morphological characterisation of FASN 
sssssssssssssdepleted prostate cancer cell lines 
3.1 Introduction  
Prostate cancer is a highly prevalent disease that is difficult to accurately diagnose and 
treat as a result of its multifactorial development (Nwosu et al., 2001). There is 
currently a growing body of literature recognising altered lipid metabolism as a 
common feature in the pathogenesis of prostate cancer (Zadra et al., 2013). It is widely 
recognised that transcriptional upregulation of the metabolic oncogene FASN is 
responsible for the exacerbated lipogenesis in cancer (Swinnen et al., 2002).  These 
lipids form a complex signalling network which has been described to have a 
pleiotropic role in cancer (Zadra et al., 2013).  
In normal cells, FASN is tightly regulated and primarily only synthesises fatty acids for 
storage which are oxidised for energy when dietary nutrients are low (Kuhajda, 2006).   
In contrast to normal cells, the majority of cancers, including prostate, have a high 
growth rate which means a controlled and expendable energy source is required to 
sustain this action. Metabolically, cancer cells fulfil this requirement by high-jacking 
FASN to continuously synthesize fatty acids de novo (Kuhajda, 2006). Overexpression 
of FASN increases the synthesis of phospholipids which are one of the main building 
blocks of the cell membrane (Swinnen et al., 2003). Additionally, FASN overexpression 
affects the lipid composition of the membrane creating platforms for the assembly of 
signal transduction pathways involved in cell proliferation (Head et al., 2014). The 
importance of FASN in cell division has been well documented and several studies have 
shown that inhibiting its activity alone is enough to halt cell division (Horiguchi et al., 
2008).    
More recently there has been a shift in focussing on a potential role for FASN in the 
metastatic progression of cancer cells (Jiang et al., 2014).  A characteristic phenotype 
of many metastatic cancer cells is the divergence in cell shape from their parental cells 
(Lyons et al., 2016). Changes in cell shape are largely dictated by the underlying 
cytoskeleton which provides the structural framework for the cell (Lyons et al., 2016). 
A few studies have observed changes in cell shape in response to altering FASN levels, 
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however for the majority of cancers it has not been documented (De Schrijver et al., 
2003; Sadowski et al., 2014).  Given that lipid enrichment of the plasma membrane and 
lipid raft formation are known to cause reorganisation of the actin cytoskeleton, it 
would be presumptive that FASN overexpression and activity is accompanied by 
changes in cellular morphology (Head et al., 2014).  
The majority of studies carried out in prostate cancer looking at the role of FASN 
revolve around prostate cancer cells which are AR-dependent. This is not surprising as 
stimulating cells with androgens significantly increases FASN expression (Menendez 
and Lupu, 2004). More recently it has been found that after the transition from AR-
dependent to AR-independent, FASN expression levels increase (Pizer et al., 2001). 
Little is known about the role of FASN in castration resistant prostate cancer cell lines 
such as PC3. However, since prostate cancer cells seem to be more dependent on 
FASN-catalysed fatty acid biosynthesis compared to exogenous lipids it would suggest 
that FASN is a viable target in the more aggressive forms of prostate cancer 
(Menendez and Lupu, 2004; Pizer et al., 2001).  
This first chapter characterises the proliferative, metabolic and morphological 
properties of two AR-independent prostate cancer cell lines against their respective 













3.2.1 FASN is expressed in multiple cancers of differing origin 
Initially detectable levels of FASN expression were monitored to confirm previous 
reports of its expression in cancer.  Cell lines derived from human embryonic kidney 
(HEK293), prostate cancer (1542, PC3 and DU145), pancreatic cancer (PATU-T and 
PATU-8902), breast cancer (MDA-MB-231), normal breast (MCF10A) and melanoma 
cancer (A375) were used in the panel to probe for FASN expression. All the prostate 
cell lines are androgen depletion-independent (ADI) meaning they do not express the 
AR or respond to androgens (Litvinov et al., 2006). This makes them suitable lines for 
studying the role of FASN in what is considered an aggressive and incurable form of 
prostate cancer (Jeong et al., 2011).  In addition, all the prostate cell lines have been 
shown to be highly migratory from studies in the literature or from work previously 
conducted in the Wells lab (Reymond et al., 2012; Wells et al., 2010).  The pancreatic 
cancer cell lines used in this panel both express a mutant K-Ras isoform which has 
been speculated to increase the dependency of tumour cells on de novo lipogenesis 
(Hamidi et al., 2014; Ventura et al., 2015).   MDA-MB-231 is a highly invasive triple 
negative breast cancer cell line, whilst MCF10A is a non-invasive normal human breast 
epithelial cell line (Nagaraja et al., 2006). The inclusion of these two lines in the panel 
is useful in determining if FASN is only expressed in cancer and if it correlates with 
invasiveness. In melanoma cancer there is evidence suggesting that FASN is useful 
prognostic marker and that its increased expression correlates with an aggressive form 
of this disease which is why the A375 cell line was included (Innocenzi et al., 2003). The 
HEK293 cell line was also used in this panel as it is a highly proliferative cell line and so 
it would be interesting to confirm if this phenotype correlates with high levels of FASN 
expression. Western blot analysis revealed that all the cell lines included in the panel 
express FASN and that there was no significant difference in FASN expression between 
cell lines of the same cancer origin, or of a different cancer origin (Figure 3.1). 
Moreover, the non-cancerous breast cell line MCF10A and the adenovirus transformed 
kidney cell line HEK293 expressed FASN to similar levels as the cancerous cell lines 


































Figure 3.1 FASN is expressed in multiple cancer cell lines: The panel of 
different cancer cell lines were immunoblotted for FASN and the loading 
control HSP90 (A) which was then quantified via densitometry analysis.  
Data represents the mean values ± SEM accumulated from three 
independent experiments.   
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3.2.2 FASN expression increases in malignant prostate cancer 
To compliment the expression profile of FASN in characterised cell lines a set of human 
primary prostate tissue samples taken from surgical biopsies were also evaluated for 
FASN expression (Figure 3.2). The panel consists of three samples that were classified 
as benign non-cancerous prostatic growths (G36, G40 and H5), and four that were 
classified as malignant tumours (F2, F4, D4 and F16). Details of the histopathological 
assessment of these specimens can be seen in Figure 3.2A. To be certain of a 
difference between malignant and benign prostate tissue, the expression level of FASN 
in all malignant samples was stratified against the benign tissue sample H5, which was 
found to have highest expression level of FASN (Figure 3.2B).  The expression of FASN 
was significantly higher in all malignant tumour samples compared to the benign 
sample H5 (Figure 3.2C). Additionally, D4, which was histopathologically the most 
malignant sample, had the highest level of FASN expression compared to all other 














































Figure 3.2 Expression of FASN in human primary prostate cancer tissue: 
Human primary prostate tissue was excised by surgical biopsy from seven 
different patients. Histopathological analysis on the samples was performed 
and documented (A). Exact histopathological data for sample F2 is missing, but 
was confirmed as a malignant sample. Whole cell lysates were prepared from 
the samples which were then tested for FASN expression levels via SDS-PAGE 
gel electrophoresis (B). Densitometry analysis was performed and relative 
quantification of FASN levels can be seen in (C). HSP90 was used as a loading 
control. Data represents the mean values ± SEM accumulated from three 
independent experiments.  Statistical significance was determined by student’s 




Patient No. Benign (%) Malignant (%) 
G36 100 0 
G40 100 0 
H5 100 0 
   
F2 - - 
F4 80 20 
D4 10 90 




3.2.3 FASN knockdown in 1542, PC3 and DU145 prostate cancer cell lines 
Having confirmed that FASN is expressed in the 1542, PC3 and DU145 prostate cancer 
cell lines, and that it is expressed at high levels in malignant tissue, it was decided to 
investigate if depleting FASN in these cells effects migratory capacity. All three 
prostate cancer cell lines are AR-independent and were excised from different sites in 
the body.  The 1542 cell line, which is considered to be a slightly unusual cell type, was 
derived from a primary adenocarcinoma (Gleason score 8) that was resected from a 
48-year old male patient (Bright et al., 1997; Topalian et al., 2006). PC3 cells were 
isolated from a lumbar metastasis of a 62-year old Caucasian male (Kaighn et al., 
1979). They have been classically referred to as an adenocarcinoma of the prostate, 
however more recent evidence suggests they have features that are characteristic of 
prostatic small cell neuroendocrine carcinoma’s (Tai et al., 2011).  DU145 is a prostate 
adenocarcinoma cell line that was isolated from the dura mater of a 69-year old 
Caucasian male and unlike PC3 and 1542 cells is characteristically colony forming 
(Stone et al., 1978). All cell lines were sent to the Dana-Farber Cancer Institute, 
Harvard (Massimo Loda group), where they were lentivirally infected to produce three 
additional population of cells, one with a non-specific RNA target, and two with RNA 
sequences targeting FASN (refer to chapter 2 Methods for more details). It was 
confirmed by SDS-PAGE that in all prostate cell lines FASN expression significantly 
decreased in both shFASN knockdown clones when compared to their respective 
shControl cells (Figure 3.3A and 3.3B). In addition, in all cases the expression of FASN 






































Figure 3.3 shRNA interference of FASN in prostate cancer cell lines: Whole 
cell lysates were prepared from 1542, PC3 and DU145 cell lines and their 
respective FASN knockdown/control generated clones. These were then 
subjected to SDS-PAGE and immunoblotted for FASN and the loading control 
HSP90 (A). Densitometry analysis was performed and relative quantification of 
FASN levels can be seen in (B) for all cell lines. Data represents the mean 
values ± SEM accumulated from three independent experiments.  Statistical 




3.2.4 FASN depletion has a significant impact on cell proliferation in prostate    
sddd cancer cell lines 
The role of FASN in cell proliferation has been well documented. Previous studies have 
shown that abolishing FASN activity causes embryonic lethality in mice and can retard 
the growth of cancer cells (Chirala et al., 2003; Wen et al., 2016).  Prior to an 
investigation on migratory capacity, it was deemed prudent to assess if there was a 
proliferation defect in the FASN knockdown cell lines so that the appropriate 
proliferation independent motility-based assays would be used.  To determine if there 
is a proliferation defect in any of the prostate cancer cell lines upon FASN depletion an 
MTT assay was carried out over the course of seven days. Wild-type, control and FASN 
knockdown cell lines were seeded onto plastic or a well coated with either matrigel or 
type I collagen.  Different matrixes were used as it has been reported that cell-matrix 
interactions can influence the proliferative behaviour of cells (Ohtaka et al., 1996). 
Moreover, changes in lipids can affect the localisation and function of certain integrins 
(Pande, 2000).   
The MTT assay confirmed that there was a significant decrease in the proliferation of 
FASN knockdown 1542 (Figure 3.4), PC3 (Figure 3.5), and DU145 cells (Figure 3.6) 
compared to their respective control cells.  Additionally, in all three prostate cell lines 
the proliferation defect could be seen on plastic and matrix-coated surfaces (Figure 
3.4-3.6). In PC3 and 1542 cells, differences in cell proliferation between control and 
FASN knockdown cells on matrix coated surfaces could be seen after Day one, whilst In 
DU145 cells proliferative differences could be seen after Day 3 (Figure 3.4-3.6).  In 
addition to looking at differences in cell number at Day 7 using t-test analysis, control 
and FASN knockdown growth curves were also compared using a pairwise permutation 
test. The result of this analysis found that there were no statistical differences 
between the growth rates of shControl and FASN knockdown cells in all prostate cell 
lines (Figure 3.4-3.6).   
Based on literature findings there is a concern that cell viability is affected when 
silencing or inhibiting FASN (Ventura et al., 2015).  The MTT assay results for 1542, PC3 
and DU145 shFASN cells showed an increase in the readout signal at day seven when 
compared to day one (Figure 3.4-3.6).  This suggests that FASN knockdown is not 
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inducing cell cycle arrest in these cells.  Moreover, no exacerbated cell death was seen 
when culturing shFASN cells and also no cell death was seen in the 2D migration assay 
movies in chapter 4. These findings indicate that the shFASN lines selected can be 


















































Figure 3.4 Depletion of FASN impairs 1542 cell proliferation: 1542, 1542 
shControl, 1542 shFASN A3 and 1542 shFASN A4 cells were seeded in the well 
of a 96-well plate either non-coated (A) or coated with Matrigel (B) or type I 
collagen (C). Cells were left to grow over the course of seven days and 
subjected to an MTT assay at days 1,-3,-5 and 7. Data represents the mean 
values ± SEM accumulated from three independent experiments.  Statistical 





































Figure 3.5 Depletion of FASN impairs PC3 cell proliferation: PC3, PC3 
shControl, PC3 shFASN A3 and PC3 shFASN A4 cells were seeded in the well of 
a 96-well plate either non-coated (A) or coated with Matrigel (B) or type I 
collagen (C). Cells were left to grow over the course of seven days and 
subjected to an MTT assay at days 1,-3,-5 and 7. Data represents the mean 
values ± SEM accumulated from three independent experiments.  Statistical 































Figure 3.6 Depletion of FASN impairs DU145 cell proliferation: DU145, DU145 
shControl, DU145 shFASN A3 and DU145 shFASN A4 cells were seeded in the 
well of a 96-well plate either non-coated (A) or coated with Matrigel (B) or 
type I collagen (C). Cells were left to grow over the course of seven days and 
subjected to an MTT assay at days 1,-3,-5 and 7. Data represents the mean 
values ± SEM accumulated from three independent experiments.  Statistical 






3.2.5 FASN knockdown leads to an altered cellular metabolome in prostate 
ssssscancer cells 
Upregulation of FASN, a metabolomic multi-enzyme, is one of the most frequent 
alterations in cancer cells (Kuhajda, 2000).  The ability to control fatty acid biosynthesis 
and in turn modulate energy homeostasis gives cancer cells a survival advantage in 
environments where oxygen and nutrients are not abundantly  available (Rohrig and 
Schulze, 2016).  In addition to increasing fatty acid synthesis, FASN has also been 
functionally linked with glycolysis and associated with several respiratory metabolites 
such as glutamate (Zaytseva et al., 2015; Zhou et al., 2016). It might therefore be 
predicted that a shFASN cell should have an altered metabolic profile when compared 
to control cells.   
To assess this NMR metabolic analysis was carried out on shControl and shFASN cells. 
Cells were cultured in 10 cm dishes (nine dishes per condition) until 80% confluent and 
then pelleted by scrapping and centrifugation. Cell pellets and 1 ml of media from each 
dish was snap frozen and then lyophilized. Samples were then rehydrated and 
subjected to high resolution-magic angle spinning nuclear magnetic resonance (HR-
MAS NMR).  
Scores plots and quality assessment (Q2) histograms for cell pellets showed good 
separation between shControl and shFASN A3 clones in 1542 (Q2 =0.973) and PC3      
(Q2 =0.783) cells (Figure 3.7A and 3.7B).  DU145 shControl and DU145 shFASN A3 cells 
also showed separation (Q2 =0.178), however it was not as well defined in this cell line 
as the other two cell lines (Figure 3.7C).  This suggests that FASN activity may not be as 
impaired in DU145 cells. Therefore subsequent metabolic disparities were analysed in 
the 1542 and PC3 cells but not in the DU145 cells.   
Analysis of the cell pellets showed there was a significant decrease in the metabolite 
glycerophosphocholine in both FASN knockdown 1542 and PC3 cells compared to their 
respective control cells (Figure 3.8A, -3.8B and Table 3.1). In 1542 cells, 
phosphocholine and glutamate levels also significantly decreased in response to FASN 
depletion (Figure 3.8A and Table 3.1).  These metabolites did not significantly alter in 
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PC3 cells, but did show a decreasing trend in response to FASN knockdown (Figure 
3.8B and Table 3.1).   
In addition to the cell pellets, good separation was observed between the media of 
shControl and shFASN A3 1542 (Q2 =0.889) and PC3 cells (Q2 =950) (Figure 3.7D and 
3.7E).  NMR spectra analysis of the media showed there was significant decrease in 
glutamate levels in response to FASN knockdown which was consistent in both cell 
lines (Figure 3.9A, -3.9B and Table 3.2).   
The NMR results presented here confirm that in the prostate cell lines 1542 and PC3, 
control and FASN knockdown cell populations are metabolically different.  Due to 
there being minimal metabolic separation between DU145 shControl and shFASN A3 
cells, it was decided to only pursue with the 1542 and PC3 cell lines in the subsequent 









































Figure 3.7 shControl and shFASN A3 separation analysis for the prostate cell 
lines 1542, PC3, and DU145 :  Scores plot showing statistical separation 
between shControl (blue) and shFASN A3 (red) cell pellets and Q2 histogram 
showing distribution of OPLS-DA models for the cell lines 1542 (A), PC3 (B), and 
DU145 (C). Similar plots but instead for media readings can be seen for 1542 


























Figure 3.8 Metabolomic changes observed in 1542 and PC3 cell pellets in 
response to FASN knockdown:  Back scale loadings plots highlighting 
differences in metabolites between shControl and shFASN A3 cell pellets for the 
1542(A) and PC3 cell lines (B).  For reference the back-scale loading plots are a 
pseudo-NMR spectrum showing which variables (chemicals shifts) in the data 
sets correlate with a class (peak height) and if that correlation is highly 


























Figure 3.9 Metabolomic changes observed in 1542 and PC3 cell medium in 
response to FASN knockdown:  Back scale loadings plots highlighting 
differences in metabolites between shControl and shFASN A3 cell medium for 



























PPM 1542               
Control v 











Glutamate 2.36 -16.75 P < 0.001 -12.60 0.089 
Phosphocholine 3.22 -29.55 P < 0.001 -8.98 0.204 
Glycerophosphocholine 3.26 -42.12 P < 0.001 -18.66 0.032 
 
Table 3.1 Changes in metabolites between shControl and shFASN A3 in 1542 and PC3 cell 
pellets: Assignment of metabolites based on their mass accuracy reading-PPM (parts per 
million). Negative (-) or positive (+) percentage (%) change in each metabolite was 
recorded in FASN knockdown cells compared to control. Statistical significance was 
determined by student’s t-test false discovery rate (FDR) adjusted.  
Metabolite 
Media 
PPM 1542               
Control v 




PC3               
Control v 




Glutamate 2.36 -4.90 0.021 -11.79 P < 0.001 
 
Table 3.2 Changes in metabolites between shControl and shFASN A3 in 1542 and PC3 cell 
media: Assignment of metabolites based on their mass accuracy reading-PPM (parts per 
million). Negative (-) or positive (+) percentage (%) change in each metabolite was 
recorded in FASN knockdown cells compared to control. Statistical significance was 
determined by student’s t-test false discovery rate (FDR) adjusted. 
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3.2.6 Reduction in FASN levels are associated with morphological changes in 
ddd  prostate cancer cells 
Having established that 1542 and PC3 shFASN cells have significantly decreased FASN 
levels, and are functionally different to shControl cells, it was decided to proceed and 
ascertain if the loss of FASN impacts on cellular behaviour. A common feature of 
cancer cells is their ability to change shape, this helps them adapt to new surroundings 
and is linked to an increased metastatic potential (Friedl and Wolf, 2003). Currently, 
FASN role in this facet of metastatic progression has been largely overlooked in 
multiple cancers. Evidence for its involvement has been shown in one study where 
FASN depletion induced marked morphological changes in LNCaP prostate cancer cells 
(De Schrijver et al., 2003).  Here, microscopic analysis was conducted on control and 
FASN knockdown 1542 and PC3 cells in order to determine if FASN is involved in 
regulating the morphology of these cell lines. Overall, 90 cells (30 from three 
independent experiments) were analysed as this has been deemed an acceptable 
number to study morphological disparities (Al-Mahdi et al., 2015). Similar to the 
proliferation studies, morphological observations were carried out on matrix coated 
coverslips, including matrigel and type I collagen, in addition to non-coated glass 
coverslips.  
Following quantification, differences in cell morphology were observed in both 
prostate cell lines in response to FASN knockdown (Figure 3.10-3.13). In 1542 and PC3 
cells, a comparable decrease in cell area and perimeter was seen in both FASN 
depleted lines compared to their respective control cells when seeded on matrigel 
(Figure 3.10-3.11A and Figure 3.12-3.13A). Morphological changes of the same nature 
as a result of FASN knockdown were also observed in both cell lines when seeded onto 
glass and type I collagen.  However, the overall decrease in cell area and perimeter was 
more modest when compared to cells that were seeded onto matrigel (Figure 3.11B-C 






Figure 3.10 1542 cell morphology on Matrigel in response to FASN 
knockdown: 1542, 1542 shControl, 1542 shFASN A3 and 1542 shFASN A4 cells 
were seeded in the well of a six-well plate containing coverslips coated with 10 
μg Matrigel. Cells were then fixed and stained for phalloidin. Images are 



























































Figure 3.11 Silencing of FASN causes morphological changes in 1542 cells: 
ImageJ was used to calculate the cell area and perimeter of 90 cells per 
condition. From this data morphological differences between cell populations 
seeded onto matrigel (A), glass (B) and type I collagen (C) were quantified. 
Data represents the mean values ± SEM accumulated from three independent 
experiments.  Statistical significance was determined by student’s t-test. 


































Figure 3.12 PC3 cell morphology on Matrigel in response to FASN knockdown: 
PC3, PC3 shControl, PC3 shFASN A3 and PC3 shFASN A4 cells were seeded in the 
well of a six-well plate containing coverslips coated with 10 μg Matrigel. Cells 
were then fixed and stained for phalloidin. Images are representative of three 































Figure 3.13 Silencing of FASN causes morphological changes in PC3 cells: 
ImageJ was used to calculate the cell area and perimeter of 90 cells per 
condition. From this data morphological differences between cell populations 
seeded onto matrigel (A), glass (B) and type I collagen (C) were quantified. 
Data represents the mean values ± SEM accumulated from three independent 
experiments. Statistical significance was determined by student’s t-test. 







In this chapter, the FASN protein expression levels in cancer were determined and 
FASN depleted AR-independent prostate cancer cell lines were characterised for cell 
proliferative, metabolomic and morphological changes.  
Within this study, FASN was found to be expressed in several different cancer cell lines 
including prostate, breast, pancreas and melanoma.  This result agrees with the 
previous documentation of FASN as a commonly overexpressed protein in cancer 
(Corominas-Faja et al., 2017; Hamada et al., 2014; Innocenzi et al., 2003; Yang et al., 
2011b). Additionally, FASN was also expressed in one non-cancerous breast cell line   
(MCF10A) and one non-cancerous transformed kidney cell line (HEK293). HEK293 cells 
have historically been selected to be a highly proliferative cell line and as such may 
have become dependent on de novo lipogenesis to accommodate this potentiated 
growth (Lin et al., 2014).  In MCF10A cells, the expression level of FASN was 
comparable to MDA-MB-231 cells which are a highly metastatic breast cancer cell line. 
This contrasts  what was observed in a study by Hopperton et al where they found MD-
MB-231 cells to have increased FASN expression relative to MCF10A cells (Hopperton 
et al., 2014).  Different results between our studies may have occurred due to the 
slightly different culture conditions of the MCF10A cells. Hopperton et al cultured 
MCF10A cells in standard growth media whilst the MCF10A cells used in this panel 
were cultured in media supplemented with insulin and EGF (Hopperton et al., 2014; 
Vazquez-Martin et al., 2008). Insulin and EGF are commonly added to the growth 
media of MCF10A cells and both have been shown to upregulate FASN expression 
(Radenne et al., 2008; Weng et al., 2007).  
In a separate panel, FASN expression was found to be significantly higher in malignant 
prostate tissue than in benign prostate tissue. Moreover, the panel evidenced that 
FASN levels are associated with increased malignancy in prostate cancer. These results 
compliment findings in the literature and confirm FASN as a marker of tumorigenesis in 
prostate cancer (Hamada et al., 2014; Karantanos et al., 2016). 
It has been well established now that FASN is upregulated in cancer to provide a 
selective proliferative advantage over normal cells (Chen et al., 2012). Inhibition of 
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FASN with RNAi or inhibitors has been shown to inhibit cellular proliferation in almost 
every type of cancer including prostate, lung, breast, ovarian, colorectal, pancreatic, 
melanoma, osteosarcoma, retinoblastoma, nasopharyngeal and liver (Daker et al., 
2012; Deepa et al., 2013; Hu et al., 2016; Nishi et al., 2016; Singh et al., 2015; Veigel et 
al., 2015; Ventura et al., 2015; Yoshii et al., 2013; Zaytseva et al., 2012; Zecchin et al., 
2011; Zhou et al., 2015).  In agreement with the studies above it was found that 
knockdown of FASN in 1542, PC3 and DU145 cells significantly impaired the rate of cell 
proliferation.  In addition, this proliferative defect occurred regardless of the surface 
the cells were seeded onto. Alternatively, growth curve analysis did not show a 
statistical difference in the rate of growth between control and FASN knockdown cells 
in any of the prostate cell lines (Figure 3.4-3.6). However, this is likely due to the fact 
that there was not a lot of difference in growth between control and FASN knockdown 
cells at Day 1 and Day 3. Typically, growth curve analysis is done on datasets with more 
time points giving a more accurate reading of the rate of change over time (Curran et 
al., 2010). Thus, in future it would be ideal to repeat the experiment measuring cell 
growth at each day.  
The MTT assay results also showed that proliferative differences occurred earlier in the 
1542 and PC3 cell line compared to the DU145 cell line upon FASN knockdown.  One 
reason for this could be because DU145 cells have a slower doubling time compared to 
PC3 cells which means the separation rate between control and FASN knockdown cell 
populations occur earlier in PC3 (Cunningham and You, 2015). The same reason could 
also provide true for 1542 cells; however the doubling time for this cell line has not 
previously been documented. Alternatively, the timing of proliferative differences 
could be due to FASN affecting the metabolism of these cell lines differently (Ventura 
et al., 2015).  
The role of FASN in cell proliferation has been extensively studied (Deepa et al., 2013; 
Knowles et al., 2004; Scaglia et al., 2014). During cell cycle progression there are 
lipogenic checkpoints at the G2/M and G1/S boundaries which require the partitioning 
of phospholipids and other fatty acids into the cell membrane in order for successful 
cell division to occur (Scaglia et al., 2014).  Key lipids that are synthesised as a result of 
FASN activity which are involved in cell proliferation include phosphatidylcholine, 
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phosphatidylethanolamine, DAG and cholesterol esters (Veigel et al., 2015).  All these 
lipids are important for membrane expansion and a reduction in their synthesis can 
cause a delay at either of the lipogenic checkpoints resulting in restricted cell division 
and growth (Scaglia et al., 2014).   
FASN also regulates the F-box protein SKP2 which is a negative regulator of cyclin-
dependent kinase inhibitors of the RB pathway such as p21 (Deepa et al., 2013).  This 
explains why cell death has been observed upon FASN inhibition in some studies as 
proteins such as p21 accumulate and induce cell cycle arrest and apoptosis (Li et al., 
2001).  All FASN knockdown cell lines showed an increase in the readout signal over 
the course of the MTT assay which was in the same trend, but not as drastic as the 
control cells. These data suggest that the depletion of FASN most likely decreases 
overall lipid availability which in turn is responsible for hindering cell proliferation in 
1542, PC3 and DU145 cells; however there is enough lipids and FASN protein not to 
induce arrest and apoptosis.  
In addition to proliferative changes, FASN depletion in 1542 and PC3 cells also led to 
metabolic alterations. One metabolite that significantly decreased in the pellets of 
both cell lines was the choline derivative glycerophosphocholine.  Choline metabolism 
is rapidly becoming regarded as a hallmark for tumour growth and progression. This 
has been evidenced by a study showing that an increase in the dietary intake of 
choline is associated with an increased risk of lethal prostate cancer (Richman et al., 
2012). Glycerophosphocholine is formed as a result of the degradation of membrane 
phospholipid phosphatidylcholine (Glunde et al., 2011). Therefore a decrease in 
Glycerophosphocholine suggests that phosphatidylcholine synthesis has also declined   
(Kwon et al., 1995). Moreover, glycerophosphocholine can additionally be metabolized 
to choline and reused as a substrate for renewed synthesis of phosphatidylcholine 
(Fernandez-Murray and McMaster, 2005). Thus decreased Glycerophosphocholine 
levels leads to a reduction in the primer substrate needed to generate membrane 
lipids (Fernandez-Murray and McMaster, 2005). Furthermore, FASN inhibition has 
been shown to impair choline kinase activity which is required for the synthesis of 
phosphocholine, the precursor molecule of phosphatidylcholine (Ross et al., 2008). 
Phosphocholine levels were found to be decreased in the 1542 NMR spectra further 
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supporting the idea of reduced phosphatidylcholine production.  Being essential in 
membrane synthesis, these changes in choline metabolism may partly aid in explaining 
the reduced proliferation phenotype seen in FASN knockdown cells.  
Glutamate was another metabolite found to decrease in both prostate cancer cell lines 
upon FASN knockdown. Glutamate is a non-essential amino acid that is extensively 
involved in metabolic and oncogenic pathways in cancer (Koochekpour, 2013).  A 
lowered intracellular level of glutamate in FASN depleted cells is most likely the result 
of reduced glutamine and α-ketoglutarate availability, key metabolites which can be 
processed to form glutamate (Hensley et al., 2013; Zhidenko et al., 1990). The 
consequence of this attenuated intracellular conversion is reduced glutamate 
secretion to trigger autocrine signalling. Evidence of this was verified in the NMR 
spectra which detailed depleted glutamate levels in the media of each cell line. High 
serum glutamate has been found to correlate with a higher Gleason score in prostate 
cancer (Koochekpour, 2013). Glutamatergic signalling is initiated upon the binding of 
glutamate to ionotropic (iGluR) and metabotropic glutamate receptors (mGluR), both 
of which have been found to be expressed in prostate cancer (Willard and 
Koochekpour, 2013). Glutamate blockage by receptor inhibition in PC3 and DU145 cells 
has been shown to decrease proliferation, migration and invasion (Koochekpour et al., 
2012).  It is possible that the synergistic loss of glutamate signalling in conjunction with 
choline depletion is contributing to the proliferative defect presented upon FASN 
knockdown in 1542 and PC3 cells.  
Whilst proliferative defects are commonly associated with the loss of FASN, changes in 
cellular morphology are less well documented. In this chapter it was confirmed that 
FASN knockdown in all prostate cancer cell lines leads to morphological aberrations.   
Typically, FASN depleted cells exhibited a smaller shape relative to their control or 
wild-type counterparts. This phenotype was most markedly and consistently seen in 
1542 and PC3 cells seeded onto matrigel. Changes in cell shape in all prostate cell lines 
was observed when seeded onto glass and collagen, however these differences were 
more modest and not always consistent between different shFASN clones.  
The mechanism for how FASN may influence cell shape is unclear. It is possible that as 
a result of losing FASN, there is an unequivocal decrease in saturated fatty acids 
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available to completely form the cell membrane. This has been suggested in one 
previous study were the silencing of FASN led to a decrease in neutral lipids in the lipid 
bilayer of LNCaP cells (De Schrijver et al., 2003).  Changes in cell shape are also 
frequently associated with reorganisation of the actin cytoskeleton. Rho GTPases 
modulate the actin cytoskeleton and silencing of their activity has been shown to 
profoundly affect cell spreading (Reymond et al., 2012; Sander et al., 1999). The link 
between FASN and Rho GTPases has not been extensively studied with only one study 
in colorectal cancer showing FASN knockdown correlates with the loss of RhoA 
expression (Zaytseva et al., 2012).  This is something that will be explored in more 
detail in the later chapters of this thesis.  
It currently is not clear why a difference in cell size was not consistently seen on all 
surfaces.  One possibility is that changes in the lipid composition of the membrane as a 
result of FASN knockdown has disrupted the clustering of specific integrins (Pande, 
2000).  This has been previously reported in A375 melanoma cells which failed to 
spread due to the loss of integrin raft integrity (Wang et al., 2013a).  Additionally, FASN 
may be regulating important proteins involved in adhesion. FASN has been shown to 
activate the tyrosine kinase Src which is essential for its ability to interact with specific 
integrin subunits (Di Vizio et al., 2008; Felsenfeld et al., 1999). Failure to interact has 
been shown to prevent fibroblast cells from being able to spread properly on 
fibronectin; however their spreading on vitronectin was unaffected (Felsenfeld et al., 
1999).   
In summary, the work presented here shows that FASN regulates cell proliferation and 
metabolic changes in prostate cancer.  Moreover, FASN depletion was shown to induce 
morphological changes in prostate cancer cells suggesting that it may mediate cell 
cytoskeletal reorganization.  Changes in the actin cytoskeleton are required for cell 
migration and invasion and so the role of FASN within this context will be explored in 






3.4 Future work 
In this chapter it was confirmed that FASN depletion induces phenotypic and 
metabolomic changes in prostate cancer. The metabolic profiling of each cell line was 
done in response to stable knockdown of FASN. In future experiments a comparison 
between stable shRNA knockdown, inducible ShRNA knockdown, siRNA knockdown 
and FASN inhibition could be conducted to identify which metabolites consistently 
change between treatments. This would help isolate key metabolites which are more 
sensitive to FASN activity and therefore more likely to be targetable.  In addition to 
this, assessing the lipidomic profile of FASN depleted 1542 and PC3 cells via NMR or 
Mass spectrometry would be helpful in determining downstream targets. Staining of 
lipids using oil-red-o or BIODIPY could also be done as a quick experiment to assess 
changes in neutral lipids.  Finally, it would also be worth investigating cell viability in 
response to FASN depletion in the prostate cell lines.  This could be done by probing 
westerns for cell death proteins such as caspase-3 and performing FACS (Fluorescence-
activated cell sorting) analysis which measures a specific dye that binds DNA allowing 

















Migratory characterisation of FASN depleted 


























Chapter 4 – Migratory characterisation of FASN depleted prostate cancer cell 
ssssssssssssslines  
4.1 Introduction  
One of the biggest challenges in modern medicine is the treatment of cancer at the 
later stages of progression (Chakraborty and Rahman, 2012).  After the development 
of primary cancer within the prostate gland, a subset of cells will undergo further 
pathological changes (Banyard et al., 2014).  These changes to the cells phenotypic 
properties are the beginning of a series of sequential and interrelated processes that 
are involved in cancer cell metastasis (Chambers et al., 2002). In prostate cancer 
widespread metastasis at the time of diagnosis occurs in approximately 20% of cases 
and is usually to the bone (Dasgupta et al., 2012). The first step of metastasis involves 
the dissemination of cells from the primary tumour mass into the surrounding stroma. 
This is followed by Intravasation of cells into local lymphatic or haematogenous 
vessels. Then eventually, a few cells will extravasate out of the vessel and into the 
surrounding tissue to form a secondary tumour site (Ye et al., 2007).  
During the initial stages of metastasis the ability of cancer cells to segregate from the 
primary tumour and migrate into their surrounding environment is dependent on both 
intrinsic and extrinsic cues (Yamaguchi et al., 2005). Stromal cells situated in the ECM 
secrete cytokines such as HGF which is capable of increasing the motility of cancer cells 
through the activation of its cognate receptor c-Met (Jiang et al., 2005). In addition, 
dynamic reciprocity between the cell and its surrounding environment is also essential 
for cell migration (Schultz et al., 2011). The cell interacts with the ECM through 
adhesion contacts which mediate a link to the actin cytoskeleton and allow adhesions 
to be utilised as traction sites. (Huttenlocher and Horwitz, 2011). All facets of migration 
including cell polarity, cell shape, actomyosin contractility and cell adhesion turnover 
require reorganization of the actin cytoskeleton (Friedl and Wolf, 2003; Friedl and 
Wolf, 2009). Both ECM contact and stimulation by motogenic factors can induce 
changes in the cells actin cytoskeleton through the activation of Rho GTPase proteins 




FASN has been implicated in the migration and invasion of several different cancers 
including breast, colorectal, bladder and ovarian (Jiang et al., 2014; Li et al., 2012b; 
Zheng et al., 2016; Zhou et al., 2016). In addition, the silencing of FASN has been 
shown to impede the invasion of AR-dependent LNCaP prostate cancer cells in vitro 
and in vivo (Yoshii et al., 2013).  However, targeting FASN specifically in AR-
independent prostate cancer cell migration with RNAi has not been reported. 
Interestingly, Rae et al found that the migratory response in a wound healing assay 
was impaired when PC3 cells were treated with a FASN inhibitor, although proliferative 
differences were not completely controlled for with cell cycle inhibitors (Rae et al., 
2015).  In a separate study it was shown that the invasion of PC3 and DU145 cells  in 
vitro was significantly reduced when the cells were incubated with ASC-J9, an 
androgen degradation enhancer which suppressed FASN expression (Wen et al., 2016).  
Whilst it is not yet completely clear how FASN drives cell migration, it is known that 
adding palmitate, the fatty acid product of FASN, to hepatocellular cancer cells induces 
morphological changes and cell invasion (Nath et al., 2015). This suggests that 
downstream fatty acid signalling may be involved in FASN-induced cell motility.  In 
addition, FASN has been shown to modulate the expression of c-Met in prostate 
cancer cells which is associated with the increased invasiveness of this cancer 
(Coleman et al., 2009; Han et al., 2014).                   
In this chapter of the thesis, all aspects of motility including morphology and adhesion 
will be investigated in response to depleting FASN levels in AR-independent prostate 
cancer cells.  1542 will be used as the principle cell line in this study as it was derived 
from the prostate and so is most likely to accurately recapitulate the biological 
behaviour of prostate tumours (Schwab et al., 2000). Key assays will be then be 









4.2.1  Overexpression of FASN is associated with an increase in the spread 
mmmmarea of prostate cancer cells  
In the last chapter it was observed that there was a decrease in the overall size of FASN 
knockdown prostate cancer cells relative to control cells.  To further examine the 
influence FASN has on cell shape both 1542 and PC3 cells were transiently transfected 
with a FASN-overexpression construct to increase its baseline expression. This 
experiment was carried out on matrigel as the most notable and consistent effects 
with regard to changes in 1542 and PC3 cell shape in response to FASN knockdown 
were seen when seeded onto this matrix. Here It was observed that both 1542 and 
PC3 cells overexpressing FASN showed a significant increase in cell area and perimeter 
relative to control cells transfected with a GFP-alone vector (Figure 4.1 and Figure 4.2). 
 
4.2.2 Palmitate rescues FASN knockdown 1542 cell morphology 
The morphological studies that have currently been presented in this thesis have 
identified a correlation between FASN expression and cell shape. The primary function 
of FASN is to synthesize the saturated fatty acid palmitate (Ventura et al., 2015). Thus, 
a rescue experiment was performed by adding exogenous palmitate to FASN depleted 
cells and assessing if they adopt a morphological phenotype similar to that of the 
control cells.  As with previous experiments, 1542 shControl and 1542 shFASN A3 cells 
were seeded onto matrigel coated coverslips. BSA alone and BSA conjugated-palmitate 
50 μM was added to two separate wells containing 1542 shFASN A3 cells. Cells were 
incubated with BSA and palmitate for 1 hour before fixing and staining. Imaging 
analysis of the staining shows that 1542 shFASN A3 cells treated with BSA alone 
exhibited a similar morphology to that of non-treated 1542 shFASN A3 cells (Figure 
4.3). In contrast, the addition of palmitate significantly increased the area and 
perimeter of 1542 shFASN A3 cells relative to BSA treated cells making them similar in 

































Figure 4.1 Overexpression of FASN causes morphological changes in 1542 cells: 
1542 cells were seeded onto matrigel coated coverslips and then transiently 
transfected with either GFP- alone or GFP-FASN (A). Cells were stained with 
DAPI and Phalloidin. ImageJ was used to calculate the cell area and perimeter of 
90 cells per condition and from this data morphological differences were 
quantified (B). Data represents the mean values ± SEM accumulated from three 
independent experiments. Scale bar = 10 µm.  Statistical significance was 



































Figure 4.2 Overexpression of FASN causes morphological changes in PC3 cells: 
PC3 cells were seeded onto matrigel coated coverslips and then transiently 
transfected with either GFP- alone or GFP-FASN (A). Cells were stained with 
DAPI and Phalloidin. ImageJ was used to calculate the cell area and perimeter of 
90 cells per condition and from this data morphological differences were 
quantified (B). Data represents the mean values ± SEM accumulated from three 
independent experiments. Scale bar = 10 µm.  Statistical significance was 





Figure 4.3 Palmitate rescues FASN knockdown morphological phenotype in 
1542 cells:   1542 shControl and 1542 shFASN A3 cells were seeded onto 
matrigel coated coverslips. BSA and BSA conjugated-palmitate 50 μM was 
added to wells containing 1542 shFASN A3 cells. Cells were incubated for one 
hour before staining with phalloidin (A). ImageJ was used to calculate the cell 
area and perimeter of 90 cells per condition. This data was used to determine 
differences in cell perimeter and area between the different conditions 
(B).Data represents the mean values ± SEM accumulated from three 
independent experiments.  Statistical significance was determined by student’s 































4.2.3 The effect of FASN knockdown on prostate cancer cell adhesion 
For cells to migrate optimally they need to be able to interact with the surrounding 
ECM (Huttenlocher and Horwitz, 2011). The coordinated assembly and disassembly of 
adhesions during migration is important for several cellular processes including cell 
spreading, polarity and directional persistence (Choma et al., 2004; Huttenlocher and 
Horwitz, 2011).  
Adhesion was measured by seeding prostate cancer cells into matrix-coated 96 well 
plates and then leaving them for one hour to attach. After this period, the wells were 
washed out with PBS to remove any non-adherent cells and then an MTT assay was 
carried out to measure the adherent cells. Adherence analysis showed that FASN 
knockdown in 1542 cells significantly increased cell-matrix adhesion when compared 
to their respective control cells (Figure 4.4A-B). A similar trend was seen in two 
independent experiments for PC3 cells also (Figure 4.4C-D)  This effect on cell adhesion 
in response to silenced FASN expression was observed on both matrigel and type I 













































Figure 4.4 FASN depletion increases prostate cancer cell adhesion: 1542, 
1542 shControl, 1542 shFASN A3 and 1542 shFASN A4 cells were seeded into 
the wells of a 96 well plate coated with matrigel (A) or type I collagen (B). 
Cells were left to adhere for one hour before being subjected to an MTT 
assay. The same experimental set up was conducted for the PC3 cell lines on 
matrigel (C) or type I collagen (D) also.  Data represents the mean values ± 
SEM accumulated from three independent experiments in 1542 cells and 
two independent experiments in PC3 cells.  Statistical significance was 






4.2.4 Focal adhesion size is dependent on FASN expression  
Previous work by Wells et al has confirmed a biphasic relationship between the size of 
paxillin-containing adhesions and the level of adherence in PAK4 silenced DU145 
prostate cancer cells (Wells et al., 2010). Upon confirming that FASN knockdown 
increases prostate cancer cell adhesion it was decided to investigate if this phenotype 
correlates similarly with an increase in focal adhesion size. As a global adhesion defect 
was seen in both prostate cell lines, focal adhesions were only analysed in more detail 
in the 1542 cells as this is the main cell line of this study.  1542 shControl, 1542 shFASN 
A3 and 1542 shFASN A4 cells were seeded onto matrigel coated coverslips and then 
stained for paxillin (Figure 4.5A).  Analysis of the staining revealed that FASN 
knockdown increases the number of 1542 cells with prominent paxillin (Figure 4.5B). In 
addition, an increase in the length of focal adhesions was observed in FASN depleted 
1542 cells when compared to 1542 shControl cells (Figure 4.5C).   
 
 
4.2.5 Paxillin associated focal adhesion length alters in response to palmitate 
sssssaddition in 1542 cells 
Having shown that the morphology of FASN depleted 1542 cells could be rescued 
when incubated with palmitate a similar experiment was carried out to determine how 
paxillin staining alters in response to palmitate treatment (Figure 4.6A).  Following 
quantification of staining, 1542 shFASN A3 cells incubated with palmitate exhibited a 
concomitant reduction in paxillin length and the number of cells with prominent 
paxillin (Figure 4.6B and 4.6C). Palmitate treatment rescued paxillin staining to similar 
levels seen in 1542 shControl cells, although the rescue response is partial as paxillin 
length between BSA and palmitate treated cells is not significantly different (Figure 
4.6B and 4.6C). Alternatively 1542 shFASN A3 cells incubated with BSA alone were 
unaffected giving them identical paxillin numbers and length to untreated 1542 A3 

































Figure 4.5 FASN Knockdown alters paxillin length in 1542 cells: 1542 shControl, 
1542 shFASN A3 and 1542 shFASN A4 cells were seeded onto matrigel coated 
coverslips (10 μg/ml) and then stained for paxillin (A). The percentage of cells with 
visible paxillin was quantified in (B). The length of paxillin was measured in imageJ 
and quantified in (C). White arrows indicate the area that was magnified.  The 
analysis is the sum of 60 cells per condition over three independent experiments. 
Data represents the mean values ± SEM. Statistical significance was determined by 

































Figure 4.6 Exogenous palmitate rescues FASN knockdown 1542 cell paxillin 
length:   1542 shControl, 1542 shFASN A3, BSA-treated 1542 shFASN A3, BSA-
Palmitate treated 1542 shFASN A3 were stained for paxillin (A). Quantification of 
the percentage of cells with visible paxillin is shown in (B). The length of paxillin 
was measured in imageJ and quantified in (C).Data represents the mean values ± 
SEM accumulated from three independent experiments. White arrows indicate 
the area that was magnified. Statistical significance was determined by student’s 





4.2.6 Reduced prostate cancer cell migration in response to FASN knockdown  
This study has now identified observable changes in cell morphology and adhesion in 
response to FASN knockdown in prostate cancer cells.  Defects in these phenotypes 
suggest a likely impact on cell migration (Hakkinen et al., 2011; Kim and Wirtz, 2013). 
HGF, a ligand that specifically complexes with c-Met, is abundantly expressed in the 
prostate microenvironment and is known to have mitogenic and motogenic activities 
on prostate cancer cells  (Ye et al., 2007). FASN has been linked with c-Met in prostate 
cancer and so it was deemed pertinent to monitor the migratory ability of FASN 
knockdown cells in response to HGF (Coleman et al., 2009).   Since a proliferation 
defect was observed in response to depleting FASN levels in both 1542 and PC3 cells 
(Figure 3.4 and Figure 3.5), a random 2D migration assay was carried out on the basis 
that the measured variable is not significantly impacted by variations in proliferation 
rate.   
In comparison to 1542 shControl cells, there was a significant reduction in the mean 
migratory speed of both 1542 shFASN A3 and 1542 shFASN A4 cells in the presence of 
HGF (Figure 4.7 and see Movies 1-4 on CD for representative movies on matrigel).  
Similarly, in the presence of HGF a reduction in cell speed was also seen in FASN 
knockdown PC3 cells when compared to PC3 shControl cells (Figure 4.8 and see 
Movies 5-8 on CD for representative movies on matrigel). Migratory ability in response 
to FASN knockdown in both cell lines was tested on matrigel and type I collagen coated 
wells which showed a consistent response across both substrata (Figure 4.7A-C and 
Figure 4.8A-C). Additionally, it should be noted that no cell death was observed in 
these movies over 16 hours supporting the notion that FASN knockdown cells are 
simply proliferating at a slower rate. These results reveal that FASN knockdown impairs 




































Figure 4.7 FASN knockdown impairs 1542 cell migration in the presence of HGF: 
1542, 1542 shControl, 1542 shFASN A3 and 1542 shFASN A4 cells were seeded into 
matrigel or type I collagen coated wells , serum starved and then stimulated with 10 
ng/ml HGF. Migration plots were created from the movies of cells migrating on 
matrigel (A) which were used as representations of each cell lines trajectory.  Cells 
were filmed for 16 hours with images being taken at 5 minute intervals using the 
Olympus IX71 inverted time-lapse microscope at 10x magnification. The manual 
tracking plugin in imageJ was used to track up to 60 cells per condition. Migration 
trajectories were placed into Mathematica and then the speed of cell migration on 
matrigel (B) and type I collagen (C) was calculated. Data represents the mean values ± 
SEM accumulated from three independent experiments. Statistical significance was 



































Figure 4.8 FASN knockdown impairs PC3 cell migration in the presence of HGF: PC3, 
PC3 shControl, PC3 shFASN A3 and PC3 shFASN A4 cells were seeded into matrigel or 
type I collagen coated wells , serum starved and then stimulated with 10 ng/ml HGF. 
Migration plots were created from the movies of cells migrating on matrigel (A) which 
were used as representations of each cell lines trajectory.  Cells were filmed for 16 
hours with images being taken at 5 minute intervals using the Olympus IX71 inverted 
time-lapse microscope at 10x magnification. The manual tracking plugin in imageJ was 
used to track up to 60 cells per condition. Migration trajectories were placed into 
Mathematica and then the speed of cell migration on matrigel (B) and type I collagen 
(C) was calculated. Data represents the mean values ± SEM accumulated from three 
independent experiments. Statistical significance was determined by student’s t-test. 
** p<0.01, *** p<0.001. 
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4.2.7 FASN inhibitors phenocopy FASN knockdown defect in HGF-induced 
sssssprostate cancer cell migration   
To further validate the role of FASN in prostate cancer cell migration a 2D migration 
assay was carried out testing the migratory response of 1542 and PC3 cells in the 
presence of HGF under the treatment of two well –known FASN inhibitors, C75 and 
orlistat.  C75 is a cerulenin-derived semi-synthetic irreversible inhibitor which targets 
the β-ketoacyl synthase, enoyl reductase and the thioesterase domains of FASN (Lόpez 
and Diéguez, 2007). Orlistat is a semi-synthetic pancreatic lipase inhibitor which was 
originally developed as anti- type II diabetes drug.  It was identified in a screen as an 
irreversible inhibitor of FASN targeting the thioesterase domain (Kridel et al., 2004).  
Both 1542 and PC3 cells treated with either C75 or orlistat displayed a significant 
decrease in the mean migratory speed following HGF addition when compared to their 
respective DMSO controls (Figure 4.9-4.10). Both FASN inhibitors were equally 
effective in decreasing the migratory speed of PC3 cells (Figure 4.10B and see Movies 
12-14 on CD for representative movies), whilst C75 appeared to be a more potent 
inhibitor in 1542 cells (Figure 4.9B and see Movies 9-11 on CD for representative 
movies). These results compliment the previous migration data and suggest FASN 

















Figure 4.9 FASN inhibitors impair 1542 cell migration in the presence of HGF:  
1542 cells were seeded into matrigel-coated wells, serum starved, incubated with 
DMSO, C75 or orlistat and then stimulated with 10 ng/ml HGF. Cells were filmed 
for 16 hours with images being taken at 5 minute intervals using the Olympus 
IX71 inverted time-lapse microscope at 10x magnification. The manual tracking 
plugin in imageJ was used to track up to 60 cells per condition. Migration 
trajectories were placed into Mathematica and then the speed of cell migration 
on matrigel (B) was calculated. Data represents the mean values ± SEM 
accumulated from three independent experiments. Migration plots for cells 
migrating on matrigel (A) were used as representations of each cell lines 
trajectory.   An additional migratory trajectory for C75 that is 3 x zoomed in was 
included to clarify the cells have not died and are still migrating but just at a 
profoundly slower rate. Statistical significance was determined by student’s t-





























































Figure 4.10 FASN inhibitors impair PC3 cell migration in the presence of HGF:  
PC3 cells were seeded into matrigel-coated wells, serum starved, incubated with 
DMSO, C75 or orlistat and then stimulated with 10 ng/ml HGF. Cells were filmed 
for 16 hours with images being taken at 5 minute intervals using the Olympus 
IX71 inverted time-lapse microscope at 10x magnification. The manual tracking 
plugin in imageJ was used to track up to 60 cells per condition. Migration 
trajectories were placed into Mathematica and then the speed of cell migration 
on matrigel (B) was calculated. Data represents the mean values ± SEM 
accumulated from three independent experiments. Migration plots for cells 
migrating on matrigel (A) were used as representations of each cell lines 




4.2.8 FASN depletion reduces prostate cancer cell invasion 
After confirming that FASN knockdown impairs prostate cancer cell migration in 2D it 
was decided to carry out a 3D invasion assay using these cell lines. Looking at cell 
motility in both models has become increasingly more important as studies are 
starting to identify differences between cell behaviour in 2D and 3D environments 
(Doyle et al., 2015). Previous work using an in vitro Boyden chamber invasion assay 
demonstrated that FASN knockdown in the prostate cells LNCaP reduced their invasive 
potential (Yoshii et al., 2013). The invasive ability of both 1524 and PC3 prostate cell 
lines was tested using the 3D inverted invasion assay.   This assay was chosen over the 
Boyden chamber assay for two primary reasons. Firstly, it has been documented that 
cells are more easily displaced from the microenvironment in the Boyden chamber 
assay. Secondly, the inverted invasion assay requires cells to invade up into the matrix 
against gravity meaning they need to be more active in order to invade (McArdle et al., 
2016).  
In the inverted invasion assay, cells are seeded onto the bottom surface of a 96 well 
plate and then overlaid with type I collagen.  Cells were left to invade into the collagen 
for 24 hours before being fixed, stained and then imaged on the confocal microscope. 
Longer time-points were not carried out on the basis that differences in proliferation 
rate between control and FASN knockdown cells occurred after 24 hours in the MTT 
assay.  The invasion of cells was measured at 50 micrometres which was compared to 
the number of cells at the bottom of the well to get a relative invasion percentile.   
From these results it has been found that a higher percentile of 1542 shControl cells 
invaded 50 μm into the collagen compared to 1542 shFASN A3 cells (Figure 4.11A-B). 
Likewise, when FASN was depleted in PC3 cells a reduction in the percentage of cells 
invading 50 μm was also seen compared to control shRNA cells (Figure 4.12A-B). The 
data from this assay show that decreasing FASN levels in AR-independent prostate 


































Figure 4.11 FASN knockdown impairs 1542 cell invasion: 1542 shControl and 
1542 shFASN A3 were seeded into the bottom of a well and overlaid with a 
type I collagen plug. Media (10% FBS) was added on top and the cells were left 
to invade for 24 hours. Collagen plugs were fixed and the cells were stained 
with Hoechst. Confocal imaging was used to image cells at 0 μm and 50 μm (A) 
and then these images were used to calculate the percentage of cells invading 
over 50 μm. Data represents the mean values ± SEM accumulated from three 
independent experiments (B) Statistical significance was determined by 



































Figure 4.12 FASN knockdown impairs PC3 cell invasion: PC3 shControl and 
PC3 shFASN A3 were seeded into the bottom of a well and overlaid with a type 
I collagen plug. Media (10% FBS) was added on top and the cells were left to 
invade for 24 hours. Collagen plugs were fixed and the cells were stained with 
Hoechst. Confocal imaging was used to image cells at 0 μm and 50 μm (A) and 
then these images were used to calculate the percentage of cells invading over 
50 μm. Data represents the mean values ± SEM accumulated from three 
independent experiments (B) Statistical significance was determined by 




This chapter focussed on identifying if FASN plays a role as a regulator of AR-
independent prostate cancer cell motility. To date there have been no studies in 1542 
or PC3 cells regarding their migratory and invasive potential in response to direct 
silencing of FASN using stable shRNA. Results presented here have shown that 1542 
and PC3 cell adhesion, migration and invasion are effected upon reducing intracellular 
FASN levels.  
Changes in cell morphology are often regarded as an indicator of invasiveness in 
cancer (Friedl and Wolf, 2003).  In chapter 3 it was shown that prostate cancer cells 
with depleted FASN levels exhibited a smaller cell shape when compared to their 
control counterparts. In this chapter FASN overexpression was found to induce the 
opposite effect and increase the overall size of both prostate cancer cell lines. 
Moreover, the addition of exogenous palmitate rescued control cell shape parameters 
in FASN knockdown prostate cancer cells.  These results indicate that there is a 
synchronous relationship between FASN protein levels and cell morphology in AR-
independent prostate cancer cells. In addition, they suggest that the morphological 
phenotype in prostate cancer is being regulated as a result of palmitate availability 
downstream of FASN.   
Studies in the literature have found that supplementation of palmitate concomitantly 
increases overall cell size and induces an EMT phenotype in hepatocellular carcinoma 
cells (Leamy et al., 2014; Nath et al., 2015). Palmitate is involved in the synthesis of 
phospholipids which are one of the major lipid groups required for cell membrane 
expansion and maintenance of cell shape (Glenn et al., 1963; Leamy et al., 2014; Llado 
et al., 2014). Silencing of FASN reduces palmitate synthesis, and in LNCaP cells has 
been shown to decrease phospholipid availability (Knowles et al., 2008; Swinnen et al., 
2003).  In addition to membrane integrity, palmitate has also been found to be 
involved in the activation of Rho GTPases such as Cdc42 and Rac1 in hepatocytes 
(Sharma et al., 2012c). Both these proteins are involved in cytoskeletal reorganisation 
in cancer (Vega and Ridley, 2008). It could be speculated that the FASN knockdown 
morphological phenotype in 1542 and PC3 cells is the result of reduced palmitate 
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synthesis, and therefore attenuated Rho GTPase activity and membrane lipid 
synthesis.  
Changes in signalling as a result of reduced expression of  a particular protein can lead 
to several aberrations in normal cellular behaviour (Martin, 2003). Interestingly, it was 
observed that adhesion in FASN knockdown 1542 and PC3 cells increased relative to 
control cells. These findings contrast two other studies which have seen a decrease in 
cell adhesion in response to FASN knockdown (Yoshii et al., 2013; Zaytseva et al., 
2012). Moreover, they conflict with one study which observed an increase in the 
adhesion of mouse embryonic fibroblasts in response to silencing AMP-activated 
protein kinase (AMPK), a negative regulator of FASN (Georgiadou et al., 2017). Perhaps 
it would be interesting in future studies to assess how AMPK levels alter in FASN 
knockdown prostate cells or if AMPK silencing in these cells produces a similar 
phenotype.  It is not clear why the opposite phenotype has been observed in response 
to FASN depletion, however it has previously been shown that disruption of lipid raft 
activity increases melanoma cell adhesion (Wang et al., 2013a).  
Adhesion and cell shape are highly interrelated, and together are both central features 
of cell migration (Schwartz and Horwitz, 2006). To further elaborate on the increased 
adhesion phenotype seen in response to FASN knockdown, paxillin was stained for in 
1542 cells. Paxillin is a signal transduction adaptor protein which is targeted to focal 
adhesions through four LIM domains present at its c-terminal region (Bellis et al., 
1995). Wells et al showed that silencing of PAK4 increased cell-substrate adhesion in 
DU145 prostate cancer cells which correlated with more elongated paxillin focal 
adhesions (Wells et al., 2010).  Staining showed that this phenotype was essentially 
recapitulated in the FASN knockdown 1542 cells. When palmitate was added to the 
1542 shFASN A3 cells, paxillin adhesion dynamics was almost fully rescued back to 
controls levels.  Interestingly, there is a biphasic relationship between motility and 
adhesion size with either higher or lower concentrations of adhesive ligands being 
associated with slower migration speeds (Schwartz and Horwitz, 2006). These results 
suggest that FASN, along with its fatty acid product palmitate, are contributing to 
adhesion turnover and therefore cells devoid of their activity have an increased 
adhesion phenotype which could be impacting on cell migration.  
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There is currently mounting evidence to suggest that FASN is involved in both initiating 
and driving cell migration (Jiang et al., 2014; Li et al., 2014a). Results from the 2D 
migration assays that were carried out in 1542 and PC3 cells showed a clear decrease 
in the migration speed of FASN knockdown cells compared to control cells in response 
to HGF. These results agree with similar findings by Cao et al who found that FASN 
inhibition using quercetin impaired HGF-stimulated melanoma cell migration (Cao et 
al., 2015).  In addition to confirming the effect of FASN knockdown in cell migration, 
this is also the first time that migratory speed has been recorded in the primary 
prostate cancer cell line 1542 in 2D.  This data shows that on matrigel both 1542 and 
PC3 cells migrate at a similar speed, whilst on type I collagen 1542 cells migrate at a 
slightly increased speed relative to PC3 cells. One reason for this increased migratory 
speed in 1542 cells on type I collagen could be due to a more compatible ratio of 
integrin-adhesion receptors for this matrix (Witkowski et al., 1993).  
The role of FASN in prostate cancer cell migration was further studied with the use of 
FASN inhibitors C75 and orlistat. Results showed that both FASN inhibitors significantly 
impeded 1542 and PC3 cell migration similar to what was observed in the shRNA 
studies. The effects of C75 and orlistat in 2D cancer cell migration have not been 
extensively studied. C75 is a more commonly used FASN inhibitor and has been cited 
to affect the wound healing response in prostate cancer and renal cancer cells 
(Horiguchi et al., 2008; Rae et al., 2015).  Orlistat has not been tested in a 2D migratory 
assay, however it has been found to reduce melanoma and oral tongue squamous cell 
cancer invasion in vivo using mice models (Agostini et al., 2014; Seguin et al., 2012). 
C75 and orlistat reduced the migratory speed of PC3 cells to a similar effectiveness. In 
1542 cells, C75 was found to be more potent than orlistat in reducing cell migration. 
This may have occurred as a result of 1542 cells being more sensitive to inhibition than 
PC3 cells at the chosen concentration of C75 used in the migration assay. The IC50 of 
inhibitors has been reported to vary in different cancer cell lines (Sadowski et al., 
2014). Both FASN inhibitors produced much more dramatic decreases in cell migration 
when compared to stable shFASN cell lines.  Several studies in the literature 
investigating the role of FASN in cancer have opted for the use of inhibitors over the 
use of RNA silencing technology (Agostini et al., 2014; Rae et al., 2015; Zhou et al., 
2016). Inhibitors used at the optimal concertation are generally better tools for 
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completely diminishing a proteins activity in the cell. This is highlighted in one study 
where the authors treated LNCaP cells with either C75 or siRNA and found upon 
comparison that C75 was more effective in reducing cellular growth (Chen et al., 2012). 
In these studies it was decided to use FASN inhibitors in conjunction with shRNA as 
long term treatment with inhibitors can have cytotoxic effects (Rae et al., 2015).  
All 2D migration assays carried out investigated the effect of FASN knockdown on 
prostate cancer cell migration in the presence of HGF. High levels of HGF circulate 
within the prostate tumour environment with its only known target being the tyrosine 
kinase receptor c-Met (Ye et al., 2007).  HGF/c-Met signalling is known to active several 
downstream pathways including PI3K/AKT and MAPK,  both of which have been 
implicated in cell survival, proliferation and migration (Organ and Tsao, 2011).   
In addition to impairing prostate cancer cell migration in 2D, FASN knockdown reduced 
the invasive capabilities of 1542 and PC3 cells through a 3D matrix. These results agree 
with several studies in the literature which have found a reduction in the invasion of 
breast, colorectal, osteosarcoma, ovarian and melanoma cancer cells in response to 
FASN knockdown (Cao et al., 2015; Jiang et al., 2014; Singh et al., 2015; Wang et al., 
2016; Wang et al., 2013b). Moreover, this data compliments the study by Wen et al 
that showed a reduction in PC3 cell invasion in response to suppressed FASN 
expression as result of ASC-J9 treatment (Wen et al., 2016). Cells navigating through a 
3D matrix usually have to adopt slightly different mechanisms to that of cells moving 
across a flat surface. One example of this is the cells dependence on matrix 
metalloproteinases (MMP) to cleave and remodel the surrounding matrix allowing 
them to move past interstitial barriers. The use of MMPs in 2D is not as essential as the 
matrix does not form the same matrix barriers that are seen in 3D (Wu et al., 2014).  
Interestingly, a study by Zaytseva et al showed that when you inhibit FASN in 
colorectal cancer cells the expression of MMP9, a metalloproteinase that degrades 
collagen, is lost (Zaytseva et al., 2014). This could be linked to c-MET/PI3K signalling 
which has been shown to upregulate MMP9 (Chen et al., 2009).  
Within this chapter it was demonstrated that the migration of both prostate cancer 
cell lines in response to HGF is dependent on the expression of FASN. Depletion of 
FASN also increased prostate cancer cell adhesion and the length of paxillin containing 
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adhesive contacts. The invasion of both 1542 and PC3 cells through a 3D collagen 
matrix was also impeded when FASN was depleted in these cell lines. Morphological 
studies carried out in the beginning of this chapter compliment the work done in 
chapter 3 and show that cell shape is dependent on FASN levels. These phenotypic 
changes in cell shape, adhesion, migration and invasion are indicative of changes in the 
actin cytoskeleton as a result of FASN knockdown. Thus in the next chapter the 
possible underlying mechanisms for the defects seen in both prostate cell lines as a 
result of reduced FASN levels will be investigated.  
 
4.4 Future work  
In future studies alternative migration assays could be performed, such as the 
chemotaxis assay, to identify if polarity as well as speed is being affected in response 
to FASN knockdown. Front-rear polarity is important in cell migration and confirming if 
this process is impacted upon the loss of FASN would help in identifying key 
downstream proteins that may be involved in FASN dependent cell migration 
(Huttenlocher, 2005). In addition, the use of conditioned media and other growth 
factors could be useful in determining if factors secreted by stromal cells could rescue 
the migration defect phenotype. Moreover, it would be interesting to assess if 
conditioned media from control prostate cells could rescue the migration of FASN 
knockdown cells. Prostate cancer cells have been shown to secrete exosomes that 
contain an abundance of FASN protein (Duijvesz et al., 2013).  Perhaps FASN 
knockdown cells incubated with a high enough concentration of exosomes secreted by 
control cells could revert to a normal phenotype on the basis of taking up enough 
exogenous FASN protein.  It would also be interesting to perform migration studies 
when overexpressing FASN.  This was initially tried however a viable transfection 
efficiency only occurred when seeding the cells at a high density. This led to 
neighbouring cells being within a close proximity of each other which limited the space 
to migrate freely. Re-seeding the cells after transfection was attempted but generally 
cells would not recover. Perhaps it would be more practical to attempt overexpressing 
FASN in a normal epithelial cell line. This would be interesting in determining if solely 




Investigation of the underlying mechanisms in 


























Chapter 5 – Investigation of the underlying mechanisms in the FASN depleted 
dddddddddprostate cancer phenotype 
5.1 Introduction  
Work within the previous two results chapters has confirmed that prostate cells with 
reduced FASN expression exhibit a different phenotype to prostate cells where 
endogenous FASN levels have not been altered. Changes in cell shape, adhesion, 
migration and invasion indicate that FASN may be directly involved in regulating 
signalling pathways and proteins that influence the actin cytoskeleton.  Although 
several studies have delineated the oncogenic nature of FASN in lipogenesis 
(Menendez and Lupu, 2007), the precise underlying mechanism through which it 
induces reorganisation of the actin cytoskeleton and drives cell migration remains to 
be elucidated.  
In chapter 4 motility in the presence of HGF was shown to be significantly impaired 
upon the silencing of FASN expression. HGF stimulation of c-Met leads to the 
activation of downstream receptor tyrosine kinase PI3K/AKT and MAPK signalling 
pathways which have been shown to induce actin cytoskeletal reorganisation (Organ 
and Tsao, 2011).  FASN activity has been intimately linked with both these pathways 
whose aberrant activation is associated with a more aggressive tumour phenotype 
(Organ and Tsao, 2011). PI3K/AKT and MAPK signalling can regulate FASN expression, 
which in turn can activate EGFR leading to the constitutive activation of these 
oncogenic cascades through an auto-stimulatory loop (Huang et al., 2016; Liu et al., 
2013b; Long et al., 2014; Menendez and Lupu, 2004).  Recently, the PI3K/AKT signalling 
pathway has become increasingly associated with FASN-induced motility in cancer (Li 
et al., 2012a; Li et al., 2012b; Long et al., 2014).  One study demonstrated that FASN 
inhibition in DU145 cells blocked the phosphorylation of c-Met and AKT which 
significantly impaired the cells ability to scatter in response to HGF (Coleman et al., 
2009).  Interestingly, another study has hypothesised a PI3K/AKT/FASN signalling axis 
whereby FASN is driving the migratory phenotype of osteosarcoma cells downstream 
of PI3K/AKT which can be abolished by PI3K inhibition (Zhou et al., 2015).  The 
evidence from these studies suggests that the cross-talk between FASN and PI3K/AKT 
is likely to be synergistically enhancing each other’s ability to drive cell migration, as 
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opposed to existing in a linear pathway. Comparatively, MAPK signalling has been 
shown to be important in cell growth; however its role within the context of FASN-
induced migration remains to be addressed (Huang et al., 2016).  
More recently, interest has been accumulating in the relatively unexplored 
palmitoylation-protein signalling network that lies directly downstream of FASN. 
Protein palmitoylation is a post-translational modification which involves the thioester 
linkage of palmitate moieties to cysteine residues (Bollu et al., 2015). The addition of 
palmitic acid allows for the specific localisation of proteins to subcellular 
compartments and ensures stable protein activity (Yang et al., 2010). In addition, 
stability through palmitoylation has been shown to be essential in some proteins with 
palmitoylation preventing their ubiquitination and protecting them from degradation 
(Linder and Deschenes, 2007).  Proteins can also undergo other types of post-
translational modifications including myristoylation and prenylation, however there 
are irreversible. In comparison, palmitoylation is a reversible modification which allows 
for more dynamic shuttling and signalling within the cell (Aicart-Ramos et al., 2011). 
The Rho GTPases are amongst the most well studied proteins involved in regulating 
the actin cytoskeleton (Vega and Ridley, 2008). Several Rho GTPase proteins have now 
been confirmed to undergo palmitoylation which is important in mediating their 
intrinsic signalling (Aicart-Ramos et al., 2011). RhoU was one of the first Rho GTPases 
whose activity was shown to be dependent on palmitoylation. NIH 3T3 cells expressing 
a RhoU mutant devoid of its palmitoylation motif had severely stunted anchorage 
independent growth relative to cells expressing the wild-type variant (Berzat et al., 
2005).  In a different study, palmitoylation was shown to be important for the stability 
of Rac1 by targeting it to actin-cytoskeleton linked, detergent-resistant membranes, 
which led to unperturbed cell spreading and migration  (Navarro-Lerida et al., 2012).  
Additionally, there is also evidence suggesting that palmitate can regulate Rho GTPases 
that do not contain a palmitoylation motif. This has been shown in a study where the 
activity of Cdc42, another well characterised Rho GTPase in cell migration, increases 




Despite FASN being the only known protein in the cell able to synthesize palmitic acid, 
there has never been a study investigating how abolishing its activity affects the 
palmitoylation of Rho GTPases. Furthermore, how FASN and palmitate may influence 
the expression, stability and activity of Rho GTPases in prostate cancer has also never 
been investigated. The current data in the literature does not evidence a strong link 
between FASN and the Rho GTPases. However, a study by Fiorentino et al showed that 
FASN overexpression increased Wnt-1 palmitoylation in prostate cancer cells 
(Fiorentino et al., 2008). This suggests that the activity of the Rho GTPases could be 
dependent on palmitate levels.  
This chapter aims to identify and investigate a possible underlying mechanism that 
may explain the phenotypic changes observed in FASN knockdown prostate cancer 
cells. A two arm approach was adopted in this investigation which included screening 
proteins in the canonical c-Met transduction signalling pathway; and exploring changes 
















5.2.1 FASN depletion leads to a reduction in c-Met but not PI3K/MAPK 
ssssssignalling  
In the previous chapter it was observed that the knockdown or inhibition of FASN 
impaired motility in the presence of HGF. The c-Met receptor is a high affinity target of 
HGF and the binding of these two molecules leads to the concomitant activation of the 
PI3K/AKT and MAPK transduction pathways (Coleman et al., 2009; Sharma et al., 
2003).   Previously published studies have shown that the silencing or inhibition of 
FASN is associated with a decrease in AKT and ERK phosphorylation in prostate cancer 
(Coleman et al., 2009; Huang et al., 2016). Thus, it was decided to investigate if these 
pathways were being affected in the 1542 and PC3 prostate cancer cell lines in 
response to FASN depletion. 
Western blot analysis revealed that total c-Met expression levels were significantly 
reduced but not depleted in FASN knockdown 1542 and PC3 cells (Figure 5.1A-B and 
Figure 5.2A-B respectively).  Phosphorylation levels of c-Met at tyrosine 1234 and 1235 
mirrored this slight reduction in both prostate cell lines, although this decrease may 
just be reflective of the overall lowered total c-Met levels (Figure 5.1A-C and Figure 
5.2A-C).  Downstream signalling from c-Met was completely unimpeded as shown by 
the indifferent AKT and ERK phosphorylation levels between control and FASN 
knockdown cells (Figure 5.1D-G and Figure 5.2D-G).  Interestingly, in the PC3 shFASN 
A4 cells a notable increase in ERK phosphorylation was observed compared to all other 































Figure 5.1 FASN depletion decreases total and phospho c-Met levels but does 
not affect downstream PI3K/MAPK signalling in 1542 cells: 1542, 1542 
shControl, 1542 shFASN A3 and 1542 shFASN A4 cells were seeded into the 
wells of a 6-well plate. On the following day growth media was removed and 
replaced with serum starve media. Cells were starved for 24 hours before 
stimulating with 10 ng HGF for 15 minutes followed by lysing.  Western blotting 
was then carried out (A) and then quantification of the antibodies c-Met (B), p-
c-Met (C), AKT (D), pAKT (E), ERK (F), and pERK (G) was performed based on 
densitometry analysis. Data represents the mean values ± SEM accumulated 
from three independent experiments.  Statistical significance was determined 
































Figure 5.2 FASN depletion decreases total and phospho c-Met levels but 
does not affect downstream PI3K/MAPK signalling in PC3 cells: PC3, PC3 
shControl, PC3 shFASN A3 and PC3 shFASN A4 cells were seeded into the 
wells of a 6-well plate. On the following day growth media was removed and 
replaced with serum starve media. Cells were starved for 24 hours before 
stimulating with 10 ng HGF for 15 minutes followed by lysing.  Western 
blotting was then carried out (A) and then quantification of the antibodies c-
Met (B),p-c-Met (C), AKT (D), pAKT (E), ERK (F), and pERK (G) was performed 
based on densitometry analysis. Data represents the mean values ± SEM 
accumulated from three independent experiments.  Statistical significance 










5.2.2 Cdc42 isoform expression in prostate cancer and mRNA levels in response 
AAAAto FASN knockdown 
Upon confirming that PI3K/AKT and MAPK signalling pathways were not significantly 
altered in response to FASN knockdown, the exploration of Rho GTPase palmitoylation 
in FASN depleted cells was carried out.  RhoU , Rac1 and a Cdc42 variant have all been 
shown to be palmitoylated proteins, however  the identification and role of 
palmitoylated Cdc42 in cancer has not been studied (Hodge and Ridley, 2016). In 
vertebrates two isoforms of Cdc42, labelled placental and brain, have arisen from 
alternative splicing (Nishimura and Linder, 2013). The localisation and activation of 
both Cdc42 isoforms relies on the attachment of lipid moieties which allows them to 
induce membrane protrusions and directed cell migration (Nishimura and Linder, 
2013; O'Neill et al., 2016).  The placental isoform is ubiquitously expressed and is the 
canonical Cdc42, whilst the brain isoform has only been found to be expressed in 
neuronal cells and platelet cells thus far (Dowal et al., 2011). There is high sequence 
homology between both Cdc42 isoforms with the main difference being that the 
placental isoform is prenylated only, whilst the brain isoform is prenylated and 
palmitoylated (Nishimura and Linder, 2013). To determine which Cdc42 isoforms are 
expressed in 1542 and PC3 cells, plasmids were purchased containing the cDNA for the 
prenylated and palmitoylated variant of Cdc42.  Both plasmids were used as controls 
for primers specifically designed to bind each variant. Reverse transcription PCR 
analysis results showed that both 1542 and PC3 cells express the prenylated isoform, 
but not the palmitoylated isoform of Cdc42 (Figure 5.3A and Figure 5.3B respectively). 
There was an issue with the prenylated Cdc42 primers binding the cDNA of the 
palmitoylated variant of Cdc42. However, the primers targeting the palmitoylation 
region of the brain splice variant of Cdc42 did not amplify any DNA extracted from the 
cell lines or the prenylated Cdc42 construct. Therefore it is highly likely that both 1542 
and PC3 cells do not express the palmitoylated Cdc42 variant which is in agreement 
with previous reports (Nishimura and Linder, 2013). With regards to the expression of 
prenylated Cdc42 in both prostate cell lines, there was no observable difference in 




















































Figure 5.3 1542 and PC3 cells express the prenylated isoform of Cdc42 which is 
not affected transcriptionally by FASN knockdown:   mRNA was extracted from 
1542 and PC3 prostate cancer cells and then reverse transcribed into cDNA. PCR 
was then carried out with primers designed to amplify the prenylated isoform of 
Cdc42 (Placental variant) or the palmitoylated isoform of Cdc42 (brain variant). 
Purchased constructs containing either the prenylated or palmitoylated isoform 
of Cdc42 were used as controls for primer specificity. The amplified products for 
1542 (A) and PC3 (B) were ran on a 2% agarose gel and then visualised under 







5.2.3 Palmitoylation of Rho GTPases RhoU and Rac1 
Since the palmitoylated isoform of Cdc42 was not found to be expressed in either 1542 
or PC3 cells, it was decided to focus on the palmitoylation of RhoU and Rac1. RhoU is 
an atypical GTPase which is exclusively modified by palmitoylation (Berzat et al., 2005).  
The role of RhoU in prostate cancer has not been extensively studied, however in one 
study it was shown that the silencing of RhoU in PC3 cells impaired migration and 
invasion, although proliferative defects were not controlled for (Alinezhad et al., 2016). 
Moreover, in a different study the silencing of RhoU increased paxillin associated 
adhesion length in breast cancer cells mirroring the adhesion phenotype observed in 
FASN knockdown 1542 and PC3 cells (Figure 4.4 and Figure 4.5),(Dart et al., 2015). 
Unlike RhoU, Rac1 is a well-studied Rho GTPase which has been shown to induce 
morphological changes and cell migration in PC3 cells (Kato et al., 2014).  Interestingly, 
both these functions of Rac1 have now been confirmed to be largely dependent on 
palmitoylation (Navarro-Lerida et al., 2012). 
A schematic depiction of the palmitoylation assay with a detailed description in the 
legend is shown in Figure 5.4. In brief, immunoprecipitation is carried out to capture 
the Rho proteins which are then incubated with NEM to block all cysteine residues.  
Following this, Rho proteins are then treated with hydroxylamine to remove palmitate 
from the cysteine residues. Biotin-BMCC is then added to bind the previously S-
acylated protein residues and the resulting lysates can be processed by western 
blotting. The level of protein palmitoylation is detected with streptavidin-HRP probing 
(Figure 5.4). The control for the palmitoylation assay is essentially a duplicate of the 
lysate which has not been incubated with hydroxylamine. The absence of a signal in 
the control confirms that in the hydroxylamine positive lysate a biotin-BMCC palmitate 
switch has occurred. To confirm assay sensitivity GFP-RhoU and GFP-Rac1 were 
overexpressed in HEK293 cells and then subjected to the palmitoylation assay. 
Western blots in Figure 5.5 show a positive exposure signal for both RhoU and Rac1 
indicating that biotin-BMCC has successfully bound to previously palmitoylated 




















































Figure 5.4 Schematic diagram of the palmitoylation assay:  1) An immunoprecipitation 
is carried out to isolate the protein of interest. 2) Lysates are then incubated with N-
ethylmaleimide (NEM) which blocks all free sulfhydryl groups. 3) Hydroxylamine 
(NH2OH) is then added to the samples to cleave the thioester bond and remove 
palmitate from the cysteine residues. 4) Cysteine residues with a now free sulfhydryl 
group can be bound by the thiol specific reagent biotin-BMCC (Btn-BMCC). 5)Proteins 
are subjected to western blotting and probed with streptavidin-HRP which has an 



















































Figure 5.5 Palmitoylation of RhoU and Rac1:  HEK293 cells were transfected 
with GFP-RhoU or GFP-Rac1 and then 48 hours the palmitoylation assay was 
carried out. The biotin-BMCC modified samples were detected using 
streptavidin-HRP. (A) Shows the palmitoylation of GFP-RhoU and (B) shows the 
palmitoylation of GFP-Rac1.  The streptavidin-HRP probed blot was stripped to 
remove the palmitoylation signal and then probed for GFP confirming the total 
amount of GFP-RhoU or GFP-Rac1 that was immunoprecipitated. The whole cell 
lysate (WCL) was run in parallel acting as a control for the experiment and was 
probed for total GFP levels and the loading control HSP90. The blots are 






5.2.4 RhoU and Rac1 palmitoylation increases when overexpressing FASN 
Having established RhoU and Rac1 palmitoylation, the influence of FASN 
overexpression was tested given that it has been previosuly reported that Wnt1 
palmitoylation alters concurently with increaseing levels of FASN (Fiorentino et al., 
2008). FLAG-FASN was co-expressed with either GFP-RhoU or GFP-Rac1 in HEK293 cells 
and then the resulting level of palmitoylation was compared to HEK293 cells 
expressing the respective Rho GTPase only. The overexpression of FASN was found to 
significantly increase the level of palmitoylation in both Rho GTPases compared to cells 
expressing either GFP-RhoU and GFP-Rac1 alone (Figure 5.6).  
 
 
5.2.5 Silencing of FASN reduces RhoU palmitoylation in prostate cancer cells 
Upon confirming that RhoU and Rac1 palmitoylation increased in response to FASN 
overexpression, the palmitoylation levels of these two Rho GTPases in FASN depleted 
cells was tested.  Before performing the palmitoylation assay endogenous levels of 
RhoU and Rac1 were probed for in order to identify whether the expression of these 
proteins changes in response to FASN knockdown. Western blot analysis showed that 
FASN knockdown in 1542 cells does not affect RhoU or Rac1 expression (Figure 5.7A 
and 5.7B respectively).   
For this experiment GFP-RhoU and GFP-Rac1 were overexpressed in 1542 shControl, 
1542 shFASN A3 and 1542 shFASN A4 cells. The palmitoylation assay was carried out in 
the exact same manner as with the HEK293 cells. RhoU palmitoylation detected in 
extracts treated with hydroxylamine was significantly decreased in 1542 shFASN A3 
(Figure 5.8A) and 1542 shFASN A4 cells (Figure 5.8B) compared to 1542 shControl 
cells. Alternatively Rac1 palmitoylation was not affected in 1542 shFASN A3 (Figure 























































Figure 5.6 FASN overexpression increases RhoU and Rac1 palmitoylation:  
HEK293 cells were transfected with either GFP-RhoU or GFP-Rac1 alone, or with 
one of the Rho GTPases and FLAG-FASN.  Cells were left for 48 hours and then the 
palmitoylation assay was carried out. The biotin-BMCC modified samples were 
detected using streptavidin-HRP. GFP-RhoU palmitoylation in response to FASN 
overexpression is shown in (A) along with the quantification of the palmitoylation 
signal which was determined by densitometry analysis. The same palmitoylation 
experiment was performed with GFP-Rac1 and is shown in (B) along with 
densitometry quantification. The streptavidin-HRP probed blots were stripped to 
remove the palmitoylation signal and then probed for GFP allowing for the 
quantification of total GFP-RhoU or GFP-Rac1. The WCL was run in parallel acting 
as a control for the experiment and probed for FASN and total GFP. Data 
represents the mean values ± SEM accumulated from three independent 





















































Figure 5.7 FASN knockdown does not affect RhoU or Rac1 expression in 
1542 cells:   Western blotting was carried out to determine the expression of 
RhoU (A) and Rac1 (B) in 1542, 1542 shControl, 1542 shFASN A3 and 1542 
shFASN A4 cell lysates. Quantification of RhoU and Rac1 was determined by 
densitometry analysis. Data represents the mean values ± SEM accumulated 





















































Figure 5.8 FASN knockdown decreases GFP-RhoU palmitoylation in 1542 cells:  
1542 shControl, 1542 shFASN A3 and 1542 shFASN A4 cells were transfected with 
GFP-RhoU. Cells were left for 48 hours and then the palmitoylation assay was 
carried out. The biotin-BMCC modified samples were detected using streptavidin-
HRP. Western blotting of RhoU palmitoylation in 1542 shControl and 1542 shFASN 
A3 along with quantification via densitometry analysis is seen in (A). The same 
experiment was performed in our second FASN knockdown cell line (shFASN A4) 
which can be seen in (B) along with quantification. The streptavidin-HRP probed 
blot was stripped to remove the palmitoylation signal and then probed for GFP 
allowing for quantification of total GFP-RhoU. The WCL was run in parallel acting as 
a control for the experiment and was probed for FASN and total GFP. Data 
represents the mean values ± SEM accumulated from three independent 





















































Figure 5.9 FASN knockdown does not affect GFP-Rac1 palmitoylation in 1542 
cells:  1542 shControl, 1542 shFASN A3 and 1542 shFASN A4 cells were transfected 
with GFP-Rac1. Cells were left for 48 hours and then the palmitoylation assay was 
carried out. The biotin-bmcc modified samples were detected using streptavidin-
HRP. Western blotting of Rac1 palmitoylation in 1542 shControl and 1542 shFASN 
A3 along with quantification via densitometry analysis can be seen in (A). The same 
experiment was performed in our second FASN knockdown cell line (FASN A4) 
which can be seen in (B) followed by quantification. The streptavidin-HRP probed 
blot was stripped to remove the palmitoylation signal and then probed for GFP 
allowing for the quantification of total GFP-Rac1. The WCL was run in parallel 
acting as a control for the experiment and was probed for FASN and total GFP. 
Data represents the mean values ± SEM accumulated from three independent 




5.2.6 FASN knockdown reduces endogenous RhoU palmitoylation levels in 
ddddprostate cancer cells 
After confirming that GFP-RhoU palmitoylation is decreasing in response to FASN 
knockdown further studies were carried out to assess how the palmitoylation of 
endogenous RhoU is being modulated in the same system. The palmitoylation assay 
was carried out identically to previous experiments however the method of protein 
capture differed.  Previous experiments used the GFP-Trap beads which required no 
addition of an IgG antibody.  In this experiment the method of immunoprecipitation 
performed required the use of an in-house anti-PAK4 antibody to capture RhoU which 
has been shown to interact with a high affinity (Dart et al., 2015).  In-house PAK4 
antibody was used as there is no anti-RhoU antibody capable of efficiently 
immunoblotting endogenous RhoU protein. Western blot analysis showed that 
endogenous RhoU palmitoylation decreased in 1542 shFASN A3 (Figure 5.10A) and 
1542 shFASN A4 cells (Figure 5.10B) compared to 1542 shControl cells. These results 
confirm that RhoU palmitoylation is FASN dependent.  
 
 
5.2.7 Paxillin S272 adhesion decreases in response to FASN knockdown   
In the previous chapter it was found that there was an increase in focal adhesion 
length and the adhesiveness of FASN knockdown prostate cancer cells.  This observed 
phenotype suggests that focal adhesion turnover is being impeded in response to 
reduced FASN expression. Previous work in the lab by Dart et al  showed that RhoU 
promotes paxillin phosphorylation and that silencing its activty led to larger and more 
numerous focal adhesions (Dart et al., 2015). In FASN knockdown cells, the 
palmitoylation levels of RhoU were found to be decreased. However, 1542 FASN 
knockdown cells treated with palmitate had a partial rescue in paxillin adhesion length 
(Figure 4.6). Thus,  the palmitoyation of RhoU may be required for paxillin 
phosphorylation and so it was decided to immunoblot for the changes in either total 
paxillin or phosphorylated paxillin in 1542 and PC3 cells. Western blot analysis 
confirmed that there was a significant decrease in paxillin phosphorylation at serine 




















































Figure 5.10 FASN knockdown decreases endogenous RhoU palmitoylation in 
1542 cells:  1542 shControl, 1542 shFASN A3 and 1542 shFASN A4 cell lysates were 
incubated with in-house PAK4 IgG for 3 hours before agarose bead capture. After 
lysates were incubated with the beads for one hour the palmitoylation assay was 
carried out. The biotin-BMCC modified samples were detected using streptavidin-
HRP. Western blotting of RhoU palmitoylation in 1542 shControl and 1542 shFASN 
A3 along with quantification via densitometry analysis can be seen in (A). The 
same experiment was performed with the second FASN knockdown cell line 
(shFASN A4) which can be seen in (B) along with the quantification. The 
streptavidin-HRP probed blot was stripped to remove the palmitoylation signal and 
immunoblotted for RhoU allowing for the quantification of total RhoU. The WCL 
was run in parallel acting as a control for the experiment and was probed for total 
RhoU. Data represents the mean values ± SEM accumulated from three 
independent experiments.  Statistical significance was determined by student’s t-




















































Figure 5.11 FASN knockdown decreases paxillin s272 phosphorylation in 
1542 and PC3 cells:   Western blotting was carried out to determine the 
expression of Paxillin and pS272 paxillin in 1542, 1542 shControl, 1542 shFASN 
A3 and 1542 shFASN A4 cell lysates. Quantification was then determined by 
densitometry analysis as seen in (A). The same was done for PC3 cells as 
shown by the western and quantification in (B). It should be noted that both 
pS272 paxillin bands were used for densitometry quantification in PC3 cells. 
Data represents the mean values ± SEM accumulated from three independent 






5.2.8 FASN depletion and inhibition leads to loss of Cdc42  
mRNA expression data showed that 1542 and PC3 cells express the prenylated, but not 
the palmitoylated variant of Cdc42.  However, in both hepatocellular and cardiac 
muscle cells palmitate has been shown to modulate the expression and activity of 
Cdc42, which based on the other findings in the literature, is the prenylated isoform 
(Puthanveetil et al., 2011; Sharma et al., 2012c). Indeed FASN knockdown decreased 
cell size and migratory capacity producing a similar phenotype in PC3 cells to what has 
previously been reported in this cell line upon Cdc42 silencing (Reymond et al., 2012). 
Thus, total Cdc42 expression levels were probed for in both prostate cell lines.  
Western blotting analysis reveals that Cdc42 protein expression decreases in FASN 
knockdown 1542 cells compared to 1542 shControl cells (Figure 5.12A). Similarly, the 
same decrease in Cdc42 expression was validated in the best FASN knockdown PC3 cell 
line (Figure 5.12B). In addition to stable knockdown cell lines, the FASN inhibitor C75 
was used to confirm if blocking FASN activity decreases Cdc42 expression.  Both 1542 
and PC3 cells treated with C75 showed a significant decrease in Cdc42 expression 








































































Figure 5.12 FASN knockdown and inhibition leads to decreased Cdc42 levels 
in 1542 and PC3 cells:   Western blotting was carried out to determine the 
expression of Cdc42 (A) in 1542, 1542 shControl, 1542 shFASN A3 and 1542 
shFASN A4 cell lysates.  Quantification was then determined by densitometry 
analysis. The same was done for PC3 cells (comparing control against best 
FASN knockdown) as shown by the western in (B). 1542 and PC3 cells were 
treated with DMSO and C75 25 μM for 24 hours before lysing. Protein lysates 
were separated by SDS-PAGE and Cdc42 was probed for in 1542 (C) and PC3 
(D) cells.  Data represents the mean values ± SEM accumulated from three 
independent experiments.  Statistical significance was determined by 







5.2.9 Cdc42 overexpression rescues FASN knockdown 1542 cell morphology 
In this chapter it has been found that Cdc42 protein levels are dependent on FASN 
expression and activity.  It has been published that Cdc42 regulates PC3 cell 
morphology through its ability to affect the actin cytoskeleton (Reymond et al., 2012). 
Thus, it was decided to investigate if re-expressing Cdc42 could rescue the FASN 
knockdown morphology defect. To assess this 1542 shFASN A3 cells were seeded onto 
matrigel coated coverslips and then transfected with either GFP or GFP-Cdc42. Cell 
shape analysis was done on the phalloidin staining in keeping with all previous 
experiments (Figure 5.13). Results show a partial rescue in cell shape in GFP-Cdc42 
expressing 1542 shFASN A3 cell compared to the same cells expressing GFP which still 














































Figure 5.13 Cdc42 overexpression rescues the FASN knockdown 
morphological phenotype in 1542 cells:   1542 shControl and 1542 shFASN A3 
cells were seeded onto matrigel coated coverslips. 1542 shFASN A3 cells were 
transiently transfected with either GFP or GFP-Cdc42. Cells were left for 24 
hours before staining with phalloidin (A). For transfected cells the Images are a 
composite of phalloidin staining (Grey) and GFP fluorescence (Green). ImageJ 
was used to calculate the cell area and perimeter of 60 cells per condition. This 
data was used to determine differences in cell perimeter and area between 
our conditions (B). Data represents the mean values ± SEM accumulated from 
three independent experiments. Statistical significance was determined by 
student’s t-test. *p<0.05  ***p<0.001  n/s= not significant. Bar= 10 μM. 
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5.2.10 Silencing of RhoU and inhibition of its palmitoylation leads to a loss in 
xxxxxxCdc42 expression 
The results so far reveal that RhoU palmitoylation and total Cdc42 expression decrease 
in a FASN knockdown background, however it is not known if these two proteins are 
linked. To investigate this, Cdc42 expression was probed for in 1542 cells with either 
depleted RhoU levels, or with normal, but non-palmitoylated RhoU levels. The 
silencing of RhoU in 1542 cells led to a significant decrease in Cdc42 expression 
compared to control cells (Figure 5.14A). Abrogating normal RhoU activity was 
accomplished by global blockage of palmitoylation with 2-bromopalmitate (2BP), a 
DHHC protein inhibitor, for 24 hours (Jennings et al., 2009). Prevention of palmitate 
incorporation did not affect total RhoU levels, however inhibition did significantly 





5.2.11 Interaction studies show that RhoU associates with Cdc42 
The results currently show that in FASN depleted cells there is a reduction in Cdc42 
protein levels (Figure 5.12), but no change in mRNA levels (Figure 5.3). Furthermore, it 
has also been shown that a decrease in RhoU protein expression or palmitoylation also 
depletes Cdc42 protein levels (Figure 5.14). All this suggests that these two proteins 
may be binding.  Cdc42 is known to homodimerize, and based on the extensive shared 
sequence homology it may also be able to heterodimerize with RhoU (Chuang et al., 
2007; Zhang and Zheng, 1998).  Mistargeting of RhoU, which has been reported in NIH 
3T3 cells expressing palmitoylation mutants, may be failing to dimerize with Cdc42, 
which may be important in protecting it from degradation (Berzat et al., 2005). In 
order to help confirm this hypothesis it was first decided to identify if these two Rho 
GTPases interact with each other. Using the GFP-Trap system it was shown that Cdc42 
























































Figure 5.14 RhoU knockdown and palmitate inhibition leads to loss of Cdc42:   
For knockdown studies 1542 cells were transfected with siControl and siRhoU 
for 48 hours before harvesting. Palmitate incorporation inhibition was carried 
out by treating the cells with 2-Bromopalmitate (2BP) 100 μM for 24 hours. A 
DMSO control was prepared in parallel. Lysates were separated by SDS-PAGE 
and then immunoblotted for RhoU and Cdc42. Quantification of bands for 
RhoU siRNA knockdown (A) and RhoU palmitoylation inhibition (B) was carried 
out by densitometry analysis. Data represents the mean values ± SEM 
accumulated from three independent experiments.  Statistical significance was 



















































Figure 5.15 Co-immunoprecipitation of Cdc42 with RhoU:   HEK293 cells were 
co-transfected with either GFP-Cdc42 and HA-RhoU or GFP alone and HA-RhoU. 
GFP was used as a negative control in this assay. After 48 hours the cells were 
lysed and a GFP-Trap was carried out.  Lysates were subjected to SDS-PAGE gel 
electrophoresis and then the Co-IP western was immunoblotted using anti-GFP 
and anti-HA antibody. The WCL was run in parallel and probed for the same 





The aim of this chapter was to elucidate molecular mechanisms that can account for 
the FASN depleted phenotype in prostate cancer.  These mechanistic changes can then 
be correlated with the cell motility and invasive phenotypes characterised in chapter 4.  
In the current literature FASN has been identified to have a migratory role in several 
cancers including prostate, however the exact molecular mechanisms driving FASN-
induced cell motility still remain to be fully elucidated (Coleman et al., 2009; Wen et 
al., 2016; Zaytseva et al., 2012).  
In this chapter it was shown that FASN knockdown led to a small, but significant 
decrease in c-Met expression. This drop in c-Met levels however to not affect 
downstream PI3K/AKT and MAPK signalling. Additionally, for the first time a unique 
role for FASN in the regulation of RhoU palmitoylation and Cdc42 expression was 
identified in the chapter. It was further demonstrated that the re-expression of Cdc42 
in FASN depleted cells could rescue the morphology defect.  This chapter also showed 
that depletion of RhoU, or prevention of its palmitoylation, decreased Cdc42 
expression.  From this data a Co-IP was carried out and it was revealed for the first 
time that RhoU and Cdc42 are binding partners, or at least exist in a complex with each 
other.  
The regulatory link between FASN and c-Met has been well documented across several 
studies (Coleman et al., 2009; Hu et al., 2016; Uddin et al., 2010). The results 
presented in this chapter showed a modest drop in c-Met levels in response to FASN 
knockdown complimenting these previously documented findings.  A study by Hu et al 
has confirmed that FASN suppression affects c-Met on the post-translational level in 
hepatocellular carcinoma cells (Hu et al., 2016). This is further clarified in another 
recently published study by Coleman et al who found that c-Met receptor trafficking 
and stability in DU145 cells was dependent on palmitoylation, and that the prevention 
of this modification leads to a loss in total c-Met (Coleman et al., 2016).  This reduction 
in palmitate, and therefore palmitoylation as a result of FASN knockdown may be the 
most likely explanation for the decrease in c-Met expression that was observed in 1542 
and PC3 cells.   
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Downstream activation of AKT and ERK was unaffected in FASN depleted prostate 
cancer cells. ERK phosphorylation did increase in the PC3 shFASN A4 line; however it is 
unlikely this was a direct result of altered FASN expression since it was not observed in 
any of the other FASN knockdown clones.  Previous studies have found that the 
inhibition of FASN usually correlates with the reduced phosphorylation of AKT and ERK 
(Chang et al., 2016; Coleman et al., 2009; Huang et al., 2016; Wang et al., 2013b). 
Reduced AKT phosphorylation has been shown to impair the FASN migratory 
phenotype in osteosarcoma cells (Zhou et al., 2015). ERK phosphorylation has not yet 
been shown to be important in FASN mediated cell migration with the majority of 
studies attributing its role mainly to growth (Coleman et al., 2009; Huang et al., 2016).  
Interestingly, in chapter 3 it was shown that FASN knockdown in 1542 and PC3 cells 
significantly decreased the rate of cellular proliferation.  Since no decrease in ERK 
phosphorylation was seen in these same cells it would suggest that ERK activation is 
not essential in FASN-mediated cell growth.  
One reason for AKT and ERK signalling being unperturbed in the FASN knockdown cell 
lines could be due to c-Met still being expressed at sufficient levels to elicit a response. 
Coleman et al found that c-Met expression was completely suppressed in response to 
FASN knockdown in DU145 cells (Coleman et al., 2009). Comparatively, in this study it 
was found that c-Met levels were still relatively high in the FASN knockdown prostate 
cancer cell lines. In addition, PC3 cells harbour a null variant of PTEN (PTEN status 
currently unknown for 1542 cells), the cells natural negative regulator of the PI3K/AKT 
signalling pathway (Majumder and Sellers, 2005). This means it may be more difficult 
to suppress AKT signalling without completely abolishing FASN activity as shown in a 
previous study with PTEN mutant cells treated with a FASN inhibitor (Ventura et al., 
2015). Alternatively, cancer cells have been documented to re-wire their internal 
signalling to compensate with the loss or reduction of a certain protein (Zhang et al., 
2014).  This has been shown in a study by Ross et al were it was found that AKT 
phosphorylation recovered after 24 hours even though the PC3 cells were still under 
orlistat treatment (Ross et al., 2008). It could be possible that the stable long term 
reduction in FASN levels in both prostate cell lines have led to AKT and ERK signalling 
adapting to not be dependent on FASN expression. Whilst this cannot be confirmed at 
this moment in time, it would be interesting in future experiments to probe for 
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phospho-AKT and ERK in both prostate cell lines at a closer time-point to the initial 
knockdown of FASN.  Regardless, this data confirms that AKT and ERK signalling is most 
likely not responsible for the migration defect seen in response to FASN knockdown in 
1542 and PC3 cells.  
In addition to looking at signal transduction pathways downstream of c-Met this 
chapter also focussed on exploring a potential role for FASN in the palmitoylation of 
Rho GTPases. The palmitoylated protein signalling network comprises over 300 
proteins and is largely unexplored in cancer (Martin and Cravatt, 2009). It is only more 
recently that researchers are starting to acknowledge FASN as a crucial regulator of 
palmitoylation mediated protein signalling. The results presented in this chapter are 
the first to confirm a novel dependency on FASN for Rho GTPase palmitoylation.  
Overexpression of FASN in HEK293 cells led to an increase in RhoU and Rac1 
palmitoylation.  These findings are consistent with a previous report which 
demonstrated that Wnt-1 palmitoylation increases in FASN-overexpressing prostate 
epithelial cells (Fiorentino et al., 2008).  Conversely, the silencing of FASN led to a 
decrease in RhoU palmitoylation. Unlike RhoU, Rac1 palmitoylation was not affected 
by FASN knockdown in 1542 cells.  To date, only one other study has shown a 
differential S-acylation response between two proteins in a FASN depleted system. 
Wei et al found that FASN knockdown in Caco-2 colorectal cancer cells decreased 
mucin 2 palmitoylation but not affect claudin-1 palmitoylation (Wei et al., 2012). There 
is currently no explanation for this phenomenon however it could be speculated that 
the reduced pool of available palmitate may be prioritized to prevent catastrophic 
effects in the cell.  Additionally, the different methods of palmitate attachment may 
also be influencing the increased likelihood of protein palmitoylation. The majority of 
cellular palmitoylation events are carried out by DHHC proteins; however substrate-
specific PAT’s and spontaneous acylation also mediate pamitoyl-CoA linkage (Corvi et 
al., 2001; Roth et al., 2006; Xue et al., 2004). Therefore it could be the case that Rac1 is 
posttranslationally modified via a different means to RhoU which may potentially give 
it more rapid or prioritized access to palmitate.  
The role of RhoU in cancer is not as well studied as some of the other Rho GTPases. 
Furthermore, the consequences of impaired palmitoylation on its function have not 
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been fully elucidated.  Tao et al first reported that RhoU could bind PAK1 to induce 
filopodium formation and stress fibre dissolution (Tao et al., 2001).  Since then RhoU 
has been found to play an important role in the regulation of cell morphology, 
adhesion turnover, and cell migration (Alinezhad et al., 2016; Dart et al., 2015).  
Palmitoylation of RhoU has been found to be important in maintaining its functional 
integrity (Berzat et al., 2005).  Blocking palmitoylation causes mislocalization and 
cytosolic accumulation of RhoU.  Mislocalization of RhoU prevents PAK1 
phosphorylation, causes changes in cellular morphology and impairs cell growth 
(Berzat et al., 2005; Tao et al., 2001). It is currently unclear how essential 
palmitoylation is for RhoU to induce cell migration.  However, one study has found 
that the RhoU-EGFR interaction is dependent on RhoU palmitoylation and that the 
resulting complex enhances EGF-induced JNK activation and cell migration (Zhang et 
al., 2011). 
It has been published that the silencing of RhoU in breast cancer cells results in 
increased cell-substrate adhesion and the formation of more elongated focal 
adhesions. This more adhesive phenotype is a consequence of reduced paxillin 
phosphorylation due to the loss of RhoU (Dart et al., 2015). This phenotype along with 
the resulting decrease in paxillin phosphorylation was essentially recapitulated here in 
the FASN knockdown prostate cancer cell lines.  These results hint that the 
palmitoylation of RhoU is also important in paxillin adhesion dynamics. To further 
support this, in chapter 3 it was shown that the addition of palmitate to FASN 
knockdown 1542 cells almost fully restored the length of paxillin adhesions to the 
length observed in control cells. Thus, this data suggests that FASN dependent 
adhesion turnover is most likely being regulated by palmitoylated RhoU. It should be 
noted however that one study reported that palmitoylation of RhoU is not required for 
its targeting to focal adhesions (Ory et al., 2007).  
In this chapter it was found that unlike RhoU and Rac1, Cdc42 protein expression levels 
decreased in response to FASN knockdown. This is the first time an association 
between FASN and the Rho GTPase Cdc42, or more specifically, the prenylated isoform 
of Cdc42, has been documented.  Moreover, this result compliments a previously 
published study which showed an increase in Cdc42 expression in cardiomyocyte cells 
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treated with exogenous palmitate (Puthanveetil et al., 2011).  Cdc42 is involved in the 
formation of filopodia and is a key protein in polarized cell motility (Keely et al., 1997).  
The silencing of Cdc42 has been shown to give PC3 cells more astrocyte-like 
morphology and impair their ability to migrate effectively through a monolayer of 
endothelial cells (Reymond et al., 2012).  In this study FASN knockdown was shown to 
decrease the overall size of 1542 and PC3 cells. Re-expression of Cdc42 in FASN 
knockdown 1542 cells was able to partially rescue the wild-type morphological 
phenotype. This data strongly supports a role for Cdc42 in driving the morphological 
changes seen in FASN depleted prostate cancer cell, most likely through its ability to 
affect the actin cytoskeleton.  It should be noted that overexpression of Cdc42 could 
have the same effect on the morphology of 1542 shControl cells, however this was not 
tested and thus something to be considered in future.  
During cell migration there is a significant amount of cross-talk between Rho GTPase 
proteins. This has been shown by the activation of Rac1 by Cdc42 through the Rac GEF 
Tiam1 (Cau and Hall, 2005; Pegtel et al., 2007).  Additionally, Rho GTPases exist in a 
signalling network where they can influence each other’s levels. This has been 
observed in the degradation of RhoA which is mediated by smurf-1, a HECT E3 ligase 
recruited by active Cdc42 complexed with Par6 and PKCζ (Wang et al., 2003).   In this 
study it was found that mRNA levels of prenylated Cdc42 did not change between 
control and FASN knockdown cell lines.  These findings infer that in a FASN depleted 
background Cdc42 is being negatively regulated post-translationally.  RhoU and Cdc42 
share significant sequence homology and are both involved in filopodia formation (Tao 
et al., 2001). Interestingly, one study found that the FASN inhibitor orlistat significantly 
reduced the number of filopodial extensions in melanoma cells (Bastos et al., 2016).  
Even though there is functional overlap between these two proteins, how they might 
influence each other’s activity has never been investigated. In this study it was shown 
that the silencing of RhoU in 1542 cells led to a decrease in Cdc42 expression. 
Moreover, RhoU and Cdc42 were identified as interacting partners. It is not clear how 
these two proteins interact,  however  Cdc42 is known to homodimerize and since it 
shares similar sequence homology with RhoU it could be binding via the same 
carboxyl-terminal polybasic domain (Zhang and Zheng, 1998). The complete inhibition 
of palmitoylation with 2BP also significantly ablated Cdc42 expression. PCR and DNA 
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gel electrophoresis results confirmed that both prostate cell lines only expressed the 
prenylated isoform of Cdc42 and not the palmitoylated isoform. This means that 
palmitoylation is not directly responsible for the changes in Cdc42 expression. 
Alternatively, the data presented here suggests that the palmitoylation of RhoU could 
be involved in regulating Cdc42 levels in the cell.  
In rat bladder carcinoma cells Cdc42 has been shown to be susceptible to poly-
ubiquitination and proteasomal degradation (Doye et al., 2002). Interestingly, it has 
been found that DHHC dependent palmitoylation of proteins increases stability and 
protection from proteasome degradation (Percherancier et al., 2001; Wang et al., 
2010). Thus, it could be the case that if Cdc42 is in a heterodimeric complex with RhoU, 
it may be less prone to targeting by E3 ubiquitin ligases.  In addition to possibly 
preventing protein degradation, the binding of RhoU to Cdc42 could potentially 
enhance cell migration in a way that is yet to be determined.  Prenylation and 
palmitoylation differ in that the latter is reversible (Aicart-Ramos et al., 2011). It may 
be that the activity of Cdc42 within the cell is increased upon binding to RhoU due to 
its ability to dynamically shuttle between intracellular compartments. Moreover, it has 
been shown that the biological activity of H-Ras, a protein that can be both prenylated 
and palmitoylated, is greatly compromised upon the prevention of one of these 
modifications (Cadwallader et al., 1994). RhoU cannot be prenylated and Cdc42 cannot 
be palmitoylated, thus the binding of these two proteins may stabilise and 
synergistically enhance each other’s signalling at the plasma membrane. 
In summary, the work presented in this chapter demonstrated that FASN regulates 
RhoU and Cdc42 post-translationally through direct and indirect means respectively.  
Additionally, an interaction between RhoU and Cdc42 was found and may be 
important in FASN-driven cell migration. Evidence for this theory is shown by FASN 
knockdown cells phenocopying the increased focal adhesion phenotype seen in RhoU 






5.4 Future work 
HGF/c-Met signalling is known to drive the activation of several downstream molecules 
(Organ and Tsao, 2011). Whilst PI3K/AKT and MAPK signalling appeared to be 
unaffected in FASN knockdown cells it would be interesting to confirm what changes, if 
any, have occurred in other downstream effector pathways of c-Met.  
It may also be worth trying to further confirm that palmitoylated Cdc42 is not 
expressed in the PC3 and 1542 cells lines. An alternative approach could be to use the 
palmitoylation assay protocol on a large concentration of protein lysate to isolate 
palmitoylated proteins specifically via streptavidin purification. Then these purified 
protein lysates can be run and separated on a western blot and probed for palmitoyl-
Cdc42 which is confirmed by a positive signal in the hydroxylamine positive lysate 
(Dowal et al., 2011). 
Exploring the effects of reduced RhoU palmitoylation in cell migration is also 
something to be investigated. This could be done by re-expressing siRNA resistant 
wild-type- and palmitoylation mutant RhoU in RhoU knockdown cells.  In addition 
elucidating how RhoU or palmitate is preventing Cdc42 degradation would be 
beneficial. Moreover, it needs to be confirmed if Cdc42 can be blotted from 
immunoprecipitated RhoU. Finally, creating domain mutants would also be useful in 
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Chapter 6 – Patho-Epidemiological study:  Is the expression of FASN, RhoU, 
sssssssssssssCdc42, c-Met and HER2 associated with prostate cancer severity? 
6.1 Introduction  
In the previous chapter of this thesis it was shown that FASN expression is linked to the 
expression of Cdc42 and the activity of RhoU in prostate cancer cell lines. In addition, 
c-Met levels were also found to be modestly reduced in a FASN knockdown 
background. To compliment these findings it was decided to perform a pilot patho-
epidemiological study which would assess the expression of FASN, along with these 
biologically linked proteins, in human prostate cancer tissue.  The epidermal growth 
factor receptor HER2 was not studied in the previous chapters, however it was decided 
to include it in the panel of proteins as there is now evidence in the literature which 
suggests that HER2 may influence prostate cancer metastasis to the bone (Day et al., 
2017). In addition, to more specific interest to this project, several papers have now 
shown that HER2 and FASN exist in a signalling axis which drives cell migration in 
osteocarcinoma and colorectal cancer cells (Li et al., 2013; Long et al., 2014). This 
raises the question of whether anti-HER2 drugs alone, or in combination with FASN 
inhibitors could be used to treat prostate cancer patients (Blancafort et al., 2015). 
Another protein included in the panel was Ki67 which is a marker that is strictly 
associated with cellular proliferation (expressed at every stage of the cell cycle except 
G0) and commonly used in TMAs (Scholzen and Gerdes, 2000). More specifically, given 
that uncontrolled cell growth is a common feature in tumours, Ki67 acts as a control to 
help confirm how ‘benign’ or ‘cancerous’ the tissue is aiding histopathological 
assessment (Scholzen and Gerdes, 2000).  
Thus, this study was set out to investigate whether the expression of FASN, RhoU, 
Cdc42, c-Met and HER2 were associated with prostate cancer severity, which is based 
on tissue type (dominant Gleason, abbreviated as DG, highest Gleason, abbreviated as 
HG, and benign tissue) and Ki67 expression levels.  It should be noted that FASN 
expression has previously been reported to increase in prostate cancer relative to 
normal prostate tissue (Rossi et al., 2003). Thus in this study FASN staining acts 
somewhat as a control which is expected to differ between the benign and cancerous 




6.2.1 High expression of FASN, RhoU, Cdc42, c-Met and HER2 in biopsy 
mmcores is predictive of prostate tissue type 
The cohort for this pilot study consisted of 85 men (mean age 67.18) who had 
undergone a radical prostatectomy. The majority of these men had a Gleason score of 
7 (60.00% 51/85), whilst the minority had a Gleason score of 5 (2.35% 2/85) (Table 
6.1). Univariate logistic regression was carried out to predict if any of the biomarkers 
were abnormally expressed in either benign or cancerous tissue (Dominant Gleason-
DG and Highest Gleason-HG).  In the univariate analysis, relative to benign tissue, both 
DG and HG cancerous tissue types were shown to be significantly associated with an 
increase in the protein expression of FASN, RhoU, Cdc42 and c-Met (Table 6.2 and 
Figure 6.1).  Additionally, the HG tissue type was found to be predictive of increased 
HER2 expression, OR 1.82 (95% CI: 1.19-2.78), when compared to benign prostate 
tissue (Table 6.2).  For the DG tissue type there was also a positive association with 
HER2 expression, however the findings were not statistically significant, OR 2.10 (95% 
CI: 0.90-4.89), (Table 6.2).  This association can also  be seen in Table 6.3 which shows 
almost twice as many DG cases with high HER2 staining (21.95% 18/82) compared to 












Factor Study Population 
(N=85) 
Mean age (SD), years 67.18 (5.81) 

















            37 (43.43) 
            14 (16.67) 
 
             9 (10.59) 
 4   (4.71) 
 
Median PSA (IQR Q1-Q3) 
 
          6.4 (4.6-8.1)        
 
Table 6.1 Baseline characteristics of radical prostatectomy patients 
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Table 6.2  Univariate odds ratios (OR) with 95% confidence intervals (CI) 
to predict abnormal expression levels of FASN, RhoU, c-Met, HER2, and 
Ki67 based on prostate tissue type (i.e. dominant and highest Gleason 





































































































































































   
   
   
   





   
   
   
   

































































































    
   
   
   
  
   
   
   









   
   
   
   









   
   
   
 
   
   
   









   
   
   









    
   
   









   
  
   
   
   









   
   
   
   
   
   
   
   
















































































































































































































































6.2.2 Ki67 expression in prostate cancer is associated with the expression of all 
ssssssbiological markers 
As mentioned in the introduction to this chapter, Ki67 has been regarded as one of the 
most promising immunohistochemical biomarkers for identifying proliferating cell 
fractions and is often correlated with the clinical course of cancer (Scholzen and 
Gerdes, 2000).  Univariate analysis in Table 6.4 reveals that the expression of FASN, 
RhoU, Cdc42, c-Met and HER2 is positively associated with Ki67 expression.  
Subsequently, when performing multivariable analyses it was found that FASN, Cdc42 
and c-Met expression remain statistically significant and positively associated with Ki67 
expression.  RhoU was also still positively associated, but the finding became not 
statistically significant, OR 2.61 (95% CI: 0.94-7.20). The association between HER2 
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Biomarker Univariate 
OR (95% CI) 
Multivariable 





















5.21 (2.85-9.51) 2.79 (1.38-5.65) 
HER2 3.25 (1.69-6.26) 1.07 (0.47-2.44) 
 
Table 6.4 Odds ratios (OR) and 95% confidence intervals (CI) for the 
association between the biomarkers FASN, RhoU, Cdc42, c-Met and 
HER2 and high expression levels of ki67: The univariate model 
assessed the association of each biomarker against Ki67 expression, 
whilst the multivariable assessed how all the biomarkers associated 


























Figure 6.1 Representative immunohistochemistry for FASN, RhoU, Cdc42, 
c-Met, HER2 and Ki67 in benign tissue and prostatic adenocarcinoma 
(dominant and highest Gleason): Images for each protein were taken from 





The aim of this part of my thesis was to identify if the proteins FASN, RhoU, Cdc42, 
HER2 and Ki67 were differentially expressed in prostate cancer tissue when compared 
to benign prostate tissue.  Indeed an increase in the expression of all proteins was 
observed in cancerous tissue.  In this study, DG prostate cancer tissue was 12.4 times, 
3.13 times, 3.30 times and 37.63 times more likely to be associated with higher 
expression levels of FASN, RhoU, Cdc42 and c-Met, respectively, than benign prostate 
tissue. Additionally, HG prostate cancer tissue was 4.24 times, 3.17 times, 2.57 times, 
6.25 and 1.82 times more likely to be associated with higher expression levels of FASN, 
RhoU, Cdc42, c-Met and HER2, respectively, than benign prostate tissue.  
The results for FASN immunohistochemical staining agree with several published 
findings in the literature which have shown it to be more highly expressed in cancerous 
prostate tissue than non-cancerous prostate tissue (Cheng et al., 2015; Hamada et al., 
2014; Rossi et al., 2003; Swinnen et al., 2002; Van de Sande et al., 2005). To date this is 
the first study to show a differential expression profile for RhoU at the protein level 
between normal prostate tissue and cancerous prostate tissue.  This result 
compliments the findings from another study by Alinezhad et al where the authors 
found RhoU mRNA levels to be increased in cancerous prostate tissue when comparing 
to benign prostate tissue (Alinezhad et al., 2016). Similar to RhoU, this is also the first 
study to show that increased Cdc42 expression is associated with prostatic carcinoma 
status. Two other studies in the literature have shown similar results but in ovarian 
and cervical cancer (Guo et al., 2015; Ye et al., 2015). Higher c-Met expression in 
prostate cancer relative to non-malignant prostate tissue has also been well 
documented in the literature (Jacobsen et al., 2013; Knudsen et al., 2002). As discussed 
in the previous chapter, c-Met and FASN are intimately linked in prostate cancer 
(Coleman et al., 2009). c-Met receptor stability is dependent on palmitoylation and 
FASN expression is dependent on the PI3K/AKT and MAPK signalling downstream of c-
Met (Coleman et al., 2016; Huang et al., 2016).  Further evidence of this has been  
observed in a study by Uddin et al who found that FASN overexpression in diffuse 
Large B-cell Lymphoma is significantly associated with the overexpression of c-Met 
(Uddin et al., 2010).  In this study, the HG prostate cancer tissue type was associated 
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with HER2 overexpression. This finding agrees with a previously published study by 
Day et al who found that HER2 expression to be low in the primary prostate tumour, 
but high in prostate cancer tissue (Day et al., 2017).  
Ki67 has been shown to be a promising biomarker for predicting prostate cancer 
disease stage (Berney et al., 2009). Univariate analysis showed that the expression of 
all the biomarkers positively associated with Ki67 expression. When performing a 
multivariable analysis, which included all the biomarkers, the association for RhoU 
became weaker and HER2 expression was no longer associated with ki67 expression.   
This suggests that FASN, Cdc42 and c-Met expression levels are better predictors for 
Ki67 expression than RhoU and HER2.    
This is not the first study to show a link between FASN and Ki67.  FASN expression has 
been shown to be significantly associated with Ki67 expression in osteosarcomas, soft 
tissue sarcomas, endometrial cancer and pancreatic cancer (Alo et al., 2007; Liu et al., 
2012; Pizer et al., 1998; Takahiro et al., 2003). In addition, one study by Swinnen et al 
showed there was a close association between the expression of FASN and Ki67 in the 
early stages of prostate cancer progression (Swinnen et al., 2002).  Similarly, the 
expression levels of c-Met and Ki67 have also previously been shown to be significantly 
associated but in non-small-cell lung cancer and gastric cancer (Masuya et al., 2004; 
Wu et al., 2009).  
This is also the first study to show that the expression of the Rho GTPases Cdc42 and 
RhoU is positively associated with the expression of Ki67 in prostate cancer. Both 
Cdc42 and RhoU have been shown to drive cell proliferation and a more aggressive 
cancer phenotype in vitro, however to date their relationship with the proliferating 
marker Ki67 has not previously been evaluated in tissue (Gao et al., 2015; Zhang et al., 







6.4 Future work 
The results generated from this pilot study have provided a good basis for looking at 
some of these proteins in a more robust study.  In the future it would be useful to look 
at the expression of these proteins in a larger sized cohort. This may help with one of 
the limitations of this study which was a weak distribution of patients between 
Gleason score categories. Since 60% of the men in this study had a Gleason score of 7, 
it was not possible to link biomarker staining based on high or low Gleason.   In 
addition to obtaining more patient tissue with different Gleason scores it would also 
be worth assessing the expression of these proteins in metastatic tissue (lymphatic, 
microvascular, perineuronal, and bone). The expression of FASN has been shown to 
increase in castrate-resistant prostate cancer which is correlated with metastatic 
disease (Pizer et al., 2001). Thus, it would be interesting to see if the expression of the 
Rho GTPase proteins also changes during metastatic progression.   
In a future study it would also be good to associate the expression of these biomarkers 
with patient characteristics such as metabolic syndrome, androgen therapy, tumour 
size, family history and ethnicity.  It is currently still not clear if FASN and de novo 
lipogenesis are strong contributors towards metabolic syndrome in prostate cancer 
patients, however there is supporting evidence (Tian et al., 2011; Wakil and Abu-
Elheiga, 2009).   Ethnicity is also a strong driving factor for prostate cancer 
development and severity.  Typically, the highest incidence of prostate cancer has 
been reported in black men followed by Caucasian men and then Asian men. At the 
moment it is still unclear why black African Caribbean men are at higher risk of 
developing prostate cancer. However it could be speculated that differences in the 
expression of some of the biomarkers at different stages of progression may be a 
driving factor for differences between ethnicities.  
Additionally, a future study would also benefit from patient survival data. It could 
more specifically look at associating some of the biomarkers with disease-free 
progression, biochemical recurrence/PSA failure rate and metastasis free survival.  This 
would give a more detailed evaluation for the use of the biomarkers as potential 
prognostic factors.    
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Lastly, it may also be worth linking disease progression with FASN levels in the blood. 
This is a relatively new avenue; however several studies have already shown that FASN 
is detectable in the serum of pancreatic, colorectal, breast, and gastric cancer patients 
and its levels seem to correlate with stage of progression (Ito et al., 2014; Notarnicola 

















































Chapter 7 – Concluding remarks 
Currently, there is mounting evidence which suggests that FASN is involved in prostate 
cancer progression, however little is known about the pathways or proteins that act 
downstream of FASN to drive a more aggressive phenotype in prostate cancer 
(Menendez and Lupu, 2007). This study focussed on investigating if FASN was involved 
in regulating proteins that induced actin cytoskeletal changes and cell migration in AR- 
independent prostate cancer.  Firstly, it was demonstrated that the depletion of FASN 
impaired cell proliferation which confirmed a well-known response to targeting this 
protein. In addition, FASN is a central protein in metabolism, and silencing its 
expression led to the generation of metabolically different prostate cancer cell lines. 
Cell shape has been linked to cell invasiveness and in this study a novel correlation 
between FASN expression levels and changes in prostate cancer cell shape was 
observed. Adhesion is also an essential process in cell migration; it was found that 
FASN knockdown concurrently increased cellular adhesion and the length of paxillin 
containing adhesions.  Additionally, FASN depletion reduced the migratory capability 
of prostate cancer cells in both 2D migration and 3D invasion assays.  The migration 
defect was also shown to be phenocopied through pharmacological inhibition of FASN. 
The mechanistic studies of this thesis revealed that RhoU palmitoylation levels were 
dependent on FASN expression levels.  Moreover, the expression of Cdc42 (prenylated 
isoform) decreased in response to FASN knockdown or inhibition. Further investigation 
showed that Cdc42 expression levels were dependent on RhoU expression and 
palmitoylation levels.  Following this, it was hypothesized that RhoU and Cdc42 could 
be interacting partners which was indeed confirmed by Co-IP.  To compliment these 
Lab based findings a pilot patho-epidemiological study was carried out and it was 
revealed that prostate cancer severity is associated with increased expression levels of 
FASN, RhoU and Cdc42.  
FASN has previously been reported to be important in the migration of several 
different cancers (Menendez and Lupu, 2007). However, this is the first study to show 
that the direct silencing of FASN in AR- independent prostate cancer significantly 
impairs cell migration and invasion. Moreover, the data from this study has revealed 
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an entirely novel mechanism by which FASN might be driving the migratory phenotype 
in prostate cancer.  
As previously discussed in chapter 5, FASN and palmitate are rarely linked despite the 
fact palmitate is solely synthesised by FASN (Kuhajda et al., 1994). Palmitate has 
several important functions in cancer including regulating the attachment of proteins 
to intracellular membranes through palmitoylation (Aicart-Ramos et al., 2011). In this 
study it was revealed that the depletion of FASN in prostate cancer leads to a decrease 
in the palmitoylation of the atypical Rho GTPase RhoU. The silencing of RhoU has been 
shown to reduce the migratory capacity of PC3 cells, MDA-MB-231 breast cancer cells 
and NIH 3T3 fibroblast cells (Alinezhad et al., 2016; Dart et al., 2015; Ory et al., 2007). 
Alternatively, nothing is currently known about how reduced palmitoylation affects 
RhoU induced cell migration.  However, it is known that prevention of this modification 
does lead to growth and morphology changes in NIH 3T3 fibroblast cells (Berzat et al., 
2005). Previously published studies have shown that the blockage of Rac1 and MMP14 
palmitoylation significantly reduces migration speed (Anilkumar et al., 2005; Navarro-
Lerida et al., 2012). Thus, since RhoU activity at the membrane is entirely dependent 
on palmitoylation, it would be reasonable to assume that a reduction in its 
palmitoylation could be having an effect on the migration of FASN depleted prostate 
cancer cells.  
One way prostate cancer cell migration could be affected upon a reduction in RhoU 
palmitoylation is through paxillin-mediated adhesion turnover. The phosphorylation of 
paxillin at serine 272 is required for adhesion disassembly (Nayal et al., 2006). 
Activated paxillin recruits and is sequestered away from adhesions by GIT1, an ARF 
GTPase-activating protein.  Failure of S272 paxillin phosphorylation prevents binding 
with GIT1 and leads to decreased adhesion turnover and cell migration (Nayal et al., 
2006).  Here, prostate cancer substrate adhesion and the length of paxillin containing 
adhesions increased in response to FASN depletion. This mirrors the adhesion defect 
that has been reported in RhoU silenced breast cancer and fibroblast cells (Dart et al., 
2015; Ory et al., 2007). In addition, the length of paxillin containing adhesions was 
rescued in FASN knockdown prostate cancer cells incubated with palmitate. Thus, it 
could be speculated that the exogenous palmitate taken up by the cells has been used 
200 
 
to restore RhoU palmitoylation and subsequent paxillin phosphorylation.  It is currently 
unclear how RhoU mediates paxillin phosphorylation, however it has been speculated 
it could be through PKC, PKA (protein kinase A), PKG (protein kinase G) or myosin light 
chain kinase (Dart et al., 2015).  
In addition to RhoU, this study also identified a second Rho GTPase, Cdc42, as a novel 
downstream target of FASN.  FASN knockdown cells were smaller in size and migrated 
at a reduced speed when compared to their control counterparts. These same 
phenotypes have previously been reported in PC3 cells silenced for Cdc42 (Reymond et 
al., 2012). Upon finding that FASN knockdown and Cdc42 knockdown PC3 cells shared 
similar phenotypes, Cdc42 levels were probed for in both prostate cell lines used in 
this study and indeed a decrease was observed.  Moreover, Cdc42 re-expression 
partially rescued the morphological defect seen in FASN knockdown cells confirming it 
as a target protein partly responsible for this phenotype.  
Due to pharmacological inhibition of FASN also decreasing Cdc42 expression, it was 
speculated that perhaps the palmitoylated splice variant of Cdc42 was being affected 
as a result of reduced palmitate biosynthesis. However, palmitoylated Cdc42 mRNA 
was un-detectable in both the 1542 and PC3 cell lines. Therefore this data suggests 
that in these prostate cell lines the prenylated, and not the palmitoylated, isoform of 
Cdc42 is being affected in response to the loss of FASN expression or activity.  
In chapter 5 it was shown that FASN knockdown led to a decrease in the protein levels 
of Cdc42, but not the mRNA levels.  This indicated that Cdc42 protein levels were 
decreasing as a result of post-translational targeting. Interestingly, further 
investigation found that Cdc42 protein levels decreased in RhoU silenced prostate 
cancer cells. Moreover, global blockage of palmitoylation also decreased Cdc42 
expression levels.  Thus, from these findings it was hypothesised that perhaps 
palmitoylated RhoU interacts with Cdc42 to prevent its subsequent degradation. It is 
not currently known if Rho GTPases can heterodimerize with other Rho GTPases. 
However, it has been shown that several Rho GTPases including Cdc42, RhoA and Rac1 
are able to homodimerize (Zhang and Zheng, 1998). Due to the extensive sequence 
homology between RhoU and Cdc42 it was speculated that these two proteins could 
be interacting partners and indeed a Co-IP in chapter 5 confirmed that this was the 
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case. Further studies will need to be carried out to determine exactly what domains of 
RhoU are interacting with Cdc42. One possibility is via the carboxyl-terminal polybasic 
domain that is responsible for Cdc42 homodimerization.  RhoU has an extended 
carboxyl-terminal domain relative to Cdc42. However there is a consensus sequence of 
amino acids in this region that may mediate the binding of these two proteins due to 
their highly positively charged surface (Zhang and Zheng, 1998).  In addition, unlike 
Cdc42 homodimerization which negatively regulates the proteins activity, the binding 
of a different sequence within this domain by RhoU may positively regulate both 
proteins (Zhang and Zheng, 1998). 
The binding of RhoU to prenylated Cdc42 could be mutually increasing the stability of 
both proteins. Protein palmitoylation promotes a more stable association with the 
membrane than prenylation, although proteins with dual acylation such as H-Ras 
demonstrate very strong membrane kinetics (Cadwallader et al., 1994; Peitzsch and 
McLaughlin, 1993; Shahinian and Silvius, 1995). Moreover, palmitoylated RhoU could 
also be regulating Cdc42 activation and localisation to different intracellular locations. 
The addition of palmitate to hepatocellular carcinoma cells has been shown to 
increase Cdc42 activation (Sharma et al., 2012c).  Interestingly, lipid rafts are enriched 
by GEFs, and have been shown to increase the activation of palmitoylated Rho 
GTPases such as Rac1 (Moissoglu and Schwartz, 2014). Prenylated proteins have a low 
affinity for lipid rafts due to the branching of the prenyl groups. However, it has been 
suggested that perhaps one of the ways that prenylated proteins are capable of 
targeting to lipid rafts is through their ability to bind  palmitoylated proteins (Brown, 
2006).  
Currently, nothing is known about how particular RhoGTPase may protect other Rho 
GTPases from protein degradation. However, palmitoylation has been shown to be 
important in modulating protein stability and degradation (Linder and Deschenes, 
2007).  Previous studies have observed that blocking palmitoylation in PC3 cells 
decreases the expression of the proteins EGFR and integrin α6β1 (Bollu et al., 2015; 
Sharma et al., 2012b). Similarly in DU145 cells, inhibition of palmitoylation has been 
shown to lead to a loss in the total levels of c-Met, EGFR and the integrin subunit β4 
(Coleman et al., 2009; Coleman et al., 2016). The role of palmitoylation in regulating 
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Rho GTPase stability has not been extensively researched. Interestingly, the current 
studies suggest that palmitoylation may affect certain Rho GTPases differently. 
Blocking palmitoylation does not lead to Rac1 or RhoU degradation, but severely 
affects their stability (Berzat et al., 2005; Navarro-Lerida et al., 2012). Conversely, 
palmitoylation has been shown to be required for rapid lysosomal degradation of RhoB 
(Perez-Sala et al., 2009).  Further studies will need to be carried out to determine how 
palmitoylated RhoU protects Cdc42 from proteasome degradation. One of the current 
difficulties with this at the moment is that the exact mechanism of Cdc42 degradation 
has not been well studied. One study has shown that cullin-1 (CUL1), a core 
component of multiple cullin-RING-SCF (S phase kinase associated protein 1 (SKP1)-
CUL1-F-box protein) ubiquitin ligase complexes, binds Cdc42 (Senadheera et al., 2001; 
Skaar et al., 2013). This interaction is believed to depend on subcellular localisation as 
it has been shown that Rac3 association and proteasomal degradation via CUL1 seems 
to specifically occur at the perinuclear region (Senadheera et al., 2001). Thus, it could 
be speculated that the binding of palmitoylated RhoU sequesters Cdc42 to different 
intracellular compartments away from ubiquitin ligases such as CUL1 that target it for 
degradation.  
Upon finding that FASN, RhoU and Cdc42 were linked in prostate cancer cell migration 
in vitro, it was decided to further investigate these proteins in a clinical setting.  In 
chapter 6, a pilot patho-epidemiology study was carried out using tissue from a cohort 
of 85 men who underwent a radical prostatectomy. Immunohistochemical staining 
revealed that the increased expression of FASN, RhoU and Cdc42 associated with 
prostate cancer severity.  This is the first study to show that the Rho GTPases RhoU 
and Cdc42 are potential biomarkers at the protein level for prostate cancer status. 
Moreover, the findings of this patho-epi study concur with the lab based findings and 
together suggest a role for FASN, RhoU and Cdc42 in prostate cancer. They also add to 
the current evidence in the literature which suggests FASN is worth targeting in 
patients with more aggressive disease in addition to the early stages of cancer (Flavin 
et al., 2011). Currently, one FASN inhibitor, named TVB-2640, has become the first 
oral, selective, and reversible FASN inhibitor to be tested clinically.  Two separate 
phase I studies in breast cancer and non-small cell lung cancer have shown favourable 
results with a median increase in patient disease-free survival and overall survival 
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whilst taking TVB-2640 alone, and in combination with other chemotherapeutic drugs 
(Brenner et al., 2017; O’Farrell et al., 2016).  
Currently a clinical trial is being undertaken in the UK assessing TVB-2640 effectiveness 
in several solid tumour types including breast, ovarian, prostate, colon, pancreatic and 
non-Hodgkins Lymphoma (ClincalTrials.gov: NCT02223247). Promising results from 
these trails could make the FASN inhibitor TVB-2640 a common combination therapy 
drug and encourage its use during the early stages of cancer development.   
In conclusion the findings from this thesis propose a novel model whereby FASN is 
responsible for the palmitoylation of RhoU which is then capable of binding Cdc42, 
preventing its degradation. This allows for un-perturbed downstream signalling from 
both of the Rho GTPases initiating proper cell spreading, adhesion turnover, and cell 











































Figure 7.1 A proposed model for the role of FASN and its downstream targets RhoU and 
Cdc42 in prostate cancer cell migration:  A) FASN synthesises palmitate which is used in 
the palmitoylation of RhoU via DHHC PATs. Palmitoylated RhoU binds prenylated Cdc42 
and both proteins tether to the cell membrane where Cdc42 can be activated by GEFs. 
Here, Cdc42 and RhoU signal and activate downstream effector proteins which induce 
changes in the actin cytoskeleton. RhoU is also involved in mediating the turnover of focal 
adhesions through paxillin phosphorylation.  These signalling events allow for unperturbed 
cell spreading and migration in prostate cancer. The palmitate moiety can also be removed 
from RhoU via APTs which would allow it and Cdc42 to dynamically localise to different 
subcellular locations. B) In a FASN knockdown or inhibited cell, palmitate synthesis is 
severely diminished abolishing RhoU palmitoylation which leads to its cytosolic 
accumulation. Palmitoylated RhoU is no longer able to sequester Cdc42 away from the 
ubiquitin ligases which lead to it being targeted for degradation.   Moreover, the 
prevention of RhoU palmitoylation leads to a decrease in paxillin phosphorylation which 
impedes focal adhesion turnover.  Perturbed RhoU and Cdc42 signalling as a result of 
targeting FASN activity abolishes proper cell spreading and migration. Proteins that don’t 
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